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Chloride and adenosine deaminase measurements in cerebrospinal fluid are still sporadically 
requested as part of tuberculous meningitis work–up. In the literature, evidence is 
contradictory and opinion is divided on their utility in clinical practice. The accuracy of both 
for the early presumptive diagnosis of tuberculous meningitis was investigated in patients in 
a region with high prevalence of tuberculosis and HIV infection in order to inform a decision 
on whether to continue offering these tests to clinicians. 
 
Methods 
A retrospective descriptive study of diagnostic accuracy was conducted at the National 
Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa. Data were 
collected on all cerebrospinal fluid specimens submitted for tuberculosis culture between 1 
January 2012 and 31 December 2014. Chloride and adenosine deaminase concentrations 




There were 2531 cerebrospinal fluid specimens submitted for tuberculosis culture during the 
study period; exclusion of duplicates yielded 2081 specimens. Chloride was requested on 
711 (34·2%) specimens; 44 (6·2%) were tuberculosis culture–positive. Adenosine deaminase 
was requested on 152 (7·3%) specimens; 20 (13·2%) were culture–positive. Chloride 
sensitivity (<120 mmol/L) for the detection of tuberculous meningitis was 93·2% (95% 
confidence interval 81·3–98·6), with specificity 62·4% (58·6–66·1), positive predictive 
value 14% (10·3–18·6), negative predictive value 99·3% (97·9–99·9), positive likelihood 
ratio 2·48 (2·18–2·81), and negative likelihood ratio 0·109 (0·037–0·326). Adenosine 
deaminase sensitivity (>6 U/L) was 70% (45·7–88·1), specificity 89·4% (82·8–94·1), 
positive predictive value 50% (30·6–69·4), negative predictive value 95·2% (89·8–98·2), 
positive likelihood ratio 6·6 (3·72–11·7), and negative likelihood ratio 0·336 (0·171–0·657). 
 
Interpretation 
In this patient population chloride and adenosine deaminase showed at best only modest 
performance as markers of tuberculous meningitis. However, very good negative predictive 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
Goals of the literature review 
The goals of this literature review were to obtain information on the following topics: 
 
1 The epidemiology of tuberculosis, HIV infection, and tuberculous meningitis (TBM) 
in South Africa. 
2 The history and available evidence on the measurement of chloride in the 
cerebrospinal fluid and its utility in the diagnosis of TBM. 
3 The history and available evidence on the measurement of adenosine deaminase in 
the cerebrospinal fluid and its utility in the diagnosis of TBM. 
4 The current clinical and laboratory approaches to TBM diagnosis. 
5 The evolving role of commercial molecular platforms. 
 
Search strategy 
The PubMed digital archive was searched up to 17 December 2015 for papers on the above 
topics published in any language. For cerebrospinal fluid chloride (as one of the index tests 
in the research study) the search strategy used combinations of key terms as follows: 
“tuberculous meningitis” OR “TB meningitis” AND “cerebrospinal fluid chloride” OR “CSF 
chloride”. The search identified 25 papers. For cerebrospinal fluid adenosine deaminase (as 
the other index test in the study) the search strategy used the following combinations of key 
terms: “tuberculous meningitis” OR “TB meningitis” AND “cerebrospinal fluid adenosine 
deaminase” OR “CSF adenosine deaminase” OR “cerebrospinal fluid ADA” OR “CSF 
ADA”. This search identified 112 papers. For the topics on epidemiology, clinical and 
laboratory approaches, and molecular platforms, searches were performed using selected key 
terms. Further papers of interest on all topics were identified via manual searching of the 
reference lists of primary papers identified through the database search. Papers were 
retrieved via the Health Sciences Library of the University of Cape Town. 
 
Quality criteria 
The abstracts of all papers initially identified were reviewed to critically assess the subject 
matter for content, results presented, and applicability to the topics of this research study. 
Suitable papers were then retrieved and read in full by the author. Quality criteria applied 
during appraisal included consideration of the study methodology and whether it was 
adequate for the research question, statistical significance of results, number of papers 
published on the subject, number of study participants, choice and recruitment of 
participants, sample size, control of confounding variables, method of data analysis, and 
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ethics considerations. The main aim was to identify studies reporting on the utility of one or 
both of CSF chloride and CSF ADA measurement in the context of TBM diagnosis. 
Preference was given to work performed in Southern Africa. There were no time limits 
applied as to when the work was published. A similar procedure was followed in the 
appraisal of papers on the topics of epidemiology of TBM, clinical and laboratory 
approaches to diagnosis, and molecular platforms. 
 
Summary of the literature 
Epidemiology of tuberculosis, HIV, and tuberculous meningitis in South Africa 
South Africa has one of the worst tuberculosis (TB) epidemics in the world.1 Data published 
by the World Health Organization (WHO) in 20152 indicate that there were a total of 318193 
cases of TB notified during 2014. This was inclusive of new cases and relapses. There were 
272078 cases of pulmonary TB notified, both bacteriologically confirmed or clinically 
diagnosed; there were 34088 cases of extrapulmonary TB (including TBM) notified. The 
incidence rate of both TB and TB/HIV co–infection was 834 per 100000 of the population 
(which was estimated at 54 million in 2014). The TB/HIV co–infection incidence rate was 
509 per 100000 of the population. There were 218231 cases tested for multi–drug resistant 
TB (MDR–TB), 18734 cases were laboratory–confirmed MDR–TB, and 11538 patients were 
started on MDR–TB treatment. During 2014 there were 295136 (93%) TB patients with 
known HIV status notified. There were 1148477 HIV–positive people screened for TB; 
179756 HIV–positive patients were notified with TB. With respect to laboratory coverage as 
of 2014, Xpert MTB/RIF testing was offered at 207 sites and second–line drug susceptibility 
testing was available in the country. South Africa’s national TB control programme budget 
stood at US$ 248 million in 2015, of which 84% was funded domestically, 8% was funded 
internationally, and 8% was unfunded. 
 
South Africa also carries one of the heaviest burdens of HIV/AIDS globally.1 Estimates 
published in 2013 by the Joint United Nations Programme on HIV and AIDS (UNAIDS)3 
showed that 6·3 million people were living with HIV, inclusive of 5·9 million adults aged 15 
years and older, and 360000 children aged 0 to 14 years. There were 2·4 million orphans 
(aged 0 to 17 years) due to AIDS. The prevalence rate among adults aged 15 to 49 was 
19·0%. Women aged 15 and older living with HIV numbered 3·5 million and there were 
200000 deaths due to AIDS. Trend analyses from 1990 up to 2013 show that the HIV 
prevalence rate for ages 15 to 49 were unchanged since 2005, while the number of people 
living with HIV had increased slightly year–on–year since 2005 (prior years showed a 
steeper yearly increase). The HIV incidence rate (ages 15 to 49), the number of new 
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infections (all ages), and the annual number of AIDS deaths had all been decreasing steadily 
since the 2000–2005 period. 
 
Tuberculous meningitis develops as a result of infection with Mycobacterium tuberculosis. It 
is one of the most severe extrapulmonary complications of TB and causes significant 
morbidity and mortality. It frequently presents in childhood, although people of all ages can 
develop the disease. A number of studies published in recent years have examined the 
epidemiology of TBM in the Western Cape province of South Africa, which is the setting for 
the proposed research study.4–7 
 
Jarvis and colleagues4 published findings on 4961 suspected cases of adult meningitis 
occurring in a setting of high TB and HIV prevalence. Patients undergoing diagnostic lumbar 
puncture at a public sector secondary–level referral hospital over a three–year period were 
studied. They recorded 5578 procedures performed on 4549 patients which represented 4961 
clinical episodes. Of 820 microbiological diagnoses, cryptococcal meningitis (CM) 
accounted for 514 (63%) of cases, TBM for 227 (28%) of cases, and bacterial meningitis for 
68 (8%) of cases. They highlighted the changing face of meningitis epidemiology, due to 
chronic meningitis caused by CM and TBM having assumed much greater prominence in 
recent years as a result of the HIV/AIDS pandemic. 
 
Marais and co–workers5 performed a retrospective review of CSF findings and clinical 
records over a period of six months in a similar setting in Cape Town, South Africa. They 
applied published case definitions of definite, probable, and possible TBM to their study 
population. TBM was diagnosed in 120 patients out of 211 enrolled (57%). In their paper, 
they identified TBM as the most common cause of meningitis when considering both 
microbiologically confirmed cases and cases diagnosed on clinical grounds. They found 
TBM accounted for 44% and CM accounted for 45% of all microbiologically confirmed 
cases of meningitis. They postulated that greater access to antiretroviral therapy (ART) 
would most likely account for the difference in their figures, compared to those of Jarvis and 
colleagues, resulting in smaller numbers of HIV–infected patients developing the severe 
levels of immunosuppression associated with CM. 
 
Van Well and colleagues6 reported on a retrospective cohort study performed in the Western 
Cape province of South Africa which examined twenty years of experience with paediatric 
TBM. It took place at a large university hospital and the study period ranged from January 
1985 to April 2005. Their cohort consisted of 554 patients. They found that 82% of positive 
TBM diagnoses were in children younger than five years of age; mean age was 37 months, 
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other similar studies yielded mean ages ranging from 23 to 49 months. Presentation 
frequently was subacute, with non–specific early symptoms. Clinical clues identified to 
support early diagnosis included recent poor weight gain, vomiting, low–grade fever, and 
recent TB contact. 
 
In summary, South Africa has a large number of people living with HIV and TB, including 
people co–infected. Cases of chronic meningitis due to TBM and CM have assumed greater 
prominence and these account for more presentations to health care facilities at present than 
do cases of acute bacterial meningitis in adults. In the paediatric population, disease often 
occurs in children younger than five. Presentation is frequently subacute, with variable and 
non–specific symptomatology. Morbidity and mortality remain unacceptably high. 
 
Cerebrospinal fluid chloride 
Chloride is the most abundant anion in plasma and interstitial fluid, including CSF. As such, 
it represents about 70% of the body’s total anion content. A number of authors writing on the 
subject of chloride in CSF credit Mestrezat with first observing and describing a decrease in 
CSF chloride in meningitis,8–10 and also noting that this decrease seemed to be most 
pronounced in cases of TBM. After a spate of these early reports, there followed a period in 
which very little was written on the subject. Present day texts still advocate for its 
measurement in suspected cases of TBM,11 crediting a low CSF chloride with being virtually 
diagnostic of this disease.12 
 
Linder and Carmichael8 studied chloride and other ions in serum and CSF in four cases of 
meningitis, which comprised two cases of TBM, one case of meningococcal meningitis, and 
one case of streptococcal meningitis. They made two general observations. One was that a 
decrease in CSF chloride was dependent on a similar decrease in serum chloride, and that the 
relative concentrations between the two compartments remained the same. The other was 
that an associated increase in the bicarbonate concentrations of both fluid compartments took 
place. This was true for all four their cases. There was no attempt to differentiate between 
the different cases based on relative ion concentrations. Their study was limited by a very 
small number of participants. Fowweather9 reported on a series of three cases of meningitis 
in children and concluded that a decrease in CSF chloride was a constant finding among 
cases. It was also stated that this reduction seemed to occur to a greater degree in cases of 
TBM than in other forms of meningitis. Study limitations included very few participants and 
no clear descriptions of reference standards. Gierson and Owens10 published results on CSF 
findings of 1788 patients at the time of admission to hospital. Their observations were that 
chloride was normal in cases of poliomyelitis, viral meningitis, and encephalitis. Chloride 
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was moderately decreased in cases of pyogenic meningitis. In cases of tuberculous and 
fungal meningitis more pronounced decreases of chloride were found. A large number of 
cases were studied, but their conclusions were based only on simple comparison of chloride 
levels across different diagnostic groups, no diagnostic accuracy measures were calculated. 
 
Ramkissoon and Coovadia13 published a paper in 1988 describing a study on chloride and 
bromide levels in a series of 148 children with TBM, bacterial, or viral meningitis. They 
compared CSF chloride levels, blood chloride levels, and blood/CSF chloride ratios between 
the groups. The conclusion was that none of these measures were useful in differentiating 
between TBM, bacterial meningitis, and viral meningitis. This was based on comparison 
across groups, no measures of sensitivity, specificity, or predictive values were determined. 
In a letter to the editor in the Journal of the American Medical Association (JAMA) in 1984, 
Schoen14 wrote that chloride measurement in CSF in cases of TBM was of little if any value. 
He quoted noted paediatric clinician Dr Edith Lincoln’s work which showed that the 
decrease in CSF chloride reflected low total–body chloride secondary to protracted vomiting. 
This clinician’s work was conducted in a first–world setting (the United States of America), 
thus limiting transferability of the results to settings in developing countries with higher 
disease prevalence. 
 
Two other mechanisms may explain decreased CSF chloride in cases of chronic meningitis, 
such as TBM. One is that of dilution of whole body chloride mediated by the syndrome of 
inappropriate ADH secretion (SIADH).15 In this syndrome there is a pathological increase in 
ADH secretion from the posterior pituitary gland which leads to increased renal reabsorption 
of water in the face of normal to increased total body water. The other is that of the 
electrolyte exclusion effect, also called the Donnan effect.16 When protein molecules 
carrying a net charge is present on one side of a semi–permeable membrane, but not the 
other, and cannot diffuse across that membrane, the distribution of ions which can diffuse is 
altered. In TBM, large negatively charged protein molecules are present in the CSF. Small 
negatively charged chloride ions will preferentially diffuse across the blood–brain barrier 
until the amounts of negative charges on both sides of the barrier are equal. The extent to 
which each of these mechanisms contribute in any given case is not known though, and 
evidence on these phenomena is lacking. 
 
To summarise, a small number of early papers reported on the observation that CSF chloride 
decreased in cases of meningitis, and that more pronounced decreases were seen in chronic 
meningitides such as TBM and fungal meningitis. Consensus among the more recent 
papers13,14 seemed to be that there is little, if any, incremental diagnostic utility in measuring 
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CSF chloride in cases of meningitis. Measures of diagnostic accuracy were not reported on 
in any of the papers. No clear evidence supporting the current reference interval (120–130 
mmol/L) could be found. 
 
Cerebrospinal fluid adenosine deaminase 
The enzyme adenosine deaminase (ADA) has a key role in purine metabolism, where it 
irreversibly hydrolyses adenosine or deoxyadenosine to inosine or deoxyinosine and 
ammonia.17,18 Almost all mammalian cells contain the enzyme and it has a key function in 
maintenance of immune competence. Severe Combined Immunodeficiency Disease (SCID) 
is associated with a lack of ADA. AIDS, anaemia, lymphoma, and leukaemia are other 
conditions associated with altered levels of the enzyme. Developing T–cells, especially those 
associated with the stomach and the intestine, and also the fetal–maternal interface, have 
been shown to have high levels of ADA. Enzyme function is important in modulating the 
effects of adenosine in various systems. Adenosine has anticonvulsant and antihypoxic 
properties and it can modulate blood flow, platelet aggregation, lipolysis, glycogenolysis, 
and neurotransmission.17 
 
Human ADA exists as one of three isoenzymes: ADA1, ADA1+CP, and ADA2.
19 Ungerer and 
colleagues
19
 studied the distribution of these after developing an electrophoretic technique to 
separate the three isoenzymes. Patterns were studied in cell and tissue homogenates and also 
in serum, both from healthy people and from patients with increased ADA levels due to 
hepatitis, infectious mononucleosis, tuberculosis, pneumonia, rheumatoid arthritis, or acute 
lymphoblastic leukaemia. Lymphocytes and monocytes were found to have the highest ADA 
activity overall. Lymphocytes had 84% ADA1 activity and 16% ADA1+CP activity, while 
monocytes had 82% ADA1 activity and 18% ADA2 activity. Differential distribution of these 
isoenzymes in CSF and neuronal tissue were not reported on. 
 
There are many papers in the literature reporting on the measurement of ADA in CSF in the 
diagnosis of TBM. A PubMed search yielded more than 100 studies on the subject. Initial 
appraisal of these suggested the presence of a trend, in the sense that studies looking at 
smaller numbers of patients in settings of lower prevalence of TB reported ADA as having 
significant diagnostic utility;20–22 while studies looking at larger numbers of patients in 
settings of high TB and TB/HIV prevalence reported ADA as having limited diagnostic 




Ribera and colleagues20 studied ADA in 205 patients and 40 normal controls. Patients were 
grouped according to disease, which included TBM, viral meningitis, purulent meningitis, 
neoplasms, stroke, and other miscellaneous conditions. They found mean enzyme levels 
higher in patients with TBM, compared to the other groups. Sensitivity for diagnosis was 1 
and specificity was 0·99. They concluded the test to be simple and reliable for early TBM 
diagnosis, as well as for follow–up of patients. Study limitations included a small number of 
patients, no clear description of the reference standard, and incomplete data analysis. In 
another paper, Agarwal and co–workers21 reported on ADA measurement in 56 patients 
presenting to hospital with clinical features of meningitis. In their cohort, 32 patients were 
shown to have TBM and of these, 28 had CSF ADA at or above their cut–off of 10 U/L. 
They calculated sensitivity of 87·5%, specificity of 83·33%, positive predictive value of 
87·5%, and negative predictive value of 83·33%. They found ADA to be simple, 
inexpensive, rapid, and specific for diagnosing TBM. Their study was limited by a small 
sample size and diagnoses of TBM made via clinical criteria only, also, no figures for 
prevalence or predictive values were given. Parra–Ruiz and colleagues22 reviewed ADA 
utility in Spain, a region with low TB prevalence. They did a retrospective study of the 
accuracy of ADA in 190 patients, which were classified as certain TBM, probable TBM, or 
not TBM, based on clinical and laboratory criteria. Receiver–operating–characteristic (ROC) 
curve analysis yielded 11·5 IU/L as optimal cut–off in their setting. At this level, they 
calculated sensitivity of 91% and specificity of 77·7% for ADA accuracy in diagnosing 
TBM. They derived a predictive algorithm based on ADA and other CSF parameters and 
concluded that it offered improved utility in diagnosing TBM, compared to ADA alone, in 
their population. Diagnostic accuracy measures were incompletely calculated (no prevalence 
figures were given and little was said about predictive values) and TBM diagnosis was based 
on clinical criteria only. 
 
Studies reporting on limited diagnostic accuracy are many. Two are highlighted here, one of 
which investigated TBM in HIV–positive patients,23 and the second of which is a recent, 
large systematic review with meta–analysis on the subject.24 Corral and co–workers23 studied 
ADA levels in 417 patients with HIV infection who presented with neurological symptoms. 
They found no association between high ADA and HIV infection, HIV–associated 
neurological disorders, or progressive multifocal leuko–encephalopathy. ROC analysis 
among patients with meningitis in their cohort yielded an optimal ADA cut–off of 8·5 IU/L 
for TBM diagnosis, with a sensitivity of 57% and a specificity of 87%. False–positive results 
were due to neurological CMV disease and cryptococcal, lymphomatous and candida 
meningitis. Their conclusion was that ADA had limited utility for diagnosing TBM in HIV–
positive patients. Tuon and colleagues24 performed a systematic review with meta–analysis 
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on ADA in TBM. They included 13 studies in their final meta–analysis, out of 522 studies 
on the topic initially identified through their literature search. There were 380 patients with 
TBM among the 13 studies. They assessed ADA over a range of values. ADA of 1–4 U/L 
were helpful in excluding TBM (sensitivity > 93%, specificity < 80%). ADA from 4–8 U/L 
could neither confirm nor exclude TBM. ADA more than 8 U/L improved diagnosis of TBM 
(sensitivity < 59%, specificity > 96%). They found that none of these cut–off ranges could 
distinguish between TBM and bacterial meningitis, although they wrote that ranges of ADA 
values may be helpful in improving diagnosis once bacterial meningitis had been ruled out. 
Different assay methodologies and heterogeneous data reporting were highlighted as barriers 
to standardisation of the test as routine. 
 
In summary, more papers have been published on CSF ADA than on CSF chloride in TBM. 
The selection of papers summarised above show that the settings in which ADA was studied 
vary quite significantly. Findings ranged along a spectrum, from some studies reporting very 
favourable findings, to other studies reporting limited to virtually no diagnostic utility for the 
marker. The meta–analysis by Tuon and colleagues24 summarises much of the other work 
that had been done, and shows that ADA has limited accuracy, but that it may have value 
when applied in certain clinical situations. 
 
Clinical and laboratory approaches to tuberculous meningitis diagnosis 
Diagnosis of TBM remains challenging, even for experienced clinicians. Published 
guidelines25 and consensus case definitions26 aim to assist with the diagnostic process by 
recommending approaches and providing the rationale behind these approaches. Guidelines 
recommend starting with a thorough history and complete physical examination, and then 
progress to special investigations which would include various laboratory tests done on 
peripheral blood and CSF specimens, as well as imaging which would include visualisation 
of the CNS and chest, and other anatomical sites which are suspected to be involved.25,26 
Although TBM is generally accepted to present differently to the acute encephalo–
meningitides, it is nevertheless prudent to take cognisance of guidelines for the acute CNS 
infections.27 Recommendations by local experts developed for the local setting should also 
be taken into account.28 
 
A number of recent papers highlight some important issues with respect to TBM 
diagnostics.29–32 Thwaites and Hien29 pointed out the non–specificity of clinical features, 
insensitivity of conventional bacteriology, and incompleteness of assessment of new 
diagnostic technology. Ho and colleagues30 reviewed a number of novel diagnostic 
techniques such as interferon–gamma release assays and various biomarkers (MTB–specific 
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antigen and antibody, cytokines, gene expression profiles, and metabolomics), but 
emphasised that further evaluation would be required to establish their diagnostic utility. 
Brancusi and co–workers31 also highlighted the absence of sensitive diagnostic tests for 
TBM. Additionally, they noted that new insights into the immunopathology of the disease, 
pathogen lineage (genotypes), and host genetics may influence susceptibility to TBM, and 
this may have implications for diagnosis. Garg32 emphasised that bacteriological 
confirmation of disease is not always possible, and that serological tests do not have 
sufficient sensitivity and specificity. 
 
Various groups have studied clinical and laboratory features in different patient populations 
and in a variety of settings with the aim of creating prediction rules and identifying features 
which would facilitate diagnosis.33–40 One such study33 identified five features as being 
predictive of TBM: age, length of history, white blood cell count, total CSF white cell count, 
and CSF neutrophil proportion. The same group of authors, in a different study,34 found 
volume of CSF, duration of symptoms, and changes in CSF neutrophil count, lactate, and 
glucose all to be independently associated with confirmation of presence of TBM. Bhigjee 
and colleagues35 studied diagnostic yield by polymerase chain reaction (PCR) in patients 
with suspected TBM in South Africa. They found that targeting the TB genome at multiple 
sites with conventional PCR did not improve diagnostic yield. They also found real–time 
PCR to be more sensitive. Their final conclusion was that none of the molecular techniques 
studied were sensitive enough to confidently exclude a diagnosis of TBM on laboratory 
grounds. In a study from Egypt, Youssef and co–workers36 attempted to identify features 
which would enable early diagnosis. They found six parameters to be predictive in their 
model: duration of history > five days, headache, CSF white cell count of < 1000 cells/mm3, 
clear CSF, lymphocyte proportion > 30%, and protein content of > 100 mg/dL (> 1 g/L). 
 
Duration of symptoms ≥ five days, age over 30 years, CSF white cell count ≤ 1000 x 103 
cells/mL (≤ 1000 cells/mm3), and CSF lymphocytosis ≥ 70% were identified as predictive 
factors in a paper by Moghtaderi and colleagues.37 Another group38 found prodrome ≥ seven 
days, optic atrophy on fundal examination, focal neurological deficit, abnormal movements, 
and CSF neutrophil proportion < 50% to be useful predictors. A group from China39 found 
independent factors for TBM diagnosis to be CSF protein > 1 g/L, CSF glucose < 2·2 
mmol/L, CSF white cell count of 10–500 cells/µL (10–500 cells/mm3), and neutrophil 
proportion > 50%. Pasco,40 in a study done in the Philippines, investigated new–onset 
seizures, focal neurological deficit, pulmonary TB on chest X–ray, CSF pleocytosis with 
lymphocyte predominance, decreased CSF glucose, and increased CSF protein, as possibly 
being associated with TBM. At result analysis he found only the combination of CSF 
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pleocytosis with decreased CSF glucose and increased CSF protein as being associated with 
a diagnosis of TBM. 
 
TBM has been studied also in patients with HIV infection.41–44 One study,41 which examined 
96 HIV positive patients, found that neurological features of TBM are not changed by HIV 
infection but that survival rates are decreased. Another study42 concluded that meningitis risk 
is increased in HIV–positive patients but that infection alters neither clinical manifestations 
nor outcome of TBM. This cohort was smaller; 35 patients with HIV infection were 
included, thus providing less robust evidence than the first study discussed. Yet another 
group43 reported that the absence of CSF pleocytosis occurred more frequently in HIV–
positive patients, that multidrug–resistant TB infection was more prevalent, and that 
mortality in hospital was higher in their HIV–positive cohort. A study from India44 reported 
similar clinical features between HIV–positive and HIV–negative patients, but noted that 
cognitive dysfunction occurred more commonly among HIV–positive patients. They also 
examined radiological features and found meningeal enhancement to be minimal to absent, 
together with absence of communicating hydrocephalus on computed tomography (CT) scan 
in HIV–positive patients. 
 
Adjunctive tests for TB diagnosis have been reviewed in the literature.
45,46
 These tests 
include serology, Interferon–Gamma Release Assays (IGRAs; including ELISPOT), PCR, 
ELISA, lipoarabinomannan, and the string test. Some of these (ELISPOT, PCR, ELISA) 
have been evaluated in the setting of TBM. While all were shown to be useful to a certain 
extent, hard data on diagnostic accuracy measures are lacking.45,46 Van Kampen and 
colleagues47 did a study on automated liquid culture systems, utilising existing published 
data to assess system performance in both high and low prevalence settings. They found that 
TB cross–contamination rates increased exponentially as the prevalence rate of TB increased 
in the population of interest. They concluded that automated systems play a valuable role in 
TB diagnostics, but that awareness of increased risks of cross–contamination should be 
maintained in settings of high disease burden. 
 
To conclude, published guidelines25,28 and the uniform case definition criteria26 were 
developed through consensus processes in order to empower clinicians to diagnose TBM. As 
can be gathered from the paragraphs above, numerous groups have done studies among 
different populations investigating all manner of variables (clinical, laboratory, and 
radiological) in order to try and improve diagnostic algorithms. It should be kept in mind that 
study findings cannot always be extrapolated to different populations and settings, and that 
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measures of diagnostic accuracy are sensitive to the context of the study, the prevalence of 
disease, and other factors. 
 
Molecular diagnosis of tuberculous meningitis 
Rapid progress in nucleic acid amplification test (NAAT) technology has shifted the 
paradigm in TB diagnostics. Initial evaluation and subsequent implementation of assays 
(first in research settings, followed by commercialisation) involved pulmonary specimens in 
the clinical setting of pulmonary TB. Following this, investigators started looking at 
applying the methods to test extra–pulmonary specimens, including CSF. A number of 
papers have investigated the accuracy of NAATs in diagnosis of TBM.48–52 
 
Thwaites and colleagues48 compared conventional bacteriology (Ziehl–Neelsen (ZN) stain 
and culture) with a NAAT (Gen–Probe amplified Mycobacterium tuberculosis direct test) in 
341 CSF specimens. They reported a sensitivity of 64% for ZN staining, a sensitivity of 59% 
for the NAAT, and a sensitivity of 83% for the two tests combined, when done on repeated 
CSF specimens. They concluded that ZN staining was at least as good as the NAAT for rapid 
MTB diagnosis, much faster, and less expensive. Pai and co–workers49 published a 
systematic review and meta–analysis on the diagnostic accuracy of NAATs in TBM. They 
found 14 papers which reported on commercial NAATs, and calculated summary estimates 
as follows: sensitivity 0·56 (95% confidence interval 0·46–0·66), specificity 0·98 (0·97–
0·99), positive likelihood ratio 35·1 (19·0–64·6), negative likelihood ratio 0·44 (0·33–0·60), 
and diagnostic odds ratio 96·4 (42·8–217·3). Their conclusion stated that commercial 
NAATs would have a potential role in confirming TBM, but that they would not be useful as 
rule–out tests given their overall low sensitivity. In two other papers appraised,50,51 the 
authors of one50 found Xpert MTB/RIF to be a good rule–in test for TBM diagnosis. This 
applied to patients with HIV infection in a setting of high TB prevalence, and performing the 
assay on a centrifuged CSF pellet. In the other paper,51 looking at NAATs (GenoType 
MTBDRplus and Xpert MTB/RIF) in childhood TBM, the authors found that commercial 
NAATs improved diagnostic accuracy incrementally, thus confirming disease rapidly 
microbiologically. However, they also found that these tests cannot serve to rule out TBM 
with any certainty. 
 
A recent WHO publication examined the performance of Xpert MTB/RIF in the detection of 
MTB in CSF.52 Combined sensitivity across 16 studies was 79·5% (62·0–90·2) while 
combined specificity was 98·6% (95·8–99·6). Although WHO in this document strongly 
recommends Xpert MTB/RIF in preference to conventional microscopy and culture as the 
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initial diagnostic test in patients with presumed TBM, given the urgency of the diagnosis, it 
does admit that current evidence for this recommendation is of poor quality. 
 
To summarise, NAATs hold great promise for the future of TBM diagnostics, especially as 
the technology keeps on evolving. These tests have been shown to have incremental utility in 
the process of investigating for TBM. However, as authors have pointed out, due to the 
limitations of the assay, it is impossible to reliably rule out the presence of TBM in a patient, 
given a negative NAAT result, even if done on repeated specimens. The WHO document52 
shows that the number of patients assessed in studies of diagnostic accuracy of Xpert 
MTB/RIF on CSF specimens is still small; there is a need for more work in this area. 
 
Identification of needs for further research 
As a general note, studies of diagnostic accuracy has been the object of interest for some 
time, as authors have noted that these need to be better planned and conducted,53 and that 
there should be adherence to certain principles.54 The STARD initiative is a consensus effort 
to provide clear guidance to study authors in accomplishing these objectives.55–57 
 
Further research needs, across the domains described in this literature review, are as follows: 
 
1 Epidemiology: More research is needed in South Africa to accurately describe the 
epidemiology of TBM in our patient population. 
2 CSF chloride and ADA: There is a need for diagnostic accuracy studies done locally 
to assess test accuracy against a reference standard in order to inform future 
decisions to continue offering the tests to clinicians. 
3 Clinical and laboratory approaches to diagnosis: More work is needed in our setting 
to establish whether current guidelines are being followed and whether this has 
resulted in improved patient care and outcomes. 
4 Commercial molecular platforms: Studies are needed to assess whether deployment 
of instruments has proceeded as planned and whether the instruments are being used 
optimally (especially looking at testing of extra–pulmonary specimens). There is also 
a need for more studies to examine the diagnostic utility of NAATs in our setting. 
 
Aim and objectives of this research study 
Aim 
To retrospectively determine the diagnostic accuracy of CSF chloride and CSF ADA 
measurement compared to automated liquid TB culture as the reference standard, in the 
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assessment of patients with suspected TBM, in order to inform a decision of whether to 
continue offering these tests to clinicians. 
 
Objectives 
1 To determine the total number of specimens processed for TB culture in the 
laboratory and to identify among these all CSF specimens submitted for TB culture. 
2 To determine the number of CSF specimens which had either chloride, or ADA, or 
both measured, and to correlate these results with those of TB culture. 
3 To outline the distribution of HIV positivity, CD4+ T–cell counts, and viral loads in 
the patient population studied. 
4 To calculate sensitivities, specificities, predictive values, likelihood ratios, diagnostic 
odds ratios, and diagnostic efficiencies of the index tests. 
5 To evaluate the index tests against the reference standard to determine whether they 
offer any diagnostic utility, in order to decide whether the results support continued 
offering of the tests to clinicians. [5272 words] 
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Chloride and adenosine deaminase measurements in cerebrospinal fluid are still sporadically 
requested as part of tuberculous meningitis work–up. In the literature, evidence is 
contradictory and opinion is divided on their utility in clinical practice. The accuracy of both 
for the early presumptive diagnosis of tuberculous meningitis was investigated in patients in 
a region with high prevalence of tuberculosis and HIV infection in order to inform a decision 
on whether to continue offering these tests to clinicians. 
 
Methods 
A retrospective descriptive study of diagnostic accuracy was conducted at the National 
Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa. Data were 
collected on all cerebrospinal fluid specimens submitted for tuberculosis culture between 1 
January 2012 and 31 December 2014. Chloride and adenosine deaminase concentrations 




There were 2531 cerebrospinal fluid specimens submitted for tuberculosis culture during the 
study period; exclusion of duplicates yielded 2081 specimens. Chloride was requested on 
711 (34·2%) specimens; 44 (6·2%) were tuberculosis culture–positive. Adenosine deaminase 
was requested on 152 (7·3%) specimens; 20 (13·2%) were culture–positive. Chloride 
sensitivity (<120 mmol/L) for the detection of tuberculous meningitis was 93·2% (95% 
confidence interval 81·3–98·6), with specificity 62·4% (58·6–66·1), positive predictive 
value 14% (10·3–18·6), negative predictive value 99·3% (97·9–99·9), positive likelihood 
ratio 2·48 (2·18–2·81), and negative likelihood ratio 0·109 (0·037–0·326). Adenosine 
deaminase sensitivity (>6 U/L) was 70% (45·7–88·1), specificity 89·4% (82·8–94·1), 
positive predictive value 50% (30·6–69·4), negative predictive value 95·2% (89·8–98·2), 
positive likelihood ratio 6·6 (3·72–11·7), and negative likelihood ratio 0·336 (0·171–0·657). 
 
Interpretation 
In this patient population chloride and adenosine deaminase showed at best only modest 
performance as markers of tuberculous meningitis. However, very good negative predictive 
values could serve to identify patients highly unlikely to have the disease. 
 
Funding 
None. [310 words] 
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Introduction 
The diagnosis of tuberculous meningitis (TBM) requires the consideration of risk factors, 
clinical assessment, laboratory tests, and imaging modalities.1,2 Rapid decision–making is 
important as this is a serious infection with severe long–term sequelae, requiring prompt 
initiation of appropriate therapy and referral for definitive management. At present, the 
interaction of various risk factors (such as tuberculosis contact, HIV, alcoholism, diabetes 
mellitus, malignancy, recent steroid use, socio–economic status, infant/young child, and 
parental education level) in the pathogenesis of this disease is incompletely understood. 
Furthermore, clinical assessment is frequently unhelpful, laboratory tests yield variable 
results, and imaging is subject to inter–operator variability. All of these hamper the 
diagnostic process. Despite this, confirming the presence of disease and delineating drug 
susceptibility patterns have become more important in the current setting of high 
tuberculosis (TB) prevalence and HIV/TB co–infection, emerging multi–drug resistant 
pathogens, and treatment access and adherence issues.3,4 
 
Current internationally–accepted practice1 with respect to laboratory testing for TBM 
includes obtaining a cerebrospinal fluid (CSF) specimen after due consideration for the 
presence of raised intracranial pressure. The usual analysis includes measurement of protein 
and glucose concentrations. Cell counts are performed either using manual cell counting 
chambers or automated technology. Improvements in automated haematology 
instrumentation and flow cytometry technology have led to a preference for these new 
platforms. Specific microbiological techniques for detection of Mycobacterium tuberculosis 
(MTB) in CSF include direct light microscopy of clinical specimens with Ziehl–Neelsen 
(ZN) staining, culture methods including automated liquid culture (mycobacterial growth 
indicator tube – MGIT) and manual culture on Löwenstein–Jensen (LJ) medium, and 
molecular platforms such as the Xpert MTB/RIF system (Cepheid, Sunnyvale, CA, USA). 
 
Advances in molecular diagnostic techniques have spearheaded renewed efforts to address 
the threats posed by TB and HIV. Xpert MTB/RIF, the most rapid detection system, was 
found to have a pooled sensitivity of 79·5% (95% confidence interval (CI) 62·0–90·2) across 
16 studies which examined 709 CSF specimens,5 and thus cannot be utilised to reliably rule 
out the presence of TBM with a negative result.1 New integrated approaches aimed at 
improving the diagnosis of TB meningitis have appeared in the literature.6 These emphasise 
rational application of diagnostic criteria and advise consensus case definitions to be used to 
aid in comparison of studies, and to improve scientific communication and patient care.6 The 
introduction of Xpert MTB/RIF, the evolution of our understanding of TBM, and changes in 
clinical and laboratory practice have brought into question the validity of continued 
30
measurement of chloride and ADA in CSF, which were initially used as proxies for the 
presence of TBM. Clinicians still sporadically request these two tests and while they have 
been measured in many centres historically, there is contradictory evidence in the literature 
regarding their diagnostic utility.  
 
Mestrezat was the first author to proclaim that very low CSF chloride levels were 
pathognomonic of TBM.7 Subsequent papers on the topic are divided.7–10 One series of 1788 
cases of suspected meningitis found that chloride was markedly decreased in TBM, based on 
comparison of CSF levels between patients.7 Another series of three cases made a similar 
observation; that chloride was decreased to a greater degree in TBM than in other forms of 
meningitis.8 A study performed in South Africa among 148 children with meningitis 
concluded that TBM could not be distinguished from bacterial or viral meningitis, based on 
comparison of CSF chloride level, blood chloride level, and blood/CSF chloride ratio.9 
Similarly, another author pointed out that CSF glucose and protein were helpful in assessing 
the course of TBM, but that CSF chloride did not provide incremental utility.10 It emerges 
that very few papers have been published on this topic, the studies investigated small 
numbers of patients, no measures of diagnostic accuracy were calculated, descriptions of 
methodology were inadequate or absent, study populations were inaccurately described, and 




ADA gained prominence as a marker of TBM quite long after chloride. This enzyme 
catalyses the deamination of adenosine and deoxyadenosine to inosine and deoxyinosine.11,12 
Enzyme activity is increased in activated T–lymphocytes, as in the case of TB.11,12 While the 
exact mechanism accounting for increased activity in body fluids (including CSF) remains to 
be elucidated,11 it has nevertheless been the subject of many studies of diagnostic utility in 
TBM. Papers on the topic examined variable numbers of patients in various different 
settings.13–15 Not all populations were equally well described, and neither were all study 
procedures and ADA assay methods equally well outlined. For example, two small series 
found ADA to be a simple, fast, and accurate method for diagnosing TBM.13,14 One paper 
based this on a sensitivity of 87·5% and a specificity of 83·3% in a cohort of 32 patients 
(classified as TBM based on limited clinical criteria, imaging, and CSF cell count and 
chemistry – neither CSF culture nor PCR were done).13 The other paper defined a reference 
standard, but then applied this inconsistently (TB culture – but performed on fluids other 
than CSF in some cases, with cases then classified as TBM based on this and compatible 
symptoms).14 A large systematic review and meta–analysis published in 2010 gave a 
balanced overview of the results of 13 different papers on ADA in TBM, concluding that 
ADA cannot distinguish between TBM and bacterial meningitis.15 However, the authors also 
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stated that ranges of ADA levels might be useful in improving diagnosis of TBM after 
bacterial meningitis had been ruled out.15 
 
This research study sought to address the question of whether to continue offering CSF 
chloride and ADA measurement in clinical laboratory practice by way of retrospective 




A retrospective data analysis of laboratory tests on CSF specimens obtained from patients 
seen at 22 different health care facilities in the greater Cape Town Metro region and the 
Western Cape Province of South Africa was performed (Figure 1). All specimens taken and 
submitted to the laboratory between 1 January 2012 and 31 December 2014 were identified 
and screened for inclusion. To qualify for inclusion, each specimen had to have TB culture 
results as well as chloride and/or ADA results. Consecutive specimens meeting these criteria 
were identified and the corresponding patient data were captured into data collection 
spreadsheets using Microsoft Office Excel. Male and female patients of all ages (including 
children) and from all ethnic groups were included. Clinical data available were limited to 
information written on the laboratory requisition forms and thus at the discretion of 
requesting clinicians. 
 
The Human Research Ethics Committee of the Faculty of Health Sciences at the University 
of Cape Town formally approved the study protocol (HREC REF: 497/2015). A waiver of 
informed consent was granted due to the retrospective nature of the study, utilisation of 
existing, de–identified laboratory data, no immediate risk of harm, and foreseeable difficulty 
in locating such a large number of patients. 
 
Procedures 
Laboratory data were extracted from the laboratory information system (LIS) via an 
algorithm which searched the laboratory database for the term “TB culture”. Management of 
data included tabulation by year (2012/2013/2014), identification of specimens which had 
ADA or chloride or both measured, and separation of results by age for the group which had 
chloride measured. The number of ADA results was insufficient to analyse by age for this 
group. ZN stain results were recorded. Results of CSF Xpert MTB/RIF tests, HIV tests, 
CD4+ T–cell counts, and viral loads, when these were performed and available on the LIS, 
were documented. Patients who had multiple CSF specimens submitted for culture were 
identified and duplicates were excluded from analysis. In these instances the first specimen 
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received for the relevant patient was included for analysis. Specimens were processed at the 
clinical pathology laboratory located at Groote Schuur Hospital in Cape Town, South Africa. 
This is a routine diagnostic laboratory accredited to ISO 15189:2007 standards. Trained 
medical technologists perform all tests according to standard operating procedures. 
Chemistry tests were usually completed on the same day whereas TB culture results were 
dependent on time–to–positivity (TTP) which spanned days to weeks. 
 
CSF chloride was measured on the Roche Modular (P–module) automated chemistry 
analyser (Roche, Basel, Switzerland) by indirect ion–specific electrode (ISE). The 
coefficient of variation (CV) for this method in this laboratory is 1·8% at a chloride level of 
72·8 mmol/L and 1·6% at a chloride level of 107·3 mmol/L. CSF ADA was measured on the 
Cobas Integra 400 Plus instrument (Roche, Basel, Switzerland) using the Diazyme ADA 
Assay (Diazyme Laboratories, Poway, CA, USA). This is a spectrophotometric method 
based on the enzymatic deamination of adenosine to inosine. The CV for this assay is 2% at 
an ADA level of 10 U/L and 5% at an ADA level of 30 U/L. 
 
Direct ZN stains were made from centrifuged CSF specimens and examined via light 
microscopy by experienced technologists. Standard BD BACTEC MGIT 960 culture bottles 
were inoculated and incubated as per manufacturer’s instructions (Beckton Dickinson 
Microbiology Systems, Cockeysville, MD, USA). All cultures were incubated for a 
maximum of 42 days (six weeks) unless these flagged positive within this time. Positive 
cultures were removed from the instrument, aliquots of culture fluid were aspirated from 
bottles, slides of ZN stains were made of these, and the slides were examined by light 
microscopy under oil immersion for the presence of acid–fast bacilli (AFB). GenoType 
MTBDRplus96 line probe assays (Hain LifeSciences, Hehren, Germany) were used for 
organism identification and detection of the presence of common mutations conferring 
resistance to rifampicin (RIF) and isoniazid (INH). 
 
Xpert MTB/RIF assays were performed according to the manufacturer’s instructions. CD4+ 
T–cell counts were performed using the CD45–assisted pan–leucogating method as 
described by Glencross and colleagues,16 on Beckman Coulter Cytomics FC 500 MPL flow 
cytometers (Beckman Coulter, Brea, CA, USA). HIV viral load quantifications were 
performed with the Abbott RealTime HIV–1 assay (Abbott, Des Plaines, IL, USA). 
 
Data analysis 
Positive culture for MTB from CSF served as the reference standard. For analysis of chloride 
and ADA as index tests, specimens were separated into two groups based on which of the 
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two analytes were measured. Analysis of combined diagnostic accuracy was not possible, as 
only a very small number of specimens had both chloride and ADA measured. The chloride 
group was further stratified into two smaller groups based on age. Data analysis was 
performed with Stata Version 12 (StataCorp, College Station, TX, USA). Sensitivity, 
specificity, predictive values, likelihood ratios, diagnostic odds ratios, and diagnostic 
efficiency were calculated for chloride and ADA; 95% confidence intervals (CIs) were 
determined for all parameters. These measures were calculated for the chloride and ADA 
groups inclusive of all patients identified according to the inclusion criteria, and were also 
separately calculated for HIV–positive and HIV–negative subsets of patients. Receiver–
operator–characteristic (ROC) curve analysis was performed for each test to delineate the 
sensitivities and specificities at various cut–off levels. Area–under–the–curve (AUC) values 
were determined, together with their respective 95% CIs. Simple descriptive statistics were 
used to describe the study population. Non–normally distributed data were summarised by 
median and interquartile ranges (IQR). In Stata "roctab" was used for ROC curve analysis, 
"diagti" was used to calculate measures of diagnostic accuracy with CIs, and "univar" was 
used to determine medians and IQRs. 
 
Results 
The laboratory processed 60758 specimens for TB culture during the three–year study 
period. Among these there were 2531 (4·2%) CSF specimens; exclusion of duplicates (two 
or more specimens submitted for the same patient within a couple of days) yielded 2081 
(3·4%) CSF specimens. Of these, 182 (8·7%) cultured TB. Exclusion of duplicate cultures 
(more than one culture on the same patient specimen) yielded 140 (6·7%) TB culture–
positive CSF specimens. In 2012, 693 specimens were processed with 51 (7·4%) culture–
positive results, while 716 specimens were processed in 2013 with 54 (7·5%) culture–
positive, and 672 specimens were processed in 2014 with 35 (5·2%) culture–positive. 
 
Chloride was requested on 711 (34·2%) of the 2081 specimens. Of these, 44 (6%) were TB 
culture–positive. ADA was requested on 152 (7·3%) specimens, of which 20 (13%) were TB 
culture–positive. Forty-seven (2·3%) specimens had both chloride and ADA measured; only 
two (4·3%) of these were TB culture–positive. HIV results were available for two thirds of 
patients. In the CSF chloride group 215 (30%) patients were HIV positive, as were 70 (46%) 
in the CSF ADA group. Among HIV positive patients in the chloride group, median CD4+ 
T–cell count was 194 x 106/L and median viral load was 10508 RNA copies/mL; in the ADA 
group these were 174 x 106/L and 189 RNA copies/mL (Table 1). 
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Among patients 0–12 years of age, chloride was measured on 276 (38·7%) specimens; 20 
(7%) of these were TB culture–positive. Among patients 13 years and older 435 (61·2%) 
specimens had chloride measurements. There were 24 (6%) TB culture–positive results in 
this group. Only two patients (1·3%) younger than 13 had ADA measured on their CSF. 
Neither of these were TB culture–positive. A summary of true and false positive and 
negative results, as were used to calculate diagnostic accuracy measures, is presented in 
Table 2. 
 
Normal CSF chloride demonstrated very good negative predictive value across all age 
groups (Table 3), with poor positive predictive value noted. The same is true for CSF ADA. 
The prevalence of CSF culture–positive TBM was low across all the groups studied. 
Analyses of diagnostic accuracy in HIV–positive and HIV–negative subsets (Table 4 and 
Table 5) similarly show high negative predictive values and low positive predictive values 
for both tests, across all the groups. Other parameters are also similar between both subsets 
and the parent groups. 
 
ROC curve analysis for CSF chloride (Figure 2) yielded an AUC value of 0·86 (95% CI 
0·83–0·89). At the lower limit of the reference interval (120 mmol/L) the test had a good 
sensitivity of 93% but only a modest specificity of 55%, compared to TB culture. ROC 
analysis for CSF ADA (Figure 2) showed an AUC value of 0·91 (0·85–0·95). At an ADA 
level of 6 U/L (the upper limit of the reference interval) test sensitivity at 75% was less than 
that of chloride, but specificity at 89% was better. As can be seen on the ADA ROC curve, 
decreasing the upper limit of the reference interval from 6 to 3 U/L would improve test 
sensitivity from 75% to ~100%; this would also improve the test’s negative predictive value. 
 
Xpert MTB/RIF testing of CSF specimens commenced in the laboratory in May 2014. By 
the end of 2014, 115 CSF specimens had both TB culture and Xpert MTB/RIF results. 
Eleven (9·6%) of these were TB culture–positive, of which only five (45·5%) were Xpert 
MTB/RIF positive. Of 104 (90·4%) TB culture–negative specimens, two (1·9%) were Xpert 
MTB/RIF positive. 
 
Positive yield on ZN stain microscopy was low. In the CSF chloride TB culture–positive 
group (n=44) only two stains (4·5%) showed AFB; in the ADA TB culture–positive group 
(n=20) there were also two positive ZN stains (10%). Median time–to–positivity (TTP) for 
TB culture–positive specimens in the MGIT automated liquid culture system was 19 days 




In this study setting, a patient with a normal CSF chloride level was more than 99% likely 
not to have TBM; while a normal CSF ADA level conferred a probability of more than 95% 
of the absence of TBM. Stated differently, less than one case of TBM would be missed in 
every 100 patients who had normal CSF chloride levels; similarly, measuring normal CSF 
ADA (≤6 U/L) in 100 patients would have missed less than five cases of TBM (decreasing 
this cut-off to 3 U/L would improve sensitivity and negative predictive value, and increase 
ADA utility even more). Additionally, all diagnostic accuracy measures appeared very 
similar across HIV–positive and HIV–negative subsets of patients in all the groups which 
were studied. Previous studies looking at the utility of these analytes in the context of TBM 
diagnosis assessed the ability of both to prove the presence of TBM, in other words, their 
value as rule–in tests. Findings vary along a spectrum, from some authors reporting the tests 
as being very useful,7,8,12–14 to others reporting them as having no value.9,10,15,17 The data 
presented here shows poor positive predictive values for both tests in this patient population. 
This means that it cannot be assumed that a low CSF chloride or a high CSF ADA is 
diagnostic of TBM. These findings are significant because they do not support the continued 
use of CSF chloride and CSF ADA as markers for the presence of TBM. However, the high 
negative predictive values found for both tests indicate that they could be used, as part of the 
initial patient assessment, to identify patients unlikely to have TBM. Guidelines for the 
management of acute meningitis18 advise against the measurement of chloride and ADA as 
these would add little value to patient management. This may remain true in the acute 
setting, with a clear history and clinical impression, where TBM would be a less likely 
cause. While the data presented here support not using CSF chloride and ADA as proxies of 
TBM, it is proposed that they be measured in all patients where TBM is suspected, as they 
can be used to identify the absence of disease with a high degree of certainty. 
 
Mycobacterium tuberculosis causes most tuberculous CNS infections. Haematogenous 
spread from foci elsewhere in the body leads to entry of the organism into the CNS. Small 
tuberculous lesions called Rich’s foci19 develop which may be located on the meninges, the 
subpial, or subependymal surfaces of the brain or spinal cord. Subsequent growth or rupture 
of these cause different types of CNS tuberculosis. Apart from TBM, other CNS 
manifestations include encephalopathy, vasculopathy, miliary disease, space–occupying 
lesions, and various forms of spinal pathology. TBM is a very serious complication with 
significant morbidity and mortality in adults and children. It remains a challenge to diagnose 
due to the existence of varying case definitions, variable clinician experience, and few 
diagnostic laboratory tests with results not always immediately available to clinicians. In 
South Africa many patients initially present to primary– or secondary–level health care 
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facilities where they are usually seen by interns or community–service medical officers who 
lack experience in diagnosing TBM. This may lead to misdiagnosis or missed diagnoses. 
Data presented here show that almost 20% of all laboratory requisition forms contain no 
clinical information on cases (Table 1). Of the forms that do contain information, in 60–80% 
of cases there was no evidence that any form of TB (even non–CNS TB) was being 
considered clinically. Diagnostic uncertainty may be an important cause of this. Use of CSF 
chloride and ADA as first–line tests here may have prevented many of these cases 
progressing to the point of requests for expensive, time–consuming TB culture; or, as 
molecular assays are assuming more prominence, requests for expensive molecular tests. It 
may also have allowed more rational use of empiric therapy, and more appropriate referral of 
patients requiring specialist management. 
 
Rapid progress in nucleic acid amplification test (NAAT) technology has shifted the 
paradigm in TB diagnostics. The Xpert MTB/RIF is a desktop instrument which is based on 
hemi–nested real–time polymerase chain reaction (PCR) technology which detects the 
presence of MTB in clinical specimens. The assay also determines susceptibility to 
rifampicin (RIF) based on the presence of common resistance mutations. The WHO recently 
assessed the performance of Xpert MTB/RIF in the detection of MTB in CSF.5 Combined 
sensitivity across 16 studies was 79·5% (95% CI 62·0–90·2) while combined specificity was 
98·6% (95·8–99·6). Although WHO strongly recommends Xpert MTB/RIF in preference to 
conventional microscopy and culture as the initial diagnostic test in patients with presumed 
TBM, given the urgency of the diagnosis, it does admit that current evidence for this 
recommendation is of poor quality.5,20,21 A major limitation of Xpert MTB/RIF is that a 
negative result does not rule out TBM, due to relatively poor sensitivity. In fact, there are no 
rule–out tests in use in TBM diagnosis at present. The authors therefore recommend that 
CSF chloride and CSF ADA be measured at first presentation in all cases of suspected TBM 
in order to identify patients who are highly unlikely to have the disease (additionally, 
decreasing the ADA cut–off from 6 to 3 U/L would improve the sensitivity and negative 
predictive value of this test). This should prompt consideration and appropriate investigation 
for other diagnoses in the differential, unless a compelling reason or high clinical index of 
suspicion exist to suggest otherwise. An algorithm for the diagnosis of suspected TBM in 
adults and children incorporating CSF chloride and ADA measurement is presented in 
Figure 3. 
 
The authors of this study have proposed several limitations. It was performed in a 
retrospective format and yielded a small number of positive CSF TB culture results for 
analysis. Predictive values as calculated apply to the local setting and patient population, so 
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caution is advised in extrapolating results to other settings. Also, as sensitivity and 
specificity are influenced by the spectrum of disease (typically higher in patient populations 
with advanced disease, and lower in children) results in studies elsewhere may differ from 
these study results. The same applies to likelihood ratios as these are derived from sensitivity 
and specificity. Performance of the index tests were assessed exclusively against the current 
gold standard for TBM diagnosis – CSF culture for MTB. A composite reference standard 
was not used. Investigation of test utility22–24 in the setting of presumed TBM based on 
application of the uniform case definition criteria6 was not done. Positive predictive value for 
both chloride and ADA may in fact improve if these criteria are also applied. CSF cell count 
and CSF protein concentration were not examined in this study. These could possibly 
become topics in future projects investigating laboratory parameters in TBM diagnosis. 
Deployment of these tests at all secondary level health care facilities would be required in 
order to decrease result turn–around times and thus provide timely decision support to 
clinicians working at the coalface. 
 
In conclusion, these findings support a decision to continue offering CSF chloride and CSF 
ADA to clinicians as part of the diagnostic work–up of a patient with presumed TBM. 
However, it calls for a fundamental change in the reason why clinicians would request these 
tests in the first instance – not to prove the presence of TBM, but to provide a highly likely 
probability for its absence. [3778 words] 
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PANEL: RESEARCH IN CONTEXT 
 
Evidence before this study 
The PubMed digital archive was searched up to 17 December 2015 for papers published in 
any language. For cerebrospinal fluid chloride the search strategy used combinations of key 
terms as follows: “tuberculous meningitis” OR “TB meningitis” AND “cerebrospinal fluid 
chloride” OR “CSF chloride”. The search identified 25 papers. For cerebrospinal fluid 
adenosine deaminase the search strategy used the following combinations of key terms: 
“tuberculous meningitis” OR “TB meningitis” AND “cerebrospinal fluid adenosine 
deaminase” OR “CSF adenosine deaminase” OR “cerebrospinal fluid ADA” OR “CSF 
ADA”. This search identified 112 papers. Further papers of interest were identified via 
manual searching of the reference lists of primary papers identified through the database 
search. Papers were retrieved via the Health Sciences Library of the University of Cape 
Town. The abstracts of all papers were reviewed to critically assess the subject matter for 
content, results presented, and applicability to the topic of this research study. Suitable 
papers were then retrieved and read in full. Quality criteria applied during appraisal included 
consideration of the study methodology and whether it was adequate for the research 
question, statistical significance of results, number of papers published on the subject, 
number of study participants, choice and recruitment of participants, sample size, control of 
confounding variables, method of data analysis, and ethics considerations. The main aim was 
to identify studies reporting on the utility of one or both of CSF chloride and CSF ADA 
measurement in the context of TBM diagnosis. Preference was given to work performed in 
Southern Africa. There were no time limits applied as to when papers were published. 
 
Added value of this study 
This study describes in detail the diagnostic accuracy of CSF chloride and CSF ADA 
measurement in the presumptive diagnosis of TBM in a patient population in a developing 
country with a high burden of HIV, TB, and HIV/TB co–infection. Additionally, it confirms 
the value of the current reference interval for CSF chloride, and it suggests that changing the 
current cut–off used for CSF ADA may in fact improve the clinical utility of this test. 
 
Implications of all the available evidence 
There remains clinical utility in measuring chloride and ADA in CSF in patients with 
presumed TBM. However, the value of these two tests really lies in identifying patients who 
are unlikely to have the disease. Continued use of both as markers for the presence of TBM 




Table 1: Patient characteristics and baseline data 
 
Test CSF chloride CSF chloride CSF chloride CSF ADA 
Age group 0–12 years ≥13 years All ages All ages 
Median agea 276, 2 (1–5) 435, 37 (29–46) 711, 26 (3–39) 152, 37 (30–45) 
Sexb     
Male 174 (63%) 204 (47%) 378 (53%) 76 (50%) 
Female 102 (37%) 231 (53%) 333 (47%) 76 (50%) 
Clinical datab,c     
TB mentioned 75 (27%) 32 (7%) 107 (15%) 15 (10%) 
TB not mentioned 166 (60%) 334 (77%) 500 (70%) 109 (72%) 
No data provided 35 (13%) 69 (16%) 104 (15%) 28 (18%) 
CSF chlorideb,d     
Low (<120 mmol/L) 135 (49%) 157 (36%) 292 (41%) – 
Normal 141 (51%) 278 (64%) 419 (59%) – 
CSF ADAb,e     
High (>6 U/L) – – – 28 (18%) 
Normal – – – 124 (82%) 
ZN stain for AFBb     
Positive 1 (0·4%) 1 (0·2%) 2 (0·3%) 2 (1·3%) 
Negative 250 (90·6%) 381 (87·6%) 631 (88·7%) 130 (85·5%) 
No result found 25 (9·0%) 53 (12·2%) 78 (11·0%) 20 (13·2%) 
TB cultureb     
Positive 20 (7%) 24 (6%) 44 (6%) 20 (13%) 
Negative 256 (93%) 411 (94%) 667 (94%) 132 (87%) 
CSF Xpert MTB/RIFb n=11 n=17 n=28 n=11 
Positive 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Negative 11 (100%) 17 (100%) 28 (100%) 11 (100%) 
HIV statusb     
Positive 39 (14%) 176 (40%) 215 (30%) 70 (46%) 
Negative 133 (48%) 125 (29%) 258 (36%) 33 (22%) 
No result found 104 (38%) 134 (31%) 238 (34%) 49 (32%) 
CD4+ T–cell counta,f 31, 463 (184–1007) 177, 171 (59–333) 208, 194 (78–380) 51, 174 (60–352) 
Viral loada,g 30, 91308 (1793–670000) 46, 1160 (40–180000) 76, 10508 (69–220000) 23, 189 (40–110000) 
 
aData shown are: number of patients, median (interquartile range). 
bData shown are: number of patients (%). 
cAny consideration of TB written on the laboratory requisition form was recorded as such. 
dLaboratory reference interval for CSF chloride: 120–130 mmol/L (all ages). 
eLaboratory reference interval for CSF ADA: ≤ 6 U/L (all ages). 
fLaboratory reference interval for CD4+ T–cell count: 500–2010 x 106/L (all ages). 
gUnits for viral load: RNA copies/mL. 
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Table 2: Summary of results used to calculate diagnostic accuracy measures 
 
Test Group Subset Number of patients True positive True negative False positive False negative 
CSF chloride 0–12 years All patients n = 276 20 141 115 0 
  HIV positive patients n = 39 1 22 16 0 
  HIV negative patients n = 133 6 73 54 0 
CSF chloride ≥13 years All patients n = 435 21 275 136 3 
  HIV positive patients n = 176 10 105 58 3 
  HIV negative patients n = 125 5 81 39 0 
CSF chloride All ages All patients n = 711 41 416 251 3 
  HIV positive patients n = 215 11 127 74 3 
  HIV negative patients n = 258 11 154 93 0 
CSF ADA All ages All patients n = 152 14 118 14 6 
  HIV positive patients n = 70 7 55 5 3 




Table 3: Measures of diagnostic accuracy for CSF chloride and CSF ADA 
 
Test CSF chloride CSF chloride CSF chloride CSF ADA 
Age group 0–12 years (n=276) ≥13 years (n=435) All ages (n=711) All ages (n=152) 
Prevalencea,b 7·2% (4·5–11) 5·5% (3·6–8·1) 6·2% (4·5–8·2) 13% (8·2–19·6) 
Sensitivityb 100% (83·2–100) 87·5% (67·6–97·3) 93·2% (81·3–98·6) 70% (45·7–88·1) 
Specificityb 55·1% (48·8–61·3) 66·9% (62·1–71·4) 62·4% (58·6–66·1) 89·4% (82·8–94·1) 
PPVb,c 14·8% (9·29–21·9) 13·4% (8·47–19·7) 14% (10·3–18·6) 50% (30·6–69·4) 
NPVb,c 100% (97·4–100) 98·9% (96·9–99·8) 99·3% (97·9–99·9) 95·2% (89·8–98·2) 
LR+d,e 2·23 (1·94–2·55) 2·64 (2·16–3·24) 2·48 (2·18–2·81) 6·6 (3·72–11·7) 
LR–d,e 0 0·187 (0·065–0·54) 0·109 (0·037–0·326) 0·336 (0·171–0·657) 
Diagnostic efficiency 58·3% 68% 64·3% 86·8% 
DORd,e ∞ 14·2 (4·41–45·2) 22·7 (7·36–69·7) 19·7 (6·66–57·9) 
Area under the ROC curvef,g – – 0·86 (0·83–0·89) 0·91 (0·85–0·95) 
 
aPrevalence of CSF TB culture–positive TBM. 
bData shown are: % (95% confidence interval). 
cPPV: positive predictive value; NPV: negative predictive value. 
dLR+: positive likelihood ratio; LR–: negative likelihood ratio; DOR: diagnostic odds ratio. 
eData shown are: ratio (95% confidence interval). 
fData shown are: fraction (95% confidence interval). 




Table 4: Accuracy of CSF chloride and CSF ADA in HIV–positive subsets 
 
Test CSF chloride CSF chloride CSF chloride CSF ADA 
Age group 0–12 years (n=39) ≥13 years (n=176) All ages (n=215) All ages (n=70) 
Prevalencea,b 2·6% (0·07–13·5) 7·4% (4–12·3) 6·5% (3·6–10·7) 14% (7·1–24·7) 
Sensitivityb 100% (2·5–100) 76·9% (46·2–95) 78·6% (49·2–95·3) 70% (34·8–93·3) 
Specificityb 57·9% (40·8–73·7) 64·4% (56·6–71·7) 63·2% (56·1–69·9) 91·7% (81·6–97·2) 
PPVb,c 5·88% (0·15–28·7) 14·7% (7·28–25·4) 12·9% (6·64–22) 58·3% (27·7–84·8) 
NPVb,c 100% (84·6–100) 97·2% (92·1–99·4) 97·7% (93·4–99·5) 94·8% (85·6–98·9) 
LR+d,e 2·38 (1·64–3·45) 2·16 (1·5–3·11) 2·13 (1·54–2·96) 8·4 (3·31–21·3) 
LR–d,e 0 0·36 (0·13–0·97) 0·34 (0·12–0·93) 0·33 (0·13–0·85) 
Diagnostic efficiency 59% 65·3% 64·2% 88·6% 
DORd,e ∞ 6·03 (1·71–21·1) 6·29 (1·82–21·6) 25·7 (5·34–123) 
 
aPrevalence of CSF TB culture–positive TBM. 
bData shown are: % (95% confidence interval). 
cPPV: positive predictive value; NPV: negative predictive value. 
dLR+: positive likelihood ratio; LR–: negative likelihood ratio; DOR: diagnostic odds ratio. 




Table 5: Accuracy of CSF chloride and CSF ADA in HIV–negative subsets 
 
Test CSF chloride CSF chloride CSF chloride CSF ADA 
Age group 0–12 years (n=133) ≥13 years (n=125) All ages (n=258) All ages (n=33) 
Prevalencea,b 4·5% (1·7–9·6) 4% (1·3–9·1) 4·3% (2·1–7·5) 9·1% (1·9–24·3) 
Sensitivityb 100% (54·1–100) 100% (47·8–100) 100% (71·5–100) 100% (29·2–100) 
Specificityb 57·5% (48·4–66·2) 67·5% (58·3–75·8) 62·3% (56–68·4) 83·3% (65·3–94·4) 
PPVb,c 10% (3·8–20·5) 11·4% (3·8–24·6) 10·6% (5·4–18·1) 37·5% (8·52–75·5) 
NPVb,c 100% (95·1–100) 100% (95·5–100) 100% (97·6–100) 100% (86·3–100) 
LR+d,e 2·35 (1·92–2·88) 3·08 (2·38–3·98) 2·66 (2·26–3·12) 6 (2·7–13·4) 
LR–d,e 0 0 0 0 
Diagnostic efficiency 59·4% 68·8% 64% 84·8% 
DORd,e ∞ ∞ ∞ ∞ 
 
aPrevalence of CSF TB culture–positive TBM. 
bData shown are: % (95% confidence interval). 
cPPV: positive predictive value; NPV: negative predictive value. 
dLR+: positive likelihood ratio; LR–: negative likelihood ratio; DOR: diagnostic odds ratio. 
eData shown are: ratio (95% confidence interval). 
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TB culture  
positive 
n = 41 
TB culture  
negative 
n = 251 
TB culture  
positive 
n = 3 
TB culture  
negative 
n = 416 
TB culture  
positive 
n = 14 
TB culture  
negative 
n = 14 
TB culture  
positive 
n = 6 
TB culture  
negative 
n = 118 
Total specimens 
for TB culture 
n = 60758 
CSF specimens 
for TB culture 
n = 2081 
Total CSF specimens 
with chloride measured 
n = 711 
Low chloride 
n = 292 
Normal chloride 
n = 419 
High ADA 
n = 28 
Normal ADA 
n = 124 
Total CSF specimens 
with ADA measured 
n = 152 
Excluded all specimens 
other than CSF 
n = 58227 
Figure 1: Study profile 
Total CSF specimens 
for TB culture 
n = 2531 
Excluded all duplicate 
CSF specimens 
n = 450 
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1 - Specificity 
CSF chloride [Area-under-the-curve = 0.86 (95% CI 0.83-0.89)]:
Current cut-off = 120 mmol/L, sensitivity = 93%, specificity = 55%
118 mmol/L, sensitivity = 91%, specificity = 69%
116 mmol/L, sensitivity = 91%, specificity = 76%
113 mmol/L, sensitivity = 80%, specificity = 84%
CSF ADA [Area-under-the-curve = 0.91 (95% CI 0.85-0.95)]:
Current cut-off = 6 U/L, sensitivity = 75%, specificity = 89%
5.5 U/L, sensitivity = 80%, specificity = 89%
3.5 U/L, sensitivity = 95%, specificity = 82%
3 U/L, sensitivity = 100%, specificity = 75%
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Suspect TBM after consideration 
of risk factors and clinical 
assessment for symptoms and 
signs of TBM 
Figure 3: Diagnostic algorithm for suspected TBM in adults and children 
(Adapted from Reference 1) 
TBM possible but not proven 
Process CSF further: 
1. ZN stain 
2. TB culture 
3. Xpert MTB/RIF 
Further management: 
According to published guidelines 
(See Reference 1) 
TBM unlikely 
Further management: 
Consider other diagnoses in the 
differential 
Investigate, treat, and/or refer as 
appropriate 
Risk factors for CNS TB: 
1. High prevalence setting 
2. Recent TB contact 
3. HIV infection 
4. Other immunocompromise 
5. Infant or young child 
6. Socio-economic status 
7. Parental education level 
8. Alcoholism 
9. Diabetes mellitus 
10. Malignancy 
11. Recent steroid use 
Symptoms and signs of TBM: 
1. Insidious onset of  fever and 
neurological abnormality 
2. Headache 
3. Poor feeding, vomiting 
4. Weight loss 
5. Irritability, lethargy 
6. Seizures (more in children) 
7. Confusion, coma 
8. Neck stiffness 
9. Cranial nerve palsies 
10. Hemiparesis 
Immediate investigations: 
1. Full blood count 
2. Urea, electrolytes 
3. Liver function tests 
4. Plasma glucose 
5. CRP, ESR 
6. Blood culture 
7. HIV test 
8. Chest X-ray 
9. CT head with contrast* 
Lumbar puncture (LP): 
1. Cell count 
2. Gram stain, culture, sensitivity 
3. Protein, glucose 
4. Cryptococcal antigen test 
Also immediately perform on CSF: 
1. Chloride level (less than 120 mmol/L?) 
2. ADA level (more than 3 U/L?) 
Any yes Both no 
*Note: 
CT head can be 
performed after the 
LP if there are no 
clinical contra-
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UNIVERSITY OF CAPE TOWN 
 
FACULTY OF HEALTH SCIENCES 
 
MMed Part III (minor dissertation) 
Guidelines for candidates, supervisors and examiners 
 
The MMed minor dissertation is one of three examination components of the MMed degree. This 
minor dissertation carries one third of the weight of a full master’s dissertation in terms of its credit 
weighting, i.e. 60 credits which approximate 600 hours of work. In order to register as a specialist in 
South Africa, the Health Professions Council of South Africa (HPCSA) requires all specialist trainees 
who register for training after 1 January 2011 to have completed a relevant research study. 
 
The dissertation must be the result of independent work of the candidate conducted under the 
guidance and direction of a supervisor(s) and should demonstrate evidence of an ability to undertake 
research, to interpret results adequately and to review the relevant literature comprehensively and 
critically. Although the research need not necessarily be original, the findings must be seen to 
advance scientific understanding. A case report is not acceptable for the dissertation, as it cannot 
meet these requirements but an unusual case series may, in some circumstances be accepted. A full 
systematic review following the format recommended by the Cochrane Collaboration is acceptable. 
The topic, study design and scope of research will depend on the particular discipline and must be 
agreed on in consultation with the supervisor(s).  
 
The dissertation may be presented in one of two formats: 
I:  Publication-ready format; 
II:  Monograph format. 
As disciplines differ in their requirements, it is important that the format chosen is acceptable to the 




Candidates intending to register for the MMed Part III are required to submit a full research protocol 
for approval to their respective Departmental Research Committees (DRC). The candidate must then 
obtain approval from the UCT Faculty of Health Sciences Research Ethics Committee (HREC) prior to 
conducting their research. Studies that involve the audit of clinical records or services also require 
formal REC approval.  Any primary research that is taking place in a provincial or local authority 
health facility, such as public sector hospitals or clinics, must also be submitted to the provincial 
government for approval, after the UCT Research Ethics Committee approval has been obtained. 
Approval to access public sector facilities for research is needed for all provincial and local 
authority facilities. There are five points where approval for research can be applied for; Groote 
Schuur Hospital, Red Cross War Memorial Children’s Hospital, Tygerberg Hopsital), the local 
authorities and "all other province". Teaching hospitals and the local authorities approve research 
projects in-house. "All other province" approvals are done via the Directorate: Health Impact 
Assessment (Sub-directorate: Research) at provincial head office. If research crosses these 
boundaries, up to five approvals may be needed. Further details can be found at 
http://www.capegateway.gov.za/other/2011/3/phrc_approval_guidelines_november_2010.pdf. The 
Provincial Health Research Committee does not approve research proposals itself, but oversees this 
approval process by reviewing difficult applications on referral. 
  
The research protocol should specifically and accurately outline the scope and content of the 
dissertation and must include the title of the proposed dissertation, name of the supervisor(s) 
and their brief curriculum vitae. The protocol should be structured according to the guidelines 
in Form FHS015, available at http://www.health.uct.ac.za/research/humanethics/forms. This full 
research protocol together with a copy of the REC approval letter and completed Form D1 
must be submitted to the postgraduate administration office, for approval by the Professional 
Masters Committee Chair and the Board of the Faculty of Health Sciences, prior to 
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commencement of the research.  If the title, aims, objectives or any other aspect of the 
research change following initial submission, an ammendment must be submitted to HREC. 
Timelines	  	  
 
Submission of the research protocol for approval should generally be made within the first 18 months 
of the registrar programme (this varies between disciplines). Heads of Departments or Divisions 
should meet with their registrars at least annually to review progress towards their research project. 
Unless otherwise stipulated by your Division / Department or constituent College of the CMSA, the 
research project should generally be completed by the end of Year 2. For a number of constituent 
Colleges, the dissertation must be submitted 6-months before writing the Part II examination. Often 
the research component of specialist training is only initiated after successful completion of the Part I 
examination. 
 
Supervisors	  	  	  
The importance of identifying a dissertation supervisor as early as possible cannot be 
overemphasized.  The supervisor should be an individual who can relate to the candidate’s research 
project, be available for frequent and regular discussion and advice, and someone with whom the 
candidate can develop a good working relationship. Where specialised equipment and/or laboratory 
work is required for the study, the supervisor should assist in facilitating access to appropriate 
facilities.  
The primary supervisor may be based outside the candidate’s home department, faculty or university. 
In such a case, an internal (co-)supervisor will also be required in addition to the primary supervisor, 
to serve as a guide and link to UCT faculty and discipline-specific procedures. Primary supervisors 
retain responsibilities to the candidate and the university until the dissertation process is complete. 
The supervisor and student must complete form D3 (supervisor appointment form) and D2a which 
describes the contractual memorandum of agreement (MOU) between supervisor and student. 
 
In order to assist a candidate with a master’s research topic the supervisor should hold a master’s 
degree or equivalent (such as a Fellowship of one of the constituent Colleges of the CMSA), and have 
relevant research experience. If the primary supervisor does not hold such a higher qualification, then 




Submission of the dissertation should include the following:   
The title page should contain the candidate’s name, dissertation title and the name of the university. 
It must also state the degree, e.g. Master of Philosophy (MPhil) in, Pulmonology, Cardiology, etc.  
       
 The Table of contents 
The declaration page should include a statement to the effect that the research reported is based on 
independent work performed by the candidate and that neither the whole work nor any part of it has 
been, is being, or is to be submitted for another degree to any other university. It must also state that 
this work has not been reported or published prior to registration for the abovementioned degree.  
 
The abstract should summarise the study rationale, methods, results, discussion and conclusion in 
fewer than 500 words.  
 
Acknowledgements. This section should acknowledge the support or input from supervisors and 
briefly describe the role of potential co-authors. In a dissertation derived from work started by others, 
e.g. analysis of data collected for another project, the candidate’s contribution must have been made 
after his/her registration for the degree and therefore under supervision. In a manuscript from a 
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potentially multi-authored project, the candidate must be first author 
 
List of Tables 
List of Figures 
Abbreviations 
 
The remainder of the dissertation may be presented in one of two formats: 
I:  Publication-ready format; 
II:  Monograph format. 
 
I:	  	  Publication	  format	  
 
The dissertation must include a manuscript in publication-ready format. A manuscriot that has already 
been published can be included if the candidate’s contribution was made during his/her registration 
for the degree and under supervision.  The body of the dissertation must be structured as follows:  
 
Chapter 1: Introduction and Literature review 
 
This section must contain a structured and comprehensive review of the literature relevant to the 
subject matter and methods of the study. The literature review must show that the student is 
sufficiently acquainted with, and is able to conduct a critical appraisal of the relevant literature. Where 
relevant, the student should demonstrate a good understanding of evidence-based medicine. The 
review should summarise and interpret the existing knowledge in the field with relevance to the 
research setting and should identify knowledge gaps and hence the rationale for the dissertation. This 
chapter should end with a clear statement reflecting the aims and objectives of the research reported 
in the publication-ready manuscript. References quoted in this chapter should appear at the end of 
the chapter, not at the end of the thesis. This chapter should be between 3 000 and 4 000 words.  
 
Chapter 2: Publication-ready Manuscript 
 
The method and results of the study must be presented in the form of a manuscript of an article for a 
named peer reviewed journal, meeting all the requirements set out in the “Instructions for Authors” of 
that journal, including the word count and referencing style. Unless specially motivated, the journal 
chosen will need to allow for at least 3000 words excluding abstract, tables, figures and references. 
The “Instructions to Authors” of the journal must be appended. The co-authors should be listed in the 
appropriate order, and each of their contributions to the manuscript stated. The journal chosen for 
publication must be appropriate to the subject matter of the dissertation and listed in the citation index 
of the Institute for Scientific Information (ISI) or accredited by the Department of Education:  
(http://www.lib.uct.ac.za/medical/index.php?html=/libs/accredjnls.htm&libid=24) 
 
Important note: The candidate need not have submitted the article for publication, nor is the 
acceptance of the article for publication a requirement for passing the degree. However, the norm is to 
publish the study with the supervisor(s) as co-author(s), and candidates are strongly encouraged to 
submit their manuscript for publication either before or shortly after examination of the minor 
dissertation. Submitting the manuscript for publication before submitting the minor dissertation has the 
advantage that addressing the peer reviewers’ comments improves the standard of the manuscript 
included in the dissertation. A candidate who fails to submit a manuscript for publication within one 
year of examination of the minor dissertation must accept that their supervisor(s) may publish their 
data with him/her as co-author.  
 
For a full systematic review, Chapters 1 and 2 are combined in the publication-ready manuscript. 
Appendices  
Append all supporting documents including:  
• Questionnaire/data capture instrument(s)  
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• Technical appendices, including, if considered necessary, any additional tables not included 
in the main manuscript for the examiner to have available. These should be accompanied by 
a brief narrative.  
• Official Ethics approval letter from the Faculty Research Ethics Committee and any other 
approvals required (e.g. Provincial Government). 
• Instructions to Authors of the chosen journal 
II:	  	  Standard	  monograph	  format	  
 
Some disciplines and constituent Colleges of the CMSA require a standard monograph format, which 
should be 16 000 to 20 000 words in length, and presented in a comprehensive and scholarly style.  
 
A recommended structure for the body of the dissertation is as follows; 
 
Chapter 1: Introduction and Literature review 
(see guidelines above) 
 
Chapter 2: Methods 
Material and methods of the study must be fully described and factually presented and must evidence 
familiarity with the laboratory and/or clinical methods used 
 
Chapter 3: Results 
 
Chapter 4: Discussion and conclusions 
Appendices  
(see guidelines above - omit the instructions to authors) 
Language	  and	  writing	  
 
Clear, grammatically correct English is essential.  
 
Supervisors may assist candidates in developing scientific communication skills but they are not 
required to do detailed editing or correction of spelling, grammar, or style. They may refer candidates 
elsewhere for this, at the candidate’s own expense. Candidates who may have difficulties are 
encouraged to seek help from the writing support facilities on main campus (see: 
http://www.ched.uct.ac.za/adp/writing/). 
 
Candidates should refer to the document D4, Guidelines on the Layout and Style of the Dissertation 
or Thesis. As long as the dissertation is readable and internally consistent, any of a number of styles 
is acceptable. For a publication-ready manuscript, references should be formatted according to the 
instructions to authors for the journal selected, and candidates should use the same style throughout 
their dissertation. For a monograph format manuscript, the Harvard style for referencing is 
recommended. In this style, referencing is by first author in parentheses in the text and the 
bibliography is listed alphabetically (rather than using numerical superscripts in the text)For reference 
management, Refworks can be downloaded from the ICTS or UCT library websites.  
 
It is suggested that candidates look at previous examples of Master’s dissertations in the library for 
appealing layouts. Master’s dissertations are available in the Health Sciences Library. A search will 
need to be done to obtain a list of titles and authors. This search can be done using search words 
(e.g. dissertation, health, health sciences, etc.). The librarian should be asked for assistance.  
 
Some of these dissertations are available online at: 
http://srvrhldig001.uct.ac.za/R/R3CAKV8FM3PHV23A363D7J4F947AN4AXGRBTHIPM2L62RSUXD
M-02943?func=collections&collection_id=1526 but this site does not yet differentiate MMed, MPhil 
and MSc dissertations within the faculty of Health Sciences, so candidates will have to open each 
dissertation to identify whether it is relevant to their minor dissertation.  
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Submission	  of	  dissertations	  
 
On completion, the dissertation should be submitted to the Faculty Postgraduate Office. The 
candidate should inform the Faculty Officer one month in advance of the intention to submit, using 
Form D8 (Intention to submit). Supervisors will be requested by the Faculty Postgraduate Officer to 
submit a letter supporting submission, and clearly specifying whether the dissertation will be 
submitted in a “Publication-ready” or “Monograph” format, so that the appropriate instructions are sent 
to the examiners. This letter should be supplied by the primary supervisor. If this supervisor is 
external, the internal supervisor must be kept informed at every stage of the process.  
 
The candidate must submit 2 copies of the dissertation, in temporary binding (e.g. plastic ring) and an 
electronic copy in a universally readable format (e.g. pdf) on a compact disc. The candidate must 
clearly state which of the formats has been chosen (“Publication-ready” or “Monograph”), so that the 
appropriate instructions are sent to the examiners. Specific submission requirements may be set by 
individual disciplines or constituent Colleges of the CMSA, and registrars are obliged to ensure that 
their research projects and dissertations meet these specific requirements.  
 
UCT Dissertation Submission deadlines: 
1. March 15th for June graduation 
2. August 15th for December graduation 
 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the beginning of the 
first quarter (first day of academic year), and before the start of the second semester (mid July) to 
qualify for a 50% fee rebate. 
 
Examiners 
The full dissertation will be submitted for examination through the Postgraduate Office of our Faculty 
to two external examiners (nominated by the supervisors and HOD).  
It is the supervisors’ responsibility to submit names of three potential examiners to the Faculty Officer 
when the candidate is ready to submit. Of the three examiners nominated, two are invited to examine, 
and one is held as an alternate. All examiners must all be external to UCT, and appointment of 
examiners from outside South Africa is encouraged. These nominations need to be approved by the 
Deputy Dean: Postgraduate Affairs on behalf of the Faculty Board and submitted to the Faculty Board 
for ratification via a Dean’s Circular.  
The examiners will be well briefed regarding the specific requirements and criteria for submission and 
examination of the minor dissertation. Such criteria will clearly explain the difference between the 
minor dissertation and a Master’s degree by dissertation alone, and between the monograph and the 
“publication-ready” format of dissertation. Details required for each examiner are: academic 
qualifications, postal and/or physical address, telephone and fax numbers and e-mail address, and 
one paragraph description of their standing in the relevant field (drawn from their CV if need be.) 
The candidate may not be informed of the identity of the examiners. After the outcome of the minor 
dissertation has been finalised, the examiners’ identities are made known if the examiners have 




The university has a moral responsibilty to publish all research undertaken when publication is stated 
as an anticipated output. A candidate who fails to submit a manuscript to a journal for publication 
within 1 year of submission of their thesis, must accept that their supervisor(s) are entitled to publish 
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Dear Dr Wojno 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Old Main Building 
Groote Schuur Hospital 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
Email: shuretta.thomas@uct.ac.za 
Website: www.hea1th.uct.ac.za/fhs/research/humanethics/forms 
PROJECT TITLE: UTILITY OF CHLORIDE AND ADENOSINE DEAMINASE MEASUREMENT IN 
CEREBROSPINAL FLUID FOR THE EARLY PRESUMPTIVE DIAGNOSIS OF TUBERCULOUS 
MENINGITIS (Masters-candidate-Dr H Swanepoel) 
Thank you for submitting your study to the Faculty of Health Sciences Human Research Ethics 
Committee. 
It is a pleasure to inform you that the HREC has formally approved the above-mentioned study. 
Approval is granted for one year until the 30th July 2016. 
Please submit a progress form, using the standardised Annual Report Form If the study continues 
beyond the approval period. Please submit a Standard Closure form if the study is completed within 
the approval period. 
(Forms can be found on our website: www.health.uct.ac.za/fhs/research/humanethics/forms) 
Please quote the HREC REF in all your correspondence. 
We acknowledge that the student, Dr Hendre Swanepoel will also be involved in this study. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Yours sincerely 
PROFESSOR M BLOCKMAN 
CHAIRPERSON. FHS HUMAN RESEARCH ETHICS COMMITTEE 
Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of Cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Clinical Research with a new drug in patients, based on the Medical 
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), International Convention on 
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How to submit your paper 
Manuscript submission 
Manuscript submission to all Lancet journals is free. Manuscripts 
should be submitted online via the The Lancet Infectious Diseases’ 





EES,	 the	 corresponding	 author	 is	 the	 person	 who	 enters	 the	
manuscript	details	and	uploads	the	submission	files
•	 Inclusion	of	illustrations	(photographs,	graphs,	diagrams,	etc)	
is	 a	 prerequisite	 for	 publication.	 Submission	 of	 original	 and	
editable	artwork	files	 is	encouraged.	Digital	photography	files	
should have a resolution of at least 300 dpi and be at least 
107 mm wide
•	 In	almost	all	cases,	if	you	have	a	finished	manuscript,	you	should	
submit	it,	rather	than	contacting	The Lancet Infectious Diseases to 
enquire	whether	an	unseen	manuscript	is	 likely	to	be	accepted.	
Unless	you	have	been	asked	by	the	Editor	to	submit	by	email,	you	
should	 use	 the	 online	 system	 for	 all	 types	 of	 submission,	
including	Correspondence
•	 If	you	have	any	technical	problems	or	questions,	please	contact	
our	 dedicated	 customer	 support	 (available	 24	 h	 a	 day,	
365	days	a	year):
For the Americas: +1 888 834 7287 (toll-free in USA 
and	Canada)
For	Asia	and	Pacific:	+81	3	5561	5032
For Europe and rest of the world: +353 61 709190
Email: IDeditorial@lancet.com
Covering letter
•	 You	 should	 upload	 your	 covering	 letter	 at	 the	
“Enter	Comments”	stage	of	the	online	submission	process
•	 Use	 the	 covering	 letter	 to	 explain	why	your	 paper	 should	 be	
published in The Lancet Infectious Diseases—the	 leading	
international infectious diseases journal—rather than 
elsewhere
•	 It	 is	helpful	to	indicate	what	could	shorten	your	paper—the	full	
paper can be reviewed and a shorter version published; a table or 
figure,	 details	 of	 a	 DNA	 sequence,	 or	 further	 references,	 for	
example,	 can	 be	 published	 on	 our	 website	 or	 made	 available	
from the authors







•	 The Lancet Infectious Diseases	will	not	publish	any	paper	unless	we	
have	the	signatures	of	all	authors
•	 We	 suggest	 you	 use	 the	 author statement form and either 
upload	 the	 signed	 copy	 with	 your	 submission,	 or	 fax	 to	





a	 primary	 interest	 (such	 as	 patients’	welfare	or	 validity	of	 research)	
may	 be	 influenced	 by	 a	 secondary	 interest	 (such	 as	 financial	 gain).	
Recommendations for the 
Conduct, Reporting, Editing, 
and Publication of Scholarly 
Work in Medical Journals 
http://www.icmje.org
COPE Code of Conduct 
http://publicationethics.org/
files/u2/New_Code.pdf
The Lancet Infectious Diseases considers any original research contribution that advocates change in or illuminates infectious disease 
clinical practice and informative reviews on any topic connected with infectious diseases. Because the journal has an international 
readership from a wide range of specialties, it is vital that articles should be written clearly and should not assume a level of knowledge 
above that of, say, a reasonably well-read, recently qualified, doctor in training. One way to find out if your article is understandable 
to those reading outside their immediate field of interest is to show the manuscript to colleagues in other specialties. If they find it 
difficult to follow, so will a good proportion of the readership. Wherever possible, figures and good quality photographs (colour or 
black and white) should be used to supplement and to enhance the text. Further details on the different sections of The Lancet 
Infectious Diseases, and how to submit to the journal, are provided below. If you require further clarification, the journal’s editorial 
staff will be pleased to help (email IDeditorial@lancet.com).
Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be 
under consideration by another journal. The Lancet journals are signatories of the Recommendations for the Conduct, Reporting, 
Editing, and Publication of Scholarly Work in Medical Journals, issued by the International Committee of Medical Journal Editors 
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Financial	 relationships	 are	 easily	 identifiable,	 but	 conflicts	 can	 also	
occur	 because	 of	 personal	 relationships	 and	 rivalries,	 academic	
competition,	 or	 intellectual	 beliefs.	 A	 conflict	 can	 be	 actual	 or	
potential,	and	full	disclosure	to	the	Editor	is	the	safest	course.	Failure	
to	disclose	conflicts	might	lead	to	publication	of	a	correction	or	even	
to retraction. All submissions to The Lancet Infectious Diseases must 
include disclosure of all relationships that could be viewed as 
presenting	 a	 potential	 or	 actual	 conflict	 of	 interest	 (see	
Lancet 2001; 358: 854–56 and Lancet 2003; 361: 8–9).	The	Editor	may	
use	such	information	as	a	basis	for	editorial	decisions,	and	will	publish	
such	 disclosures	 if	 they	 are	 believed	 to	 be	 important	 to	 readers	 in	
judging	 the	 manuscript.	 Agreements	 between	 authors	 and	 study	
sponsors	that	interfere	with	authors’	access	to	all	of	a	study’s	data,	or	
that	interfere	with	their	ability	to	analyse	and	interpret	the	data	and	to	
prepare	 and	 publish	 manuscripts	 independently,	 may	 represent	
conflicts	of	interest,	and	should	be	avoided.
•	 At	 the	 end	 of	 the	 text,	 under	 a	 subheading	 “Declaration	 of	
interests”,	 all	 authors	 must	 disclose	 any	 financial	 and	 personal	
relationships	 with	 other	 people	 or	 organisations	 that	 could	
inappropriately	 influence	 (bias)	 their	work.	 Examples	 of	 financial	
conflicts	 include	 employment,	 consultancies,	 stock	 ownership,	
honoraria,	 paid	 expert	 testimony,	 patents	or	 patent	 applications,	
and	travel	grants,	all	within	3	years	of	beginning	the	work	submitted.	
If	there	are	no	conflicts	of	interest,	authors	should	state	that
•	 All	 authors	 are	 required	 to	 provide	 a	 Conflict	 of	 Interest	




form	 has	 been	 modified	 by	 the	 ICMJE	 following	 consultation	
with authors and editors. Further information is available in a 
joint	 ICMJE	 statement	 published	 on	 July	 1,	 2010.	 For	 more	
information see Lancet 2009; 374: 1395–96
•	 For	Comment	and	Reviews,	The Lancet Infectious Diseases will not 
publish	if	an	author,	within	the	past	3	years,	and	with	a	relevant	
company	 or	 competitor,	 has	 any	 stocks	 or	 shares,	 equity,	 a	
contract	 of	 employment,	 or	 a	 named	 position	 on	 a	 company	
board;	 or	 has	 been	 asked	 by	 any	 organisation	 other	 than	
The Lancet Infectious Diseases	to	write,	be	named	on,	or	to	submit	
the paper (see Lancet 2004; 363: 2–3)
Role of the funding source





interpretation	of	data;	 in	 the	writing	of	 the	 report;	 and	 in	 the	
decision to submit the paper for publication





the decision to submit for publication







•	 We	 require	 signed	 statements	 from	 any	 medical	 writers	 or	
editors	 declaring	 that	 they	 have	 given	 permission	 to	
be	 named	 as	 an	 author,	 as	 a	 contributor,	 or	 in	 the	
Acknowledgments	section
Patient and other consents
•	 Appropriate	written	consents,	permissions,	and	releases	must	be	
obtained	where	you	wish	 to	 include	 any	 case	details,	 personal	
information,	 and/or	 images	of	 patients	or	other	 individuals	 in	
The Lancet	 journals	 in	order	 to	 comply	with	 all	 applicable	 laws	
and	 regulations	 concerning	privacy	and/or	 security	of	personal	
information. Studies on patients or volunteers need approval 




sample	 forms;	 this	 is	 your	 responsibility.	 Your	 affiliated	
institution should be able to provide an appropriate form
•	 For	 the	 purposes	 of	 publishing	 in	 The Lancet	 journals,	 a	
consent,	 permission,	 or	 release	 should	 include,	 without	
limitation,	 publication	 in	 all	 formats	 (including	 print,	
electronic,	 and	 websites),	 in	 sublicensed	 and	 reprinted	
versions	 (including	 translations),	 and	 in	 other	 works	 and	
products
•	 To	 respect	 your	 patient’s	 and	 any	 other	 individual’s	 privacy,	
please	do	not	send	signed	forms	to	The Lancet Infectious Diseases. 
Please instead complete the patient consent section of the 
Author statements	while	retaining	copies	of	the	signed	forms	in	
the	event	they	should	be	needed
•	 If	 consent,	 permission,	 or	 release	 is	 made	 subject	 to	 any	













•	 Use	 of	 copyright-protected	 material—signed	 permission	
statements from author and publisher
These	 statements	 can	 be	 scanned	 and	 submitted	 electronically	 to	
eesTheLancetID@lancet.com.	 To	 minimise	 delays,	 we	 strongly	
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Types of article and manuscript requirements
Please	 ensure	 that	 anything	 you	 submit	 to	
The Lancet Infectious Diseases	 follows	 the	 guidelines	 provided	 for	
each	article	type.	For	instruction	on	how	to	format	the	text	of	your	
paper,	 including	 tables,	 figures,	 panels,	 and	 references,	 please	 see	
our Formatting guidelines.
Red section (Articles) 
Articles
•	 The Lancet Infectious Diseases	 prioritises	 reports	 of	 original	
research	 that	 are	 likely	 to	 change	 clinical	 practice	 or	 thinking	
about a disease
•	 We	 invite	 submission	 of	 all	 clinical	 trials,	 whether	
phase	 1,	 2,	 3,	or	 4.	 For	 phase	 1	 trials,	we	 especially	 encourage	
those	of	 a	 novel	 substance	 for	 a	 novel	 indication,	 if	 there	 is	 a	
strong	or	unexpected	beneficial	or	adverse	response,	or	a	novel	
mechanism of action
•	 We	 require	the	 registration	of	 all	 interventional	trials,	whether	
early	 or	 late	 phase,	 in	 a	 primary	 register	 that	 participates	 in	
WHO’s	 International	Clinical	Trial	Registry	Platform	 (see Lancet 
2007; 369: 1909–11).	We	also	encourage	full	public	disclosure	of	
the	minimum	20-item	trial	 registration	dataset	 at	 the	time	of	
registration	and	before	recruitment	of	the	first	participant	(see	
Lancet 2006; 367: 1631–35).	The	registry	must	be	independent	
of	for-profit	interest
•	 Reports	 of	 randomised	 trials	 must	 conform	 to	
CONSORT	2010	guidelines and should be submitted with their 
protocols
•	 All	reports	of	randomised	trials	should	include	a	section	entitled	
Randomisation	 and	 masking,	 within	 the	 Methods	 section.	
Please refer to The Lancet’s	 formatting	 guidelines for 
randomised trials
•	 Cluster-randomised	 trials	 must	 be	 reported	 according	 to	
CONSORT	extended	guidelines
•	 Randomised	 trials	 that	 report	 harms	 must	 be	 described	
according	to	extended	CONSORT	guidelines
•	 Studies	 of	 diagnostic	 accuracy	must	 be	 reported	 according	 to	
STARD	guidelines
•	 Observational	 studies	 (cohort,	 case-control,	 or	 cross-sectional	
designs)	must	be	reported	according	to	the	STROBE	statement,	
and should be submitted with their protocols
•	 Studies	of	molecular	 epidemiology	 in	 infectious	diseases	must	
be	 reported	 	 according	 to	 the	 STROME-ID	 statement	 (see	
Lancet  Inf  Dis 2014; 14: 341–52)
•	 We	encourage	the	registration	of	all	observational	studies	on	a	
WHO-compliant	registry	(see	Lancet 2010; 375: 348)
•	 Genetic	 association	 studies	 must	 be	 reported	 according	 to	
STREGA	guidelines
•	 Meta-analyses	 must	 be	 reported	 according	 to	 PRISMA	
guidelines
•	 To	 find	 reporting	 guidelines	 see:	 http://www.equator- 
network.org
All Articles should, as relevant:
•	 Be	up	to	3000	words	with	30	references
•	 Include	 an	 abstract	 (semistructured	 summary),	 with	 five	
paragraphs	 (Background,	 Methods,	 Findings,	 Interpretation,	
and	 Funding),	 not	 exceeding	 250	 words.	 Our	 electronic	
submission	system	will	ask	you	to	copy	and	paste	this	section	at	
the	“Submit	Abstract”	stage
•	 For	 randomised	trials,	the	abstract	 should	adhere	to	CONSORT	
extensions:	abstracts	(see	Lancet 2008; 371: 281–83)
•	 For	 intervention	 studies,	 the	 abstract	 should	 include	 the	
primary	outcome	expressed	as	the	difference	between	groups	
with	 a	 confidence	 interval	 on	 that	 difference	 (absolute	




non-proprietary	 name	 (rINN)	 for	drug	 names.	 Ensure	 that	 the	
dose,	 route,	 and	 frequency	 of	 administration	 of	 any	 drug	you	
mention are correct




the	 information	 recommended	 by	 the	 MIAME	 guidelines. 
Authors	should	also	submit	their	experimental	details	to	one	of	
the	publicly	available	databases:	ArrayExpress or GEO
•	 Include	 any	 necessary	 additional	 data	 as	 part	 of	 your	
EES submission
•	 All	 accepted	 Articles	 should	 include	 a	 link	 to	 the	 full	 study	
protocol	 published	 on	 the	 authors’	 institutional	 website	
(see Lancet 2009; 373: 992 and Lancet 2010; 375: 348)
Putting research into context
•	 From	Jan	1,	2015,	all	research	papers	(apart	from	meta-analyses)	
submitted	 to	 any	 journal	 in	 The Lancet	 family	must	 include	 a	
panel	 putting	 their	 research	 into	 context	with	 previous	work,	
with	 an	 enhanced	 structure	 and	 subheadings	 compared	 with	
papers submitted before this date (see Lancet 2014; 384: 


















































of that evidence; and the pooled estimate derived from meta-
analysis	of	the	evidence,	if	appropriate.
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Blue section (Comment, Correspondence, 
Newsdesk, Media Watch, etc) 
Editorial
•	 Editorials	are	the	voice	of	The Lancet Infectious Diseases,	and	are	
written	 in-house	 by	 the	 journal’s	 editorial-writing	 team	 and	
signed	“The	Lancet	Infectious	Diseases”
Comment
•	 Commentaries	 may	 discuss	 articles	 in	 The Lancet Infectious 




•	 See	Conflicts of Interest guidelines
Correspondence
•	 Letters	 should	 be	 written	 in	 response	 to	 previous	 content	
published in The Lancet Infectious Diseases
•	 Letters	for	publication	in	the	print	journal	must	reach	us	within	
6	weeks	 of	 publication	 of	 the	 original	 item	 and	 should	 be	 no	
longer	than	400	words
•	 Only	 one	 table	 or	 figure	 is	 permitted,	 and	 there	 should	 be	 no	
more	than	five	references	and	five	authors
•	 All	 accepted	 letters	 are	 edited,	 and	 proofs	will	 be	 sent	 out	 to	
authors before publication
Newsdesk
•	 Most	 of	 the	 writers	 of	 Newsdesk	 articles	 are	 professional	
journalists,	but	an	 important	event	 in	your	country	that	might	
be	 of	 wider	 interest	 can	 be	 brought	 to	 the	 attention	 of	 our	
Newsdesk	editors	via	IDeditorial@lancet.com
Media Watch
•	 Readers	with	 an	 interest	 in	 contributing	 book,	 film,	TV,	 or	web	
reviews should contact the Editor via IDeditorial@lancet.com.	In	
general,	these	submissions	should	be	between	350	and	400	words
Corrections
•	 Any	 substantial	 error	 in	 any	 article	 published	 in	
The Lancet Infectious Diseases should be corrected as soon as 
possible.	Blame	is	not	apportioned;	the	important	thing	is	to	set	
the	record	straight




Green section (Reviews, Historical Reviews, 
Personal Views, Grand Rounds, Clinical Pictures, etc)
From	 July	 1,	 2015,	 papers	 submitted	 for	 the	Green	 section	of	 the	
journal	will	be	eligible	only	for	online	publication,	with	the	exception	
of	Clinical	Pictures	(see	Lancet Inf Dis 2015; 15: 760)
Reviews
•	 Reviews	 may	 be	 commissioned	 or	 submitted	 unsolicited,	
although	in	the	latter	case	it	would	be	wise	to	send	the	Editor	a	
one-page	outline	first	(IDeditorial@lancet.com) to ensure that a 
review	on	the	same	subject	has	not	already	been	commissioned.	





criteria”	 stating	 the	 sources	 (including	 databases,	 MeSH	 and	
free	 text	 search	 terms	 and	 filters,	 and	 reference	 lists	 from	
journals	or	books)	of	the	material	covered,	and	the	criteria	used	
to	include	or	exclude	studies.	Citations	to	papers	published	in	
non-peer-reviewed	 supplements	 are	discouraged.	 Since	these	
papers	 should	 be	 comprehensive,	 we	 encourage	 citation	 of	
publications	 in	 non-English	 languages.	An	 example	 is	 shown	
below:
•	 Systematic	 reviews	 that	 do	 not	 include	 meta-analysis	 will	 be	
considered	 under	 the	 Review	 heading	 and	 must	 be	 reported	
according	to	the	PRISMA	guidelines
•	 Reviews	 should	 be	 3000–5000	words,	with	 a	maximum	of	 150	
references.	 A	 150-word	 unstructured	 summary	 should	 be	
included.	These	papers	 should	 include	about	five	 illustrations	to	
aid the reader
Historical Reviews




•	 These	 should	 be	 around	 1500–3000	 words	 in	 length,	 with	 a	
maximum	of	75	references




the Editor (IDeditorial@lancet.com) before submission to ensure 
that the proposed topic is suitable for the journal
Grand Rounds
•	 These	use	a	brief	case	report	as	the	starting	point	for	a	review	of	
the	 patient’s	 diagnosis.	 Rather	 than	 rarity,	 we	 are	 looking	 for	









cited in those articles were reviewed. Articles published in 
English,	French,	and	German	were	included.
For The Lancet journals’ policy 
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review of the implications of the case
•	 The	 case	 report	part	of	the	text	 should	be	no	 longer	than	800	
words	 and	 the	 review	 part	 no	 longer	 than	 3000.	 Up	 to	 75	
references are allowed
•	 Consent	 for	 publication	 in	 print	 and	 electronically	 must	 be	
obtained	from	the	patient	or,	 if	this	 is	not	possible,	the	next	of	
kin before submission. See Patient and other consents
Clinical Pictures
•	 The	ideal	Clinical	Picture	provides	visual	information	that	will	be	
useful to other clinicians
•	 Clinical	 Pictures	 should	 be	 interesting,	 educational,	 and	
respectful of the patient. The Lancet Infectious Diseases is less 
interested	in	pictures	that	simply	illustrate	an	extreme	example	
of a medical condition
•	 Authors	must	 obtain	 signed	 informed	 consent	 for	 publication	








(http://webshop.elsevier.com/languageservices) to provide an 
English	translation	of	their	manuscript	for	submission
Title page
•	 A	 brief	 title,	 author	 name(s),	 preferred	 degree	 (one	 only),	
affiliation(s),	and	full	address(es)	of	the	authors	must	be	included.	













•	 Do	 not	 use	 the	 automated	 features	 of	 your	 software,	 such	 as	
hyphenation,	 endnotes,	 headers,	 or	 footers	 (especially	 for	
references).	You	can	use	page	numbering
References












“…15[tab]Saito	 N,	 Ebara	 S,	 Ohotsuka	 K,	 Kumeta	
J,	 Takaoka	 K.	 Natural	 history	 of	 scoliosis	 in	 spastic	
cerebral	palsy.	Lancet 1998; 351:	1687–[en	rule]92.”
•	 Give	 any	 subpart	 to	 the	 title	 of	 the	 article.	 Journal	 names	 are	
abbreviated in their standard form as in Index	Medicus
•	 If	there	are	six	authors	or	fewer,	give	all	six	in	the	form:
surname space initials comma
•	 If	there	are	seven	or	more	give	the	first	three	 in	the	same	way,	
followed	by	et	al








Guidelines for web extra material
All	 material	 should	 be	 submitted	 as	 one	 PDF	 (with	 numbered	
pages)	with	the	paper	and	will	be	peer	 reviewed.	Material	will	be	








•	 Main	 table	 heading	 should	 be	 in	 10	 point	Times	 New	 Roman	
font BOLD
•	 Legends	should	be	in	10	point,	single	spaced
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—Smith	 A,	 Jones,	 B,	 Clements	 S.	 Clinical	
transplantation	 of	 tissue-engineered	 airway.	
Lancet 2008; 372: 1201–09. 





•	 All	 images	 must	 have	 a	 minimum	 resolution	 of	 300	 dpi,	
width 107 mm




•	 The	 paper	 to	 which	 the	 audio	 or	 video	 clip	 relates	 should	 be	
mentioned	in	the	recording
•	 Audio	clip	and	video	files	should	be	accompanied	with	brief	text	
explaining	 the	 content	 of	 the	 audio,	 names	 of	 interviewers/
interviewees,	date	of	recording,	and	place	of	recording	if	relevant










•	 We	welcome	 your	 videos	 and	 invite	 you	 to	 submit	 any	 video	
material	(reports,	 interviews,	scans,	 imaging)	for	consideration	
in the online journal. Please ensure that all those featured in the 
video	have	given	permission	for	publication	(see	also	the	above	
section on Patient and other consents)
•	 All	video	files	can	be	submitted	alongside	your	article	in	EES
Disclosure of results before publication
•	 Presentation	of	data	at	a	scientific	meeting,	as	a	poster,	abstract,	
orally,	on	a	CD,	or	 as	 an	abstract	on	the	web	does	not	 conflict	
with submission to The Lancet Infectious Diseases
•	 As	a	member	journal	of	the	International	Committee	for	Medical	
Journal	 Editors,	 The Lancet Infectious Diseases	 does	 not	 regard	
results	that	are	posted	in	the	same	clinical	trials	registry	in	which	
primary	registration	resides	as	prior	publication,	if	the	results	are	
presented in the form of a brief structured abstract or table 
(<500	 words;	 see	 Lancet 2007; 369: 1909–11).	 However,	
presentation of results in other circumstances 
(eg,	 investors’	 meetings)	 is	 discouraged	 and	 could	 jeopardise	





•	 All	 accepted	 Articles	 will	 be	 published	 online	 (Online	 First	
Publication)	before	appearing	in	the	print	journal
•	 The	 online	 article	 does	 not	 differ	 from	 the	 version	
subsequently	 published	 in	 print	 and	 is	 citable	 by	 the	 digital	
object	 identifier	 (DOI)	 assigned	 at	 the	 time	 of	 online	
publication
•	 All	 other	 manuscripts	 will	 be	 peer-reviewed	 via	 our	 standard	
process
•	 See	Articles section for manuscript requirements
Online First publication
•	 The Lancet Infectious Diseases	 increasingly	 publishes	 articles	
online	ahead	of	print	publication.	You	will	be	informed	at	least	a	
week	in	advance	of	the	Online	First	publication	date
•	 The	 online	 article	 is	 identical	 to	 the	 version	 subsequently	
published	 in	 the	 print	 journal,	 and	 is	 citable	 by	 the	 digital	
object	 identifier	 (DOI)	 assigned	 at	 the	 time	 of	 online	
publication
How The Lancet Infectious Diseases handles your 
paper 
Acknowledgment
•	 Receipt	 of	 your	 paper	 will	 be	 acknowledged	 by	 an	 email	
containing	 a	 reference	 number,	 which	 should	 be	 used	 in	 all	
future communications
Checking for plagiarism, duplicate publication, and text 
recycling
•	 All	 Reviews,	Personal	Views,	 and	 similar	non-research	material	
that	we	are	 interested	 in	publishing	will	be	checked	by	editors	




•	 Every	 Article,	 Review,	 Historical	 Review,	 Personal	 View,	 or	
Grand	 Round	 published	 in	 The Lancet Infectious Diseases has 
been	 peer	 reviewed.	 Occasional	 contributions	 (eg,	
commentaries) are accepted without peer review
•	 On	submission	to	The Lancet Infectious Diseases,	your	report	will	
first	be	read	by	one	or	more	of	the	 journal’s	staff	of	physicians	
and	 scientists.	 This	 is	 an	 important	 feature	 of	 our	 selection	
process	 that	 many	 papers	 are	 turned	 away	 on	 the	 basis	 of	
in-house	 assessment	 alone.	 That	 decision	 will	 be	
communicated	quickly
•	 Research	 papers	 and	 most	 other	 types	 of	 paper	 that	 receive	
positive	in-house	reviews	are	followed	by	peer	review	by	at	least	
three	 reviewers.	You	will	 receive	notification	of	which	editor	 is	
handling	the	peer	review	of	your	paper
Decision
•	 Submissions	 that	 survive	 in-house	 and	 peer	 review	 might	 be	
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present	 the	 best	 possible	 paper	 for	 further	 scrutiny	 by	 the	
journal; it is not an acceptance
•	 Authors	 should	 give	 priority	 to	 such	 revisions;	 the	 journal	will	
reciprocate	by	making	a	final	decision	quickly




The Lancet journals and other Elsevier journals
•	 If	 your	 paper	 is	 rejected	 by	 The Lancet Infectious Diseases,	 we	








please	 state	why	you	think	the	decision	 is	mistaken,	 and	 set	
out	your	specific	responses	to	any	peer	reviewers’	comments	
if those seem to have been the main cause of rejection




is	 likely	 that	 your	 paper	 will	 be	 substantially	 edited	 after	
acceptance	to	ensure	that	it	is	accurate,	clear,	and	understandable	
to a wide readership
•	 All	figures	will	be	redrawn	into	The Lancet Infectious Diseases style	
by	our	in-house	illustrators
•	 You	 will	 receive	 a	 proof	 from	 an	 Assistant	 Editor.	 That	 proof	




occasionally	 take	 part	 in	 or	 conduct	 editorial	 research.	 Your	




Open access and funding
Open access
•	 The Lancet journals are committed to support authors in 
making	their	research	publicly	and	freely	available.	The	editors	
encourage	 all	 authors	 to	 post	 a	Word	 version	 of	 their	 peer-
reviewed,	 accepted	 article	 on	 their	 personal	 or	 institutional	
websites	 any	 time	 after	 publication	 in	 print	 or	 online.	 Your	
document	should	indicate	the	article’s	citation	and	a	link	to	the	
published article on The Lancet website
•	 For	 authors	of	 research	 articles	 funded	by	one	of	 the	Research	
Councils	 UK,	 Wellcome	 Trust,	 Cancer	 Research	 UK,	 Arthritis	
Research	Council,	 British	Heart	 Foundation,	UK	Department	of	
Health,	 UK	 Chief	 Scientist	 Office,	 Austrian	 Science	 Fund,	 or	
Parkinson’s	UK,	we	offer	either	a	“gold”	open	access	choice	with	a	
creative	commons	licence	after	payment	of	an	article	processing	
charge	of	US$5000,	or	 a	 “green”	open	 access	 solution—where	
authors can deposit the final accepted version of their paper in 
any	 repository	 they	 choose	 6	 months	 after	 publication.	 In	
addition,	for	authors	who	choose	the	green	open	access	solution,	




•	 These	 options	 apply	 only	 to	 research	 papers	 submitted	 for	
publication in The Lancet	 journals	 after	April	 1,	 2013.	They	will	
not	be	applied	retrospectively
Authors funded by NIH
•	 Authors	funded	by	the	National	Institutes	of	Health	(NIH)	can	
comply	 with	 the	 NIH’s	 public-access	 policy	 via	 the	 Journal	
Publishing	Agreement	(copyright	transfer	form),	which	is	sent	
to	the	 corresponding	 author	of	 accepted	Articles.	All	Howard	
Hughes	 Medical	 Institute	 scientists	 who	 are	 authors	 of	
accepted Articles can also have their accepted manuscripts 
deposited	 in	 PubMed	 Central	 if	 they	 complete	 the	 relevant	
section	of	the	Journal	Publishing	Agreement
Click	here	for	Elsevier’s	agreements	with	funding	bodies.
What happens after publication?
Press release
Press	 releases	 are	 issued	 by	 The Lancet	 journals’	 press	 office	 for	
selected	 content	 published	 in	 our	 journals.	You	will	 be	 advised	 in	
advance	if	your	paper	has	been	selected	for	press	release.	The Lancet 
journals’	 media	 relations	 team	 will	 contact	 you	 with	 detailed	






contact	 you	 to	 arrange	 a	 pre-recorded	 interview	 to	 discuss	 your	
paper.	For	more	information,	see	Audio
Offprints and Reprints
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some	authors	(eg,	government	employees	in	some	countries)	
are	unable	to	transfer	copyright.	However,	such	policies	do	not	
provide	 anyone	 other	 than	 The Lancet journals the	 right	 to	
make	in	any	form	facsimile	copies	of	the	version	printed
•	 Gold	 open	 access	 articles	 are	 published	 under	 Creative	
Commons	licensing,	which	enables	authors	to	retain	copyright	
while	allowing	others	to	copy,	distribute,	and	make	some	uses	
of	 their	 work,	 provided	 full	 credit	 is	 given	 to	 them	 as	
originators.	Authors	will	 be	 offered	 a	 choice	 of	 two	 licences	
(CC	BY or CC	BY-NC-ND)	depending	on	whether	or	not	they	
wish to allow commercial reuse of their work and whether or 
not	they	wish	to	allow	others	to	alter	their	work	in	the	course	
of	its	reuse.	Authors	will	be	asked	to	sign	an	exclusive	licence	




•	 All	 requests	 to	 reproduce	 or	make	 available	 anything	 in	 the	
journal—in	 whole	 or	 in	 part,	 in	 electronic	 or	 in	 any	 other	
form,	 including	 translation—should	 be	 made	 through	 our	
Rightslink	 Service.	 For	more	 information,	 please	 visit	http://
www.elsevier.com/authors/obtaining-permission-to-re-use-
elsevier-material
•	 Authors	 may	 wish	 to	 visit	 our	 Permission-Seeking	 FAQ	
available at http://www.elsevier.com/authors/permission-
seeking-guidelines-for-elsevier-authors
•	 For	 general	 permissions	 queries,	 please	 contact	 Elsevier’s	
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Table 1. The STARD 2015 list
Section & Topic No. Item
TITLE OR ABSTRACT
1 Identification as a study of diagnostic accuracy using at least one measure of accuracy
(such as sensitivity, specificity, predictive values, or AUC)
ABSTRACT
2 Structured summary of study design, methods, results, and conclusions (for specific
guidance, see STARD for Abstracts)
INTRODUCTION
3 Scientific and clinical background, including the intended use and clinical role of the
index test
4 Study objectives and hypotheses
METHODS
Study design 5 Whether data collection was planned before the index test and reference standard
were performed (prospective study) or after (retrospective study)
Participants 6 Eligibility criteria
7 On what basis potentially eligible participants were identified (such as symptoms,
results from previous tests, inclusion in registry)
8 Where and when potentially eligible participants were identified (setting, location and
dates)
9 Whether participants formed a consecutive, random or convenience series
Test methods 10a Index test, in sufficient detail to allow replication
10b Reference standard, in sufficient detail to allow replication
11 Rationale for choosing the reference standard (if alternatives exist)
12a Definition of and rationale for test positivity cut-offs or result categories of the index
test, distinguishing pre-specified from exploratory
12b Definition of and rationale for test positivity cut-offs or result categories of the
reference standard, distinguishing pre-specified from exploratory
13a Whether clinical information and reference standard results were available to the
performers/readers of the index test
13b Whether clinical information and index test results were available to the assessors of
the reference standard
Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy
15 How indeterminate index test or reference standard results were handled
16 How missing data on the index test and reference standard were handled
17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from
exploratory
18 Intended sample size and how it was determined
RESULTS
Participants 19 Flow of participants, using a diagram
20 Baseline demographic and clinical characteristics of participants
21a Distribution of severity of disease in those with the target condition
21b Distribution of alternative diagnoses in those without the target condition
22 Time interval and any clinical interventions between index test and reference standard
Test results 23 Cross tabulation of the index test results (or their distribution) by the results of the
reference standard
24 Estimates of diagnostic accuracy and their precision (such as 95% confidence
intervals)
25 Any adverse events from performing the index test or the reference standard
DISCUSSION
26 Study limitations, including sources of potential bias, statistical uncertainty, and
generalisability
27 Implications for practice, including the intended use and clinical role of the index test
OTHER INFORMATION
28 Registration number and name of registry
29 Where the full study protocol can be accessed
30 Sources of funding and other support; role of funders
Special Reports
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Number Labno Locn Ward PatID Age Sex Specimen Date Specimen Clinical Data TB Culture ID and TTP CSF Cl CSF ADA ZN Stain GeneXpert HIV CD4 Viral Load
1 SCH5625496 RED  D1   108398512 2 F 04/01/2012 CSF  Tuberculous meningitis Positive for AFB MTB - 16 days 108 Neg Neg
2 SCH5625648 GRS  G17  122812936 50 F 04/01/2012 CSF  Investigation Negative 118 Neg Positive 449
3 SCH5625816 RED  D1   105871131 10 F 04/01/2012 CSF  Tuberculous meningitis Negative 110 Neg
4 SCH5628446 RED  S11  122951478 1 M 05/01/2012 CSF  New onset seizures Negative 120 Neg Neg
5 SCH5631794 RED  D1   40441289 3 M 08/01/2012 CSF  Meningitis Negative 124 Neg Neg
6 SCH5645402 RED  D1   96059605 6 F 15/01/2012 CSF  Tuberculous meningitis Negative 126 Neg Neg
7 SCH5645404 RED  S11  96059613 11  15/01/2012 CSF  Tuberculous meningitis ? Negative 122 Neg Neg
8 SCH5648221 RED  ICU  123144651 9 F 17/01/2012 CSF  Tuberculous meningitis ? Negative 117 Neg Neg
9 SCH5660181 RED  D1   122831084 34d F 21/01/2012 CSF  No clinical details supplied Negative 111 Neg Neg
10 SCH5661163 RED  S11  115277436 1 M 23/01/2012 CSF  Meningitis ? Negative 119 Neg Neg
11 SCH5674262 RED  B2   123326787 18d M 27/01/2012 CSF  Sepsis Negative 112 Neg
12 SCH5675927 GRS  G5   57059578 48 F 29/01/2012 CSF  Laboratory investigation Negative 121 Positive 121
13 SCH5675987 RED  A9   20824223 9 F 29/01/2012 CSF  No diagnosis supplied Negative 122 Neg Positive
14 SCH5677299 RED  A9   121952006 87d F 30/01/2012 CSF  Gastro Enteritis Negative 128 Neg Positive 6 485
15 SCH5688032 RED  D1   122167919 5m F 03/02/2012 CSF  Hydrocephalus empyema Negative 105 Neg Neg
16 SCH5688451 GRS  G22  114568140 35 F 03/02/2012 CSF  Laboratory investigation Negative 129 Neg Positive 3
17 SCH5705767 RED  S11  120620216 6m F 11/02/2012 CSF  Sepsis Negative 122 Neg
18 SCH5713557 RED  S11  119100246 8m M 15/02/2012 CSF  Meningitis ?,IRRITABLE,FEVER,VOMITING Negative 120 Neg Neg
19 SCH5713702 RED  S11  115144776 1 M 15/02/2012 CSF  Meningitis ? Negative 122 Neg Neg
20 SCH5718729 RED  S11  26387076 5 M 17/02/2012 CSF  Meningitis ?TBM Negative 124 Neg Neg
21 SCH5718738 RED  S11  123792236 9m M 17/02/2012 CSF  Tuberculous meningitis Negative 119 Neg Positive 2 256 10 000 000
22 SCH5724141 RED  S11  107163826 2 M 20/02/2012 CSF  Convulsion seizures Negative 124 Neg Neg
23 SCH5729919 GRS  E7   37056041 35 M 22/02/2012 CSF  Dementia Negative 129 2.6 Neg Positive
24 SCH5732163 RED  S11  115951824 1 F 23/02/2012 CSF  Convulsion SEIZURE Negative 123 Neg Neg
25 SCH5732320 GRS  C15  48113989 33 M 23/02/2012 CSF  Laboratory investigation palsy Negative 62 Neg Positive 355
26 SCH5733974 RED  S12  111622924 1 F 24/02/2012 CSF  seizures Negative 125 Neg Neg
27 SCH5734708 GRS  G17  65425001 32 F 24/02/2012 CSF  Negative 144 <1.0 Neg
28 SCH5735440 RED  S11  87230967 11 M 24/02/2012 CSF  Tuberculous meningitis ? Negative 123 Neg Neg
29 SCH5747021 GRS  G25  20859658 39 F 01/03/2012 CSF  Laboratory investigation Negative 151 Neg Positive
30 SCH5751224 GRS  C15  20027249 27 F 03/03/2012 CSF  Subarachnoid haemorrhage Negative 122 Neg
31 SCH5754196 RED  B1   117900126 3 M 06/03/2012 CSF  Meningitis ? Negative 116 Neg
32 SCH5754197 RED  B1   123530941 31d M 06/03/2012 CSF  No diagnosis supplied Negative 136 Neg Neg
33 SCH5758780 GRS  E7   110097102 57 M 07/03/2012 CSF  Investigation Negative 121 Neg Neg
34 SCH5761953 RED  S11  115144123 1 M 08/03/2012 CSF  Meningitis ? Negative 120 Neg
35 SCH5762760 GRS  C15  123950446 24 F 09/03/2012 CSF  Pregnant Negative 110 Neg Positive
36 SCH5763821 GRS  C15  102890597 50 M 09/03/2012 CSF  Investigation Negative 127 Neg
37 SCH5764010 RED  D1   107012551 2 M 09/03/2012 CSF  drain - HCP Negative 122 Neg
38 SCH5776534 GRS  E7   108391947 49 M 15/03/2012 CSF  Laboratory investigation Negative 123 Neg Positive
39 SCH5778295 WYN  CAS  124112780 11 F 16/03/2012 CSF  Investigation Positive for AFB MTB - 13 days 107 Neg
40 SCH5778460 GRS  C15  29314093 36 F 16/03/2012 CSF  Tuberculous meningitis Negative 126 <1.0 Neg Neg
41 SCH5779751 RED  S11  16056665 11 M 16/03/2012 CSF  Meningitis Negative 124 Neg Neg
42 SCH5779826 GRS  C15  82943143 44 M 16/03/2012 CSF  Illegible diagnosis/ICD10 Negative 124 Neg
43 SCH5782270 RED  D1   117989590 1 M 18/03/2012 CSF  Hydrocephalus Positive for AFB MTB - 11 days 107 Neg
44 SCH5784315 GRS  G16  124375502 15 F 19/03/2012 CSF  Meningitis Negative 129 Neg Neg
45 SCH5786604 GRS  E7   120065560 24 M 20/03/2012 CSF  Investigation Negative 130 Neg Neg
46 SCH5787079 RED  B1   122852239 4m M 20/03/2012 CSF  Failure to thrive Negative 115 Neg Positive
47 SCH5789470 RED  S12  117333971 1 M 22/03/2012 CSF  complex febrile seizures Negative 125 Neg Neg
48 SCH5790247 WYN  PAED 108414327 2 F 22/03/2012 CSF  Negative 127 Neg Neg
49 SCH5790255 WYN  PAED 115044943 1 M 22/03/2012 CSF  Meningitis Negative 125 Neg
50 SCH5795962 RED  S11  121515126 10 F 25/03/2012 CSF  Tuberculous meningitis ? Negative 121 Neg Neg
51 SCH5797103 GRS  G25  16406027 42 M 26/03/2012 CSF  Investigation Positive for AFB MTB - 23 days 100 Neg Positive 230
52 SCH5806323 RED  S12  36925014 4 M 30/03/2012 CSF  Meningitis ? Negative 122 Neg Neg
53 SCH5816303 RED  S11  117049924 1 M 04/04/2012 CSF  Meningitis ? Negative 122 Neg Neg
54 SCH5817559 GRS  G25  104008487 39 M 04/04/2012 CSF  Investigation Negative 116 Neg Positive 79 738 415
55 SCH5823405 GRS  G16  62070685 38 M 08/04/2012 CSF  Laboratory investigation Negative 124 <1.0 Neg Neg
56 SCH5828253 GRS  E7   114056419 32 F 11/04/2012 CSF  Laboratory investigation Negative 142 Neg Positive
57 SCH5828262 GRS  E7   53630521 49 F 11/04/2012 CSF  Laboratory investigation Negative 85 Neg
58 SCH5828819 RED  ICU  87129052 11 F 11/04/2012 CSF  Tuberculous meningitis Negative 104 Neg Positive 28 <20
59 SCH5830103 GRS  G12  112855853 33 F 12/04/2012 CSF  Investigation Negative 120 Neg
60 SCH5835294 GRS  C15  124065988 52 M 14/04/2012 CSF  Investigation Negative 122 Neg Neg
61 SCH5842622 RED  S12  124847492 11 M 18/04/2012 CSF  Negative 117 Neg Neg
62 SCH5842857 GRS  E7   87158242 44 M 18/04/2012 CSF  Laboratory investigation Negative 112 Neg Neg
63 SCH5865795 RED  D1   124855081 39d M 30/04/2012 CSF  Hydrocephalus ? Meningitis Negative 106 Neg Neg
64 SCH5866849 RED  ICU  125016113 2 M 01/05/2012 CSF  Encephalopathy ?cause Negative 120 Neg
65 SCH5869327 GRS  C15  85589299 53 F 02/05/2012 CSF  Meningitis ? Negative 120 Neg Neg
73
66 SCH5869956 GRS  E7   102741154 33 F 03/05/2012 CSF  No clinical details supplied Negative 125 Neg Positive 688
67 SCH5873852 RED  D1   117699736 1 F 04/05/2012 CSF  Hydrocephalus Negative 107 Neg Neg
68 SCH5875762 RED  ICU  125142513 10m M 05/05/2012 CSF  ?subdural haematoma Negative 118 Neg
69 SCH5876629 WYN  CAS  37797123 6 M 06/05/2012 CSF  Investigation Negative 127 Neg
70 SCH5889784 RED       124434713 48d M 11/05/2012 CSF  Investigation Negative 119 Neg
71 SCH5890002 RED  B1   125137430 11m M 11/05/2012 CSF  Meningitis Negative 131 Neg Positive
72 SCH5905802 RED  ICU  17474313 6 F 19/05/2012 CSF  Hydrocephalus ?tbm Positive for AFB MTB - 16 days 109 Neg
73 SCH5907295 RED  S12  124365321 65d M 20/05/2012 CSF  Meningitis uti Negative 121 Neg Neg
74 SCH5917181 RED  B1   125485862 5m M 24/05/2012 CSF  Tuberculous meningitis ? Negative 118 Neg Neg
75 SCH5918769 RED  S11  34548586 12 M 25/05/2012 CSF  Meningitis ? Positive for AFB MTB - 18 days 106 Neg
76 SCH5924105 GRS  G12  55623441 62 F 28/05/2012 CSF  Investigation Negative 123 Neg
77 SCH5925100 RED  B2   89078539 9 F 29/05/2012 CSF  Tuberculous meningitis ? Negative 115 Neg Neg
78 SCH5934412 GRS  C15  125637942 45 M 01/06/2012 CSF  Investigation Negative 132 Neg Neg
79 SCH5935423 RED  S12  123875700 1 M 02/06/2012 CSF  Meningitis Negative 122 Neg Neg
80 SCH5936706 RED  B1   124117292 3m F 03/06/2012 CSF  Meningitis jml Negative 120 Neg Neg
81 SCH5940101 GRS  C15  16377541 20 M 05/06/2012 CSF  Meningitis Negative 118 Neg Neg
82 SCH5959327 RED  ICU  43507789 3 M 14/06/2012 CSF  Meningitis Negative 120 Neg Neg
83 SCH5959556 GRS  C15  20542197 33 F 14/06/2012 CSF  Meningitis Negative 123 Neg Positive 251
84 SCH5959932 RED  ICU  119621902 1 M 14/06/2012 CSF  Laboratory investigation Negative 112 Neg Neg
85 SCH5962675 WYN  CAS  46502019 6 M 15/06/2012 CSF  Laboratory investigation Negative 123
86 SCH5972967 RED  B2   107900060 2 M 20/06/2012 CSF  Meningitis Negative 117 Neg Neg
87 SCH5974685 GRS  C15  105333074 37 M 21/06/2012 CSF  Laboratory investigation Negative 118 Neg Positive 479
88 SCH5976853 GRS  E7   31806680 47 F 22/06/2012 CSF  Laboratory investigation Negative 128 Neg Neg
89 SCH5988226 GRS  D13  27257278 42 M 28/06/2012 CSF  Laboratory investigation Negative 118 Neg Neg
90 SCH5991383 GRS  E7   102138211 36 M 29/06/2012 CSF  Laboratory investigation Negative 126 Neg Positive 663
91 SCH5998205 RED  E2   123840852 9 F 03/07/2012 CSF  #MS Negative 123 Neg
92 SCH5999561 GRS  F7   102061470 50 F 04/07/2012 CSF  Investigation Negative 104 Neg Positive 352
93 SCH6004607 GRS  G16  116824095 36 M 06/07/2012 CSF  Investigation Negative 130 Neg Positive 171
94 SCH6005448 RED  S11  124263898 4m M 06/07/2012 CSF  Meningitis HIV/?BCG Negative 122 Neg Positive 10 000 000
95 SCH6008969 GRS  K41  124761495 28 F 09/07/2012 CSF  Laboratory investigation Negative 121 Neg Positive 217
96 SCH6017363 GRS  G42  23086614 33 F 12/07/2012 CSF  Investigation Negative 120 Neg 250
97 SCH6019831 RED  MREG 30263867 5 F 13/07/2012 CSF  Tuberculous meningitis Negative 101 Neg Neg
98 SCH6024488 WYN  CUR3 123446007 6m M 16/07/2012 CSF  Pneumonia Negative 112 Neg Positive 403 1 967 875
99 SCH6029391 GRS  E7   107576704 49 M 18/07/2012 CSF  Investigation Negative 121 Neg Positive
100 SCH6032345 GRS  C15  13643366 28 M 19/07/2012 CSF  No clinical details supplied Negative 118 Neg Positive 20
101 SCH6038791 RED  B1   103854766 11 F 23/07/2012 CSF  Tuberculosis Negative 122 Neg Positive 155 104 415
102 SCH6051189 GRS  C15  68968460 49 M 29/07/2012 CSF  No clinical details supplied Negative 108 Neg Neg
103 SCH6051451 GRS  C15  12863486 32 F 29/07/2012 CSF  Tuberculous meningitis Negative 105 Neg Positive 94
104 SCH6051553 GRS  C15  129304614 32 F 29/07/2012 CSF  Psychosis Negative 124 Neg Positive 121
105 SCH6055186 GRS  E7   117122358 37 M 31/07/2012 CSF  Investigation Negative 121 Neg Positive 514 <LoD
106 SCH6059490 GRS  C15  129373270 23 M 02/08/2012 CSF  Laboratory investigation Negative 121 Neg
107 SCH6063452 GRS  E7   36331825 33 F 03/08/2012 CSF  Laboratory investigation Negative 131 Neg Positive 32 3 166 981
108 SCH6066155 GRS  C15  22681969 42 F 05/08/2012 CSF  Investigation Negative 113 Positive 88
109 SCH6071769 GRS  C15  129463352 51 M 08/08/2012 CSF  Investigation Negative 126 Neg Neg
110 SCH6079505 GRS  F17  16955130 26 F 13/08/2012 CSF  Investigation Negative 116 Neg Positive 155 56 280
111 SCH6080251 GRS  C27  115127409 56 M 13/08/2012 CSF  Investigation Negative 119 Neg Neg
112 SCH6080317 RED       114959646 1 F 13/08/2012 CSF  Meningitis Negative 120 Neg Positive 682 63 905
113 SCH6082292 RED  ICU  26105031 5 F 14/08/2012 CSF  Tuberculous meningitis HCP Positive for AFB MTB - 15 days 110 Neg
114 SCH6083178 RED  B1   119878163 1 F 14/08/2012 CSF  Pulmonary tuberculosis Negative 119 Neg Neg
115 SCH6083872 WYN  CUR3 120984356 11m F 14/08/2012 CSF  Tuberculous meningitis ? Negative 123 Neg Positive 131 119 945
116 SCH6084480 SOM  KING 19744903 38 M 15/08/2012 CSF  Meningitis Negative 128 1.5 Neg Neg
117 SCH6084558 SOM  1FL  35223627 57 M 15/08/2012 CSF  Laboratory investigation Negative 120 Neg Positive 5 868
118 SCH6085688 RED       118095546 1 M 15/08/2012 CSF  Meningitis Negative 123 Neg
119 SCH6101404 SOM  CAS  125850966 38 M 22/08/2012 CSF  Investigation Negative 118 Neg Positive 10
120 SCH6104648 RED  D1   33218306 4 F 23/08/2012 CSF  Tuberculosis abdomen, HCP Negative 120 Neg
121 SCH6107147 GRS  C15  74270067 43 M 24/08/2012 CSF  Investigation Negative 124 Neg Positive 341 176 118
122 SCH6107153 GRS  E7   16825176 25 F 24/08/2012 CSF  Investigation Negative 124 Neg Neg
123 SCH6108697 GRS  C15  108694084 20 F 25/08/2012 CSF  Laboratory investigation Negative 131 Neg Neg
124 SCH6109018 SOM  CAS  126022995 38 M 25/08/2012 CSF  Investigation Negative 127 <1.0 Neg
125 SCH6110469 GRS  C15  86567385 43 M 27/08/2012 CSF  Laboratory investigation Negative 119 Positive 43
126 SCH6110736 GRS  C15  103127023 34 F 27/08/2012 CSF  Laboratory investigation Negative 142 <1.0 Neg Positive 188
127 SCH6112157 RED  B2   14134407 7 F 27/08/2012 CSF  No clinical details supplied Negative 125 Neg Neg
128 SCH6116751 GRS  G17  20149902 26 F 29/08/2012 CSF  Investigation Negative 133 Neg Positive 12 5 654 080
129 SCH6119306 RED  S11  119468429 1 F 30/08/2012 CSF  Laboratory investigation Negative 122 Neg
130 SCH6119572 GRS  G7   80074206 55 F 30/08/2012 CSF  Investigation Negative 101 Neg Neg
131 SCH6122130 GRS  C15  129872487 34 M 31/08/2012 CSF  Investigation Negative 124 Neg
74
132 SCH6126552 GRS  G16  129814497 20 M 03/09/2012 CSF  Investigation Negative 121 Neg Positive 213
133 SCH6130119 GRS  E7   102676418 52 F 04/09/2012 CSF  Meningitis Negative 129 Neg
134 SCH6133954 GRS  E7   19671809 30 M 05/09/2012 CSF  Cryptococcal meningitis Negative 114 Neg Positive 7 113 894
135 SCH6135821 GRS  G17  12962049 37 F 06/09/2012 CSF  Investigation Negative 131 Neg
136 SCH6137903 RED  B1   123580300 7m M 07/09/2012 CSF  Investigation Negative 116 Neg Positive 1 201 24 840
137 SCH6139588 GRS  C15  124130204 25 M 07/09/2012 CSF  Laboratory investigation Positive for AFB MTB - 18 days 96 Positive AFB Positive 77 1 345
138 SCH6140959 GRS  D13  20547089 49 M 08/09/2012 CSF  Investigation Negative 120 Neg Neg
139 SCH6142053 SOM       102945516 36 M 09/09/2012 CSF  Illegible diagnosis/ICD10 Negative 128 Neg Positive 34
140 SCH6143701 RED  B1   31420391 5 M 10/09/2012 CSF  Tuberculous meningitis ? Negative 106 Neg Neg
141 SCH6144303 RED  S11  119434934 1 M 10/09/2012 CSF  Tuberculous meningitis Negative 121 Neg
142 SCH6145422 RED  S11  47783154 9 M 11/09/2012 CSF  Laboratory investigation Negative 123
143 SCH6146313 MOS  C    2347292 41 F 11/09/2012 CSF  Negative 113 Neg Positive 304
144 SCH6150140 RED  S11  36135705 7 F 12/09/2012 CSF  Meningitis Negative 125 Neg Positive 431 24 621
145 SCH6150251 GRS  C13  81778664 17 F 12/09/2012 CSF  Meningitis Negative 119 Neg Positive 346
146 SCH6152796 GRS  G16  129807673 30 M 13/09/2012 CSF  Laboratory investigation Negative 121 Neg Neg
147 SCH6156280 GRS  C15  28653707 33 M 14/09/2012 CSF  Encephalopathy Positive for AFB MTB - 14 days 111 Neg
148 SCH6157286 GRS  C15  37430766 28 F 15/09/2012 CSF  No clinical information Negative 120 <1.0 Neg
149 SCH6157326 FAL       117395350 25 F 15/09/2012 CSF  Meningitis Negative 100 Positive 187
150 SCH6157976 SOM       16922106 27 F 15/09/2012 CSF  Laboratory investigation Negative 122
151 SCH6159506 RED       124610155 1 M 17/09/2012 CSF  Meningitis Negative 114 Neg Neg
152 SCH6160685 RED  S11  120505482 1 M 17/09/2012 CSF  No clinical details supplied Negative 120 Neg Neg
153 SCH6160686 RED  MREG 32455974 10 M 17/09/2012 CSF  No clinical details supplied Negative 119 Neg
154 SCH6167044 GRS  E7   25349598 53 F 19/09/2012 CSF  Investigation Negative 123 Neg Neg
155 SCH6167105 SOM  KING 129887741 22 M 19/09/2012 CSF  Investigation Negative 132 Neg Neg
156 SCH6170773 RED  MOPD 118498831 1 F 21/09/2012 CSF  No clinical details supplied Positive for AFB MTB - 24 days 104 Neg
157 SCH6172005 GRS  E7   12744470 42 F 21/09/2012 CSF  Laboratory investigation Negative 123 Neg Positive 344
158 SCH6173172 WYN  CAS  14722466 11 M 21/09/2012 CSF  Meningitis ? Negative 128
159 SCH6173933 RED       125216101 5m M 22/09/2012 CSF  Meningitis Atypical Febrile seizures Negative 121 Neg Neg
160 SCH6174054 KNY  2 20613147 44 M 22/09/2012 CSF  Tuberculous meningitis Negative 123 Neg Neg
161 SCH6175036 SOM  KING 23094774 62 M 23/09/2012 CSF  Laboratory investigation Negative 98 Neg Neg
162 SCH6177936 RED  B1   111961397 4 M 25/09/2012 CSF  Sepsis TB Negative 119 Neg Positive 184 673 880
163 SCH6179454 RED       45519733 3 M 26/09/2012 CSF  Laboratory investigation Negative 119 Neg
164 SCH6187661 GRS  C15  81988859 41 F 29/09/2012 CSF  Investigation Negative 126
165 SCH6188969 RED  MREG 123709685 2 M 01/10/2012 CSF  Hydrocephalus meningitis Negative 115 Neg Neg
166 SCH6190255 GRS  G16  26339382 46 F 01/10/2012 CSF  Investigation Negative 117 Neg Positive 145
167 SCH6191446 RED  MREG 89088256 9 F 02/10/2012 CSF  Meningitis ? Negative 122 Neg Neg
168 SCH6199004 SOM  BICK 130220163 29 F 04/10/2012 CSF  Investigation Negative 119 Neg Positive 289 <LoD
169 SCH6199220 RED  MREG 124225053 6 F 04/10/2012 CSF  Meningitis ? Negative 121 Neg
170 SCH6201701 SOM  BICK 88044854 64 F 05/10/2012 CSF  Investigation Negative 141 <1.0 Neg Neg
171 SCH6201765 GRS  C15  61974820 48 F 05/10/2012 CSF  Laboratory investigation Negative 123 Neg Neg
172 SCH6201860 RED  S11  130466915 1 M 05/10/2012 CSF  Tuberculous meningitis ? Negative 121 Neg Neg
173 SCH6204414 GRS  MOPD 33718248 46 F 07/10/2012 CSF  Tuberculosis Positive for AFB MTB - 15 days 125 Neg Positive 76
174 SCH6206350 RED  ICU  15224736 11 F 08/10/2012 CSF  Meningitis ? Negative 105 Neg
175 SCH6206523 RED  B1   116252438 1 M 08/10/2012 CSF  Tuberculous meningitis Negative 115 Neg Neg
176 SCH6218089 GRS  G16  31502461 60 M 12/10/2012 CSF  Laboratory investigation Negative 124 <1.0 Neg Neg
177 SCH6218223 WYN       130608276 3 M 12/10/2012 CSF  Tuberculous meningitis Negative 125 Neg
178 SCH6219322 GRS  C15  44435444 34 F 13/10/2012 CSF  Laboratory investigation Negative 123 Neg Positive 305 975
179 SCH6219908 GRS  C15  70241468 26 F 13/10/2012 CSF  No clinical details supplied Negative 127 Neg 333
180 SCH6220636 RED  B1   105852099 2 F 14/10/2012 CSF  Investigation Negative 122 Neg Positive 1 007 78 200
181 SCH6220648 RED  S11  128915998 1 M 14/10/2012 CSF  Investigation Negative 118 Neg Neg
182 SCH6226875 RED  S11  26679902 5 F 17/10/2012 CSF  No clinical details supplied Negative 116 Neg Neg
183 SCH6230450 RED  S11  111421707 3 M 18/10/2012 CSF  Laboratory investigation Negative 120 Neg Neg
184 SCH6234676 GRS  C15  106838089 21 F 19/10/2012 CSF  Meningitis Negative 124 Neg
185 SCH6236480 SOM  KING 55062285 53 M 20/10/2012 CSF  Laboratory investigation Negative 132 <1.0 Neg
186 SCH6237200 GRS  C15  86724382 38 F 22/10/2012 CSF  Meningitis ? Positive for AFB MTB - 15 days 112 Neg Positive 45
187 SCH6238619 RED  S12  114482938 2 M 22/10/2012 CSF  Investigation Negative 122 Neg Neg
188 SCH6238935 GRS  G17  24237448 40 F 22/10/2012 CSF  Laboratory investigation Negative 138 Neg Positive 54
189 SCH6240291 GRS  G17  120221221 29 M 23/10/2012 CSF  Meningitis Negative 129 Neg Positive 1 005
190 SCH6241751 SOM  KING 130676836 44 M 23/10/2012 CSF  Investigation Negative 140 1.8 Neg
191 SCH6243451 RED  MREG 117791954 1 F 24/10/2012 CSF  Sepsis low LOC Negative 111 Neg
192 SCH6244002 KNY  2 20155487 32 M 24/10/2012 CSF  ?MENINGITIS Negative 120 <1.0 Neg Positive 299 <20
193 SCH6246954 KNY       21561451 57 F 25/10/2012 CSF  Cerebro-vascular accident Negative 121 <1.0 Neg
194 SCH6247473 GRS  G17  129990198 38 M 25/10/2012 CSF  Laboratory investigation Negative 131 Neg Positive 24
195 SCH6247798 GRS  G5   89260376 9 M 25/10/2012 CSF  Laboratory investigation Negative 125 Neg
196 SCH6253715 SOM  EDB  23769383 18 F 29/10/2012 CSF  Investigation Negative 123 Neg
197 SCH6254228 WYN  CAS  124700949 7 M 29/10/2012 CSF  Laboratory investigation Negative 135 Neg
75
198 SCH6257389 SOM  CAS  130900459 44 M 30/10/2012 CSF  Investigation Negative 118 Neg Neg
199 SCH6260034 LEN       124295882 23 F 31/10/2012 CSF  Investigation Negative 125 Neg Neg
200 SCH6267454 GRS  C15  17754128 65 M 03/11/2012 CSF  Investigation Positive for AFB MTB - 16 days 113 Neg
201 SCH6269062 GRS  C15  12950291 33 F 05/11/2012 CSF  Investigation Negative 109 Neg Positive
202 SCH6278894 WYN  CAS  11142213 13 M 08/11/2012 CSF  Meningitis Negative 126 Neg
203 SCH6282048 GRS  C15  130943681 21 M 10/11/2012 CSF  Laboratory investigation Negative 125 Neg Neg
204 SCH6282350 RED  ICU  131100018 4m M 10/11/2012 CSF  No clinical details supplied Negative 120 Neg Neg
205 SCH6282387 SOM  CAS  131122640 31 F 10/11/2012 CSF  Investigation Negative >150 Neg Positive 97
206 SCH6285271 SOM  BARK 85425031 25 F 12/11/2012 CSF  Laboratory investigation Negative 141 Neg
207 SCH6288428 SOM  BICK 47842943 80 F 13/11/2012 CSF  Laboratory investigation Negative 148 Neg
208 SCH6290009 RED  MREG 115020646 2 F 14/11/2012 CSF  Meningitis ?,hcp Negative 120 Neg
209 SCH6291095 SOM  KING 131076630 34 M 14/11/2012 CSF  Laboratory investigation Negative 118 Neg Neg
210 SCH6291662 GRS  G12  57822140 71 M 14/11/2012 CSF  Delirium Negative 123 Neg
211 SCH6299405 RED  B2   131250623 6 M 17/11/2012 CSF  Meningitis Negative 123 Neg Neg
212 SCH6301104 WYN  CAS  40214769 10 F 19/11/2012 CSF  Laboratory investigation Negative 107 Neg
213 SCH6301934 RED  S11  39949599 8 M 19/11/2012 CSF  Tuberculous meningitis ? Negative 120 Neg Neg
214 SCH6303940 GRS  E7   119272912 22 F 20/11/2012 CSF  Laboratory investigation Negative 125 <1.0 Neg
215 SCH6304195 RED  S11  131260598 11 M 20/11/2012 CSF  Tuberculous meningitis ? Negative 122 Neg Positive 226 157 082
216 SCH6304581 SOM  KING 35241447 47 M 20/11/2012 CSF  Laboratory investigation Negative 121 Neg
217 SCH6310323 RED  S12  37953684 4 M 22/11/2012 CSF  Laboratory investigation Negative 119 Neg
218 SCH6311992 RED  MREG 123330771 1 M 23/11/2012 CSF  Tuberculous meningitis Negative 101 Neg Neg
219 SCH6313251 GRS  G16  13793088 29 F 23/11/2012 CSF  Laboratory investigation Negative 120 Neg 594
220 SCH6315745 GRS  C15  116744947 31 F 26/11/2012 CSF  No clinical details supplied Negative 109 3.4 Neg Positive
221 SCH6319536 GRS  C15  10052496 33 F 27/11/2012 CSF  Investigation Positive for AFB MTB - 14 days 103 Positive
222 SCH6320024 GRS  C15  40412751 34 M 27/11/2012 CSF  Laboratory investigation Negative 122 Neg
223 SCH6325215 GRS  G22  33490913 44 F 29/11/2012 CSF  Psychosis Negative 123 <1.0 Neg Positive 245
224 SCH6325464 GRS  G25  61490827 66 M 29/11/2012 CSF  Negative 119 Neg Neg
225 SCH6326844 GRS  C15  43789718 27 F 30/11/2012 CSF  Meningitis TB? Negative 121 <1.0 Neg Positive 36
226 SCH6326982 KNY       20205050 44 F 30/11/2012 CSF  No clinical details supplied Negative 120 Neg
227 SCH6327603 GRS  G16  50502236 54 M 30/11/2012 CSF  Negative 108 Neg
228 SCH6329940 WYN  CAS  123245771 32 M 01/12/2012 CSF  Investigation Negative 119 Neg Positive 86
229 SCH6340839 GRS  C15  124287244 41 M 06/12/2012 CSF  Meningitis ? Negative 122 Neg 47
230 SCH6345046 RED  D1   131049280 32d F 09/12/2012 CSF  Meningitis Negative 103 Neg
231 SCH6347186 GRS  C15  33513102 53 M 10/12/2012 CSF  Laboratory investigation Negative 121 5.8 Neg Positive 123
232 SCH6348863 GRS  F5   41090390 37 F 11/12/2012 CSF  Laboratory investigation Negative 128 <1.0 Neg Positive 545
233 SCH6349678 RED  ICU  46516571 3 F 11/12/2012 CSF  Miliary TB ? Negative 120 Neg
234 SCH6352410 GRS  G25  63247506 68 F 12/12/2012 CSF  Laboratory investigation Negative 120 Neg Positive 36
235 SCH6352480 SOM  EDB  131592818 32d M 12/12/2012 CSF  ? Meningitis Negative 119
236 SCH6359871 GRS  G17  19791912 61 F 16/12/2012 CSF  No clinical details supplied Negative 130 Neg Neg
237 SCH6361304 GRS  C15  103084083 48 F 18/12/2012 CSF  Laboratory investigation Negative 120 Neg
238 SCH6361980 GRS  C15  20463055 30 F 18/12/2012 CSF  Laboratory investigation Negative 121 270
239 SCH6364201 GRS  C15  26352252 40 M 19/12/2012 CSF  Tuberculous meningitis Negative 140 Neg Positive 223
240 SCH6365877 GRS  C15  10617280 33 M 20/12/2012 CSF  Investigation Negative 118 <1.0 Neg Neg 128
241 SCH6366876 RED  B2   131770216 8m M 20/12/2012 CSF  Meningitis Negative 122 Neg
242 SCH6374305 RED  B2   36467405 9 F 27/12/2012 CSF  Meningitis ? Negative 118 Neg Neg
243 SCH6375471 GEOSA      109734459 47 F 28/12/2012 CSF  Pulmonary tuberculosis Negative 107 Neg
244 SCH6375908 WYN  CAS  130167380 40 M 28/12/2012 CSF  Laboratory investigation Negative 126
245 SCH6375911 GRS  C15  25505991 66 M 28/12/2012 CSF  Laboratory investigation Negative 122 Positive 114
246 SCH6377865 RED  MREG 103887683 3 F 31/12/2012 CSF  Hydrocephalus Negative 115 Neg
247 SCH6378225 GRS  C15  131870289 80 M 31/12/2012 CSF  Laboratory investigation Negative 128 Neg Neg
248 SCH6378545 RED  MREG 46075933 3 M 31/12/2012 CSF  Investigation Negative 125 Neg Neg
249 SCH6380520 RED  E2   85998375 13 F 02/01/2013 CSF  Post renal transplant Negative 128 Neg Neg
250 SCH6382598 KNY  1 20140059 48 M 04/01/2013 CSF  Negative 111 Neg
251 SCH6382601 KNY  4 20863361 38 F 04/01/2013 CSF  Meningitis Negative 111 Neg 14
252 SCH6382602 KNY  2 20415402 36 M 04/01/2013 CSF  ?CONFUSION Negative 123 Neg Positive 100
253 SCH6382797 KNY       20411617 37 F 04/01/2013 CSF  Diagnosis not stated Negative 116 Neg Positive
254 SCH6383937 GRS  G16  72289358 47 F 04/01/2013 CSF  Investigation Negative 127 Neg Neg
255 SCH6385814 GRS  E12  74734526 25 M 06/01/2013 CSF  Investigation Negative 124 Neg Neg
256 SCH6389426 RED  A9   131549198 35d M 08/01/2013 CSF  Sepsis ?meningitis Negative 120 Neg Neg
257 SCH6395584 KNY  1 21445697 3 F 11/01/2013 CSF  SEIZURES Negative 122 Neg
258 SCH6405626 GRS  D13  54666953 35 M 16/01/2013 CSF  Laboratory investigation Negative 124 Neg
259 SCH6405680 GRS  G25  67876433 41 M 16/01/2013 CSF  Investigation Negative 109 Neg Neg
260 SCH6414875 GRS  C15  47617212 28 M 21/01/2013 CSF  ? Pulmonary TB Negative 125 Neg
261 SCH6416343 GRS  C15  80577372 77 M 21/01/2013 CSF  Laboratory investigation Negative 125 Neg
262 SCH6418245 GRS  G17  56219322 61 M 22/01/2013 CSF  Investigation Negative 131 Neg Neg
263 SCH6421616 KNY  4 21580758 28 F 23/01/2013 CSF  Tuberculous meningitis Negative 117
76
264 SCH6424832 GRS  C15  86924446 37 M 24/01/2013 CSF  Investigation Negative 125 Neg Neg
265 SCH6433656 KNY       20976155 10 F 29/01/2013 CSF  Diagnosis not stated Negative 123 Neg
266 SCH6439283 WEF  ARV  46557765 37 F 31/01/2013 CSF  Investigation Negative 124 <1.0 Positive
267 SCH6440810 KNY       20760583 39 F 01/02/2013 CSF  ?TB MENINGITIS Negative 117 Neg 200
268 SCH6451776 RED  S11  115686420 2 M 06/02/2013 CSF  Meningitis ? Negative 117 Neg Neg
269 SCH6451778 RED  MOPD 14525042 7 M 06/02/2013 CSF  Meningitis Negative 119 Neg Neg
270 SCH6456981 KNY  OPD  20125365 35 M 08/02/2013 CSF  Negative 103 Neg
271 SCH6458775 GRS  G8   62115209 64 M 08/02/2013 CSF  Investigation Negative 111 Neg Neg
272 SCH6461059 GRS  G17  63922926 55 M 10/02/2013 CSF  No clinical details supplied Negative 121 Neg Neg
273 SCH6465174 KNY  4 21317698 20 F 12/02/2013 CSF  Negative 121 Neg
274 SCH6465912 GRS  G17  112493911 15 F 12/02/2013 CSF  Tuberculous meningitis Negative 115 Neg Positive 400
275 SCH6466615 RED       131944225 46d M 12/02/2013 CSF  Meningitis ? Negative 116 Neg
276 SCH6469153 LEN  16A  125328815 37 F 13/02/2013 CSF  Illegible diagnosis/ICD10 Negative 123 Neg 388
277 SCH6472498 RED  B1   45155934 4 M 14/02/2013 CSF  TBM ? Negative 104 Neg Neg
278 SCH6474231 RED  S11  119316099 8 F 15/02/2013 CSF  Investigation Negative 121 Neg Neg
279 SCH6477269 RED  B1   123118937 1 M 16/02/2013 CSF  Tuberculous meningitis ? Negative 127 Neg Positive 169
280 SCH6478217 RED  MREG 132734534 1 F 17/02/2013 CSF  No clinical details supplied Negative 120 Neg Neg
281 SCH6479666 GRS  F7   129182739 17 M 18/02/2013 CSF  Investigation Negative 121 Neg
282 SCH6480555 SOM  CAS  103232252 31 F 18/02/2013 CSF  Meningitis Negative 122 Neg
283 SCH6482031 SOM       111070009 25 M 19/02/2013 CSF  Meningitis Negative 122
284 SCH6483540 BROCH B    121374946 1 F 19/02/2013 CSF  Laboratory investigation Negative 122 Neg
285 SCH6484836 RED  S11  43650654 4 M 20/02/2013 CSF  Meningitis ? Negative 122 Neg
286 SCH6486360 SOM       42574228 15 M 20/02/2013 CSF  Laboratory investigation Negative 123 Neg
287 SCH6490358 KNY       21600028 9 F 22/02/2013 CSF  Diagnosis not stated Negative 111 Neg Neg
288 SCH6491430 GRS  G25  132754979 72 F 22/02/2013 CSF  Investigation Negative 105 Neg Neg
289 SCH6493824 GRS  E7   32829475 43 M 23/02/2013 CSF  Laboratory investigation Negative 127 Neg Positive <LoD
290 SCH6495169 GRS  C15  58854118 38 M 24/02/2013 CSF  Laboratory investigation Negative 116 Neg Neg
291 SCH6498600 GRS  D13  19401736 40 F 26/02/2013 CSF  Investigation Positive for AFB MTB - 14 days 108 Neg
292 SCH6499584 KNY  2 21588314 41 M 26/02/2013 CSF  Retroviral Disease Negative 102 Neg
293 SCH6499879 GRS  C15  89024475 42 F 26/02/2013 CSF  TBM on Rx Positive for AFB MTB - 20 days 95 Neg Positive 402
294 SCH6500779 RED  D1   124690363 10m M 27/02/2013 CSF  Hydrocephalus Negative 114 Neg
295 SCH6501819 RED  B1   13253331 12 M 27/02/2013 CSF  large vessel vasculopathy Negative 122 Neg Neg
296 SCH6502634 SOM  BAIL 41029729 36 F 27/02/2013 CSF  Investigation Positive for AFB MTB - 34 days 128 Neg Positive 13
297 SCH6510580 RED  S11  37322575 6 M 03/03/2013 CSF  delirius Positive for AFB MTB - 17 days 107 Neg Positive <LoD
298 SCH6511372 RED  S11  131975948 56d F 04/03/2013 CSF  seizures Negative 123 Neg Neg
299 SCH6514477 RED  S11  132948365 1 M 05/03/2013 CSF  Investigation Negative 122 Neg Neg
300 SCH6515726 RED  D1   123148454 7 F 05/03/2013 CSF  Tuberculous meningitis Negative 110 Neg
301 SCH6517589 SOM  CAS  15885262 36 F 06/03/2013 CSF  Laboratory investigation Negative 127 Neg
302 SCH6518316 GRS  G17  85997419 36 F 06/03/2013 CSF  Laboratory investigation Negative 131 Neg Positive 51 233 654
303 SCH6518594 GRS  E7   20822052 37 M 06/03/2013 CSF  Laboratory investigation Negative 124 Neg Positive 230 <LoD
304 SCH6518990 GRS  G17  125416438 43 M 06/03/2013 CSF  Meningitis Negative 112 Neg Positive 116
305 SCH6520156 RED  S12  13683776 8 M 07/03/2013 CSF  Meningitis Negative 115 Neg
306 SCH6521964 FAL       124497793 1 F 07/03/2013 CSF  Laboratory investigation Negative 130 Neg Positive 463 10 000 000
307 SCH6523072 RED  ICU  88607734 10 M 08/03/2013 CSF  Encephalitis Negative 124 Neg
308 SCH6523341 KNY  4 20195467 29 F 08/03/2013 CSF  Tuberculous meningitis Negative 126 Neg 552
309 SCH6524657 SOM  EDB  133088328 12 F 08/03/2013 CSF  Meningitis Infarct Negative 120 Neg Positive 35 138 555
310 SCH6528001 GRS  G17  65696940 28 F 11/03/2013 CSF  Laboratory investigation Negative 118 2.1 Neg Neg
311 SCH6532816 KNY       21603287 26 F 13/03/2013 CSF  TB Investigation Negative 121 Neg
312 SCH6535210 RED  ICU  133166306 2 M 14/03/2013 CSF  Meningitis TB Positive for AFB MTB - 14 days 112 Neg
313 SCH6536521 RED  E2   47775978 4 F 14/03/2013 CSF  No clinical details supplied Negative 123 Neg Neg
314 SCH6537027 RED  A9   118435601 1 M 14/03/2013 CSF  Tuberculous meningitis Negative 115 Neg Positive 297
315 SCH6538196 RED  S12  41392283 11 F 15/03/2013 CSF  Meningitis Negative 121 Neg
316 SCH6538264 KNY  4 20153789 44 F 15/03/2013 CSF  Diagnosis not stated Negative 117 Neg
317 SCH6547330 KNY  1 20129698 43 M 19/03/2013 CSF  Laboratory investigation Negative 117 Neg Positive
318 SCH6547331 GRS  G12  61251773 39 F 19/03/2013 CSF  Laboratory investigation Negative 122 Neg Positive 89
319 SCH6556500 RED  MREG 125124651 11m F 23/03/2013 CSF  Tuberculous meningitis ? Negative 121 Neg
320 SCH6561264 RED  A9   111196002 3 M 26/03/2013 CSF  ?MENINGITIS Negative 118 Neg
321 SCH6561374 KNY  4 21045893 37 F 26/03/2013 CSF  ?TOXO Negative 122 Neg
322 SCH6561871 GRS  G25  59973560 47 F 26/03/2013 CSF  Laboratory investigation Negative 122 1.2 Neg Neg
323 SCH6562616 GRS  E7   129993473 39 F 26/03/2013 CSF  Investigation Negative 117 Neg
324 SCH6565401 RED  S11  125350264 1 M 28/03/2013 CSF  Laboratory investigation Negative 122 Neg Neg
325 SCH6573238 RED  D1   133500744 13 M 01/04/2013 CSF  Hydrocephalus Negative 105 Neg Neg
326 SCH6577146 OUD  4 20234662 16 M 03/04/2013 CSF  Laboratory investigation Negative 116 Neg
327 SCH6579507 KNY  1 21606306 55 M 04/04/2013 CSF  Laboratory investigation Negative 129 Neg Positive 300
328 SCH6584475 GRS  C15  45743184 39 F 06/04/2013 CSF  Meningitis Negative 120 Neg
329 SCH6585105 GRS  C15  73220824 76 M 06/04/2013 CSF  Delirium Negative 122 Neg Neg
77
330 SCH6588059 GRS  G17  76779859 65 F 08/04/2013 CSF  Meningitis Negative 126 Neg
331 SCH6589350 GRS  G42  45713344 22 F 09/04/2013 CSF  Laboratory investigation Negative 118 Neg
332 SCH6590868 WYN  SMF  59343806 67 F 09/04/2013 CSF  Meningitis Negative 125 Neg 320
333 SCH6592891 GRS  C15  86869781 53 F 10/04/2013 CSF  Investigation Negative 125 <1.0 Neg Positive 159 84
334 SCH6596930 RED  B2   39227095 5 M 12/04/2013 CSF  Laboratory investigation Negative 117 Neg
335 SCH6600761 GRS  C15  70389275 25 F 14/04/2013 CSF  Investigation Negative 123 Neg
336 SCH6602527 GRS  C15  84631019 37 F 15/04/2013 CSF  No clinical information Negative 125 <1.0 Neg
337 SCH6614637 KNY       20403192 28 F 19/04/2013 CSF  Investigation Negative 120
338 SCH6621477 KNY  2 20060083 63 M 23/04/2013 CSF  Negative 119 2.5 Positive 352
339 SCH6622770 RED  B2   41528456 8 M 23/04/2013 CSF  already on TB Rx/septic Negative 125 Neg Neg
340 SCH6625111 GRS  G12  16021818 29 F 24/04/2013 CSF  Laboratory investigation Negative 132 Neg Neg
341 SCH6630695 GRS  G17  56104284 33 M 26/04/2013 CSF  Pulmonary tuberculosis Negative 122 <1.0 Neg Neg
342 SCH6640324 KNY  2 20614491 32 M 02/05/2013 CSF  Pulmonary tuberculosis Positive for AFB MTB - 18 days 111 4.1 Neg Neg
343 SCH6645690 GRS  G17  121619019 71 M 04/05/2013 CSF  Laboratory investigation Negative 121 Neg Neg
344 SCH6648110 GEO  A2   116474834 51 F 06/05/2013 CSF  Tuberculosis Negative 102 Neg
345 SCH6652189 WYN  CAS  131467664 45 M 07/05/2013 CSF  Meningitis ? Negative 117 Neg 301
346 SCH6653868 GRS       12754552 37 F 08/05/2013 CSF  Laboratory investigation Negative 109 Neg Positive 282 287
347 SCH6654523 RED  S11  134177013 16d M 08/05/2013 CSF  Meningitis ?/seizures Negative 118 Neg
348 SCH6657584 RED  D1   131871535 4m M 09/05/2013 CSF  ventriculitis Negative 113 Neg
349 SCH6661620 RED  ICU  120076856 1 M 11/05/2013 CSF  Meningitis ? Negative 144 Neg Positive 667 2 568 200
350 SCH6662427 RED  S12  131822520 5m M 12/05/2013 CSF  Laboratory investigation Negative 119 Neg Neg
351 SCH6667277 KNY  4 21082763 20 F 14/05/2013 CSF  Investigation Negative 110 Neg
352 SCH6669634 RED  MREG 123386302 2 F 15/05/2013 CSF  Encephalopathy ?meningitis Negative 125 Neg
353 SCH6672770 RED  S11  134306125 9d M 16/05/2013 CSF  Sepsis neonatal Negative 120 Neg
354 SCH6673257 GRS  G17  10830859 46 M 16/05/2013 CSF  Laboratory investigation Negative 134 Neg Neg
355 SCH6686729 GRS  G12  46437679 37 M 22/05/2013 CSF  Retroviral Disease Negative 94 Neg Positive 10
356 SCH6687617 RED  MREG 120344916 1 M 23/05/2013 CSF  Meningitis ? Negative 119
357 SCH6693576 RED  S11  39971841 4 M 25/05/2013 CSF  No clinical information Negative 111 Neg Neg
358 SCH6702119 RED  S11  48241673 4 M 29/05/2013 CSF  Meningitis ? Positive for AFB MTB - 26 days 96 Neg Neg
359 SCH6711419 SOM  BICK 134475656 53 F 03/06/2013 CSF  Laboratory investigation Negative 115 Neg
360 SCH6718646 HER       692058086 42 M 06/06/2013 CSF  Retroviral Disease Negative 115 Neg Positive
361 SCH6718802 GRS  G25  76973916 40 F 06/06/2013 CSF  Laboratory investigation Negative 126 Neg Positive
362 SCH6718803 GRS  G25  31928419 31 M 06/06/2013 CSF  Laboratory investigation Negative 124 Neg Positive 25
363 SCH6721136 GRS  G42  117205773 28 F 07/06/2013 CSF  Investigation Negative 121 Positive <LoD
364 SCH6726618 GRS  G25  119419877 54 F 10/06/2013 CSF  Investigation Negative 112 Neg Positive 282
365 SCH6727547 RED  D1   132825712 5m M 10/06/2013 CSF  Tuberculous meningitis Negative 116 Neg
366 SCH6729390 RED  B1   134702612 3m F 11/06/2013 CSF  Tuberculous meningitis ? Positive for AFB MTB - 13 days 103 Positive AFB
367 SCH6729416 WYN  CUR3 125264796 1 M 11/06/2013 CSF  Investigation Negative 127 Neg
368 SCH6737213 RED  MREG 134743921 7 M 14/06/2013 CSF  Investigation Negative 121 Neg
369 SCH6744078 RED  B2   113443899 6 F 18/06/2013 CSF  Meningitis ? Negative 126 Neg Neg
370 SCH6746329 GRS  G16  81426223 36 M 19/06/2013 CSF  Investigation Negative 131 Neg Positive 377 948
371 SCH6750275 GEO  TR   125119883 33 F 21/06/2013 CSF  Laboratory investigation Negative 107 Neg Positive 58
372 SCH6750281 GEOSA      67094508 31 F 21/06/2013 CSF  Laboratory investigation Negative 120 Neg
373 SCH6750285 KNY  2 21124870 15 M 21/06/2013 CSF  Laboratory investigation Negative 115 Neg
374 SCH6756610 GRS  G17  35805241 65 F 24/06/2013 CSF  Laboratory investigation Negative 129 Neg Neg
375 SCH6758311 GRS  G22  118322569 35 F 25/06/2013 CSF  Investigation Negative 139 Neg
376 SCH6765683 RED  D1   135031078 6m F 28/06/2013 CSF  Hydrocephalus complicated meningitis Negative 120 Neg
377 SCH6769398 GRS  C15  133997510 22 F 30/06/2013 CSF  Laboratory investigation Negative 119 Neg Positive 210
378 SCH6771016 RED  MREG 135055861 4 F 01/07/2013 CSF  Investigation Negative 118 Neg Neg
379 SCH6774628 SOM  CAS  110906930 40 F 03/07/2013 CSF  No clinical details supplied Negative 136 Neg 230
380 SCH6774635 SOM       35496751 30 F 03/07/2013 CSF  Meningitis Negative 145 Neg Positive 91
381 SCH6774734 RED  D1   105791628 14 M 03/07/2013 CSF  Meningo encephalitis Negative 117 Neg Neg
382 SCH6776207 GRS  G16  113482954 20 F 03/07/2013 CSF  Investigation Negative 142 Neg Positive 80
383 SCH6779052 GRS  C15  15168792 32 F 04/07/2013 CSF  Laboratory investigation Negative 126 Neg Positive 569
384 SCH6782192 RED  S11  133264416 3m F 06/07/2013 CSF  No clinical details supplied Negative 122 Neg
385 SCH6783801 RED  S12  15902075 7 M 07/07/2013 CSF  Meningitis ? Negative 120 Neg Neg
386 SCH6784022 RED  S12  132173600 5m M 07/07/2013 CSF  Sepsis presumed Negative 119 Neg Neg
387 SCH6784936 RED  S11  133616813 3m M 08/07/2013 CSF  Meningitis ? Negative 120 Neg Neg
388 SCH6790821 GRS  G17  135150209 27 F 10/07/2013 CSF  Laboratory investigation Negative 126 280
389 SCH6791259 SOM  CAS  27611565 39 M 10/07/2013 CSF  Laboratory investigation Negative 128 Neg Neg
390 SCH6802028 GRS  G16  16208944 25 F 15/07/2013 CSF  Laboratory investigation Negative 113 Neg Positive 59
391 SCH6809850 SOM  1FL  48346951 29 M 18/07/2013 CSF  ? Myelopathy Negative 124 Neg Positive 127
392 SCH6810325 RED  S12  104227590 25 F 18/07/2013 CSF  Meningitis ? Negative 121 Neg
393 SCH6812735 GRS  E7   135206415 37 M 19/07/2013 CSF  Investigation Negative 124 Neg Positive 337
394 SCH6814512 RED  ICU  131006850 8m M 20/07/2013 CSF  Tuberculous meningitis Positive for AFB MTB - 23 days 106 Neg
395 SCH6815692 RED  D1   135321966 5 F 21/07/2013 CSF  Tuberculous meningitis Negative 116 Neg
78
396 SCH6817299 GRS  F17  117506964 47 M 22/07/2013 CSF  Investigation Positive for AFB MTB - 21 days 116 Neg Neg
397 SCH6820186 RED  B2   111623526 3 M 23/07/2013 CSF  Meningitis ?/?HLH Negative 121 Neg Positive 89 228
398 SCH6825315 GRS  C15  103191912 37 M 25/07/2013 CSF  Investigation Positive for AFB MTB - 11 days 115 Neg 89
399 SCH6825324 GRS  C23  31385735 31 M 25/07/2013 CSF  Investigation Negative 124 Neg Neg
400 SCH6830769 RED  B2   135516128 10m M 27/07/2013 CSF  Sepsis ? Negative 120 Neg
401 SCH6832572 GRS  E7   26130443 40 M 29/07/2013 CSF  Investigation Negative 128 Neg Positive 179
402 SCH6834209 RED  S12  121838247 1 F 30/07/2013 CSF  Meningitis ? Negative 120 Neg Neg
403 SCH6840440 SOM  CAS  122692049 37 F 01/08/2013 CSF  Tuberculous meningitis Negative 110 Neg
404 SCH6842020 RED  ICU  40504888 5 M 02/08/2013 CSF  Investigation Negative 122 Neg
405 SCH6842750 GRS  C15  70087952 25 M 02/08/2013 CSF  Laboratory investigation Negative 114 Neg Neg
406 SCH6842769 GRS  F7   135158194 18 F 02/08/2013 CSF  Laboratory investigation Negative 130 Neg Positive 512
407 SCH6844102 RED  A9   132469032 6m F 03/08/2013 CSF  Meningitis ? Negative 125 Neg Neg
408 SCH6852895 RED  B2   129567897 11m M 07/08/2013 CSF  Meningitis ?,on cef d2 Negative 103 Neg Neg
409 SCH6854887 GRS  C15  79306288 47 F 08/08/2013 CSF  Laboratory investigation Negative 123 Neg Neg
410 SCH6856580 RED  S11  104141585 4 M 09/08/2013 CSF  Meningitis ? Positive for AFB MTB - 34 days 107 Neg Neg
411 SCH6858540 RED  S11  134865195 55d M 10/08/2013 CSF  Pyrexia Negative 119 Neg
412 SCH6860124 WYN  CAS  86432283 39 M 11/08/2013 CSF  Laboratory investigation Negative 128 Neg Positive 426
413 SCH6862518 SOM  BAIL 135656205 36 M 12/08/2013 CSF  Investigation Positive for AFB MTB - 24 days 103 Neg Positive 36 2 968 923
414 SCH6866654 GRS  G16  135746022 18 M 14/08/2013 CSF  Laboratory investigation Negative 123 Neg Positive 506
415 SCH6867968 RED  D1   135700631 3m F 14/08/2013 CSF  thalamic lesion Negative 111 Neg
416 SCH6874885 WYN  SMF  13606603 37 F 16/08/2013 CSF  Retroviral Disease ? CVA Negative 124 Neg Positive 233
417 SCH6875759 RED  S11  121307862 4 F 17/08/2013 CSF  Meningitis ? Negative 122 Neg
418 SCH6876025 GRS  C15  135854628 F 17/08/2013 CSF  No clinical details supplied Negative 122 Neg Positive 153
419 SCH6881350 MOS  CAS  2205045 28 F 20/08/2013 CSF  Meningitis Negative 122 <1.0 Positive
420 SCH6895028 RED  MREG 33858283 9 M 26/08/2013 CSF  Meningitis ? Negative 110 Neg
421 SCH6895304 SOM       25134248 38 M 26/08/2013 CSF  Meningitis Negative 109 Neg Positive 56
422 SCH6897750 RED  S12  130340771 1 F 27/08/2013 CSF  Vomiting ? meningitis, temp 39 Negative 123 Neg Neg
423 SCH6904753 RED  D1   125094953 1 M 30/08/2013 CSF  Hydrocephalus Negative 106 Neg
424 SCH6905557 RED  S11  136108198 4 F 30/08/2013 CSF  No clinical details supplied Negative 112 Neg
425 SCH6907266 SOM  BICK 35069517 31 F 31/08/2013 CSF  meningism? Negative 122 Neg Positive 186
426 SCH6918889 GRS  C12  58251323 49 M 05/09/2013 CSF  Laboratory investigation Negative 125
427 SCH6922339 SOM  KING 136206000 51 M 06/09/2013 CSF  No clinical details supplied Negative 122 Neg
428 SCH6922485 GRS  E7   33311887 53 M 06/09/2013 CSF  No clinical details supplied Negative 138 Neg Neg
429 SCH6922902 SOM  CAS  121730295 28 F 06/09/2013 CSF  Illegible diagnosis/ICD10 Negative 128 Neg
430 SCH6923150 SOM  CAS  67156000 28 F 06/09/2013 CSF  Tuberculous meningitis Negative 114 Neg Positive 5 212 571
431 SCH6924252 GRS  C15  83357608 16 F 07/09/2013 CSF  Encephalitis Positive for AFB MTB - 45 days 111 Neg Neg
432 SCH6925059 GRS  C24  12830287 31 F 08/09/2013 CSF  Meningitis ? Negative 130 Neg Positive
433 SCH6928282 GRS  G25  79707519 20 M 10/09/2013 CSF  Meningitis Negative 113 Neg Positive 142
434 SCH6928893 GRS  C15  51399111 36 M 10/09/2013 CSF  Meningitis Negative 121 Neg Neg
435 SCH6938855 RED  TH   135433993 1 M 13/09/2013 CSF  Hydrocephalus Negative 119 Neg Neg
436 SCH6941034 RED  ICU  125519934 1 M 14/09/2013 CSF  Meningitis ?, seizures Negative 122 Neg Positive
437 SCH6946853 MITDH      134797133 21 F 17/09/2013 CSF  Meningitis RVD Negative 122 Neg Positive
438 SCH6954757 SOM       37128451 31 F 20/09/2013 CSF  HIV Negative 126 Neg
439 SCH6956590 KNY  2 20924015 45 M 21/09/2013 CSF  Laboratory investigation Negative 105 Neg 439
440 SCH6958810 RED  D1   134834167 4m M 23/09/2013 CSF  Hydrocephalus Negative 112 Neg
441 SCH6959015 GRS  C15  71036560 27 F 23/09/2013 CSF  Laboratory investigation Negative 127 Neg 328
442 SCH6960801 GRS  C15  107776940 17 M 24/09/2013 CSF  Laboratory investigation Negative 127 Neg Neg
443 SCH6961847 RED  MREG 130292816 1 M 25/09/2013 CSF  Tuberculous meningitis ? Positive for AFB MTB - 26 days 110 Neg Neg
444 SCH6962507 MITDH      113406086 29 F 25/09/2013 CSF  Laboratory investigation Negative 128 Neg Neg
445 SCH6963816 GFJ  CAS  131485161 37 M 25/09/2013 CSF  No clinical details supplied Negative 121 Neg
446 SCH6967788 RED  S12  129060463 1 F 27/09/2013 CSF  Meningitis ?,?tbm Negative 116 Neg Neg
447 SCH6969778 GFJ       136574217 31 M 28/09/2013 CSF  Meningitis Negative 113 Neg
448 SCH6969884 GFJ       73605099 24 M 28/09/2013 CSF  Meningitis ? Positive for AFB MTB - 18 days 113 Neg Positive 51
449 SCH6972022 SOM  CAS  51667467 37 M 30/09/2013 CSF  Laboratory investigation Negative 115 Neg 569
450 SCH6972251 RED  TH   136570918 6 M 30/09/2013 CSF  HCP Negative 127 Neg
451 SCH6976699 GFJ  CAS  118738764 35 M 02/10/2013 CSF  No clinical details supplied Negative 133 Neg Positive 39
452 SCH6977414 GFJ  CAS  136630563 27 F 02/10/2013 CSF  Laboratory investigation Positive for AFB MTB - 33 days 106 Positive 151
453 SCH6978331 GRS  C15  136612355 33 M 02/10/2013 CSF  Laboratory investigation Negative 119 Neg Positive 42
454 SCH6979997 RED  S12  118054220 2 M 03/10/2013 CSF  Laboratory investigation Negative 120 Neg Neg
455 SCH6984975 GRS  G17  29048816 35 F 04/10/2013 CSF  Laboratory investigation Negative 127 Neg Positive 16 783
456 SCH6985544 GRS  C15  17288069 56 F 04/10/2013 CSF  Delirium Negative 127 Neg
457 SCH6986973 GRS  C15  25343658 32 F 05/10/2013 CSF  Retroviral Disease Program Negative 127 Neg Positive 127
458 SCH6986983 GRS  C15  32374720 54 M 05/10/2013 CSF  SEIZURES Negative 126 Neg Neg
459 SCH6992456 SOM  CAS  77776318 49 M 08/10/2013 CSF  Negative 118 Neg Positive
460 SCH6994940 GRS  C15  65660920 47 F 09/10/2013 CSF  Laboratory investigation Negative 124 Neg Neg
461 SCH7000684 RED  D1   44231587 5 F 11/10/2013 CSF  Sepsis Negative 117 Neg
79
462 SCH7001017 GRS  C27  86597853 47 M 11/10/2013 CSF  Investigation Negative 117 Neg
463 SCH7001102 RED  S12  119646503 2 M 11/10/2013 CSF  Meningitis SUSPECTED,FEVER,LETHARGY Negative 125
464 SCH7008067 GRS  C15  69188837 26 F 15/10/2013 CSF  Meningitis Negative 118 Neg Positive 108
465 SCH7008605 RED  B1   119996379 2 M 15/10/2013 CSF  Tuberculous meningitis ? Negative 116 Neg Positive 813 279 465
466 SCH7008745 GRS  K41  33393323 33 F 15/10/2013 CSF  Laboratory investigation Negative 123 Neg Positive 2 090
467 SCH7010987 GRS  E7   59486977 49 F 16/10/2013 CSF  Laboratory investigation Negative 127 Neg
468 SCH7016211 RED  D1   119494136 2 F 18/10/2013 CSF  No clinical details supplied Negative 98 Neg
469 SCH7017287 RED  B1   112915673 3 F 18/10/2013 CSF  Tuberculous meningitis ? Negative 101 Neg Neg
470 SCH7019238 GFJ  CAS  129248829 16 F 20/10/2013 CSF  Meningitis Negative 115 Neg 193
471 SCH7027715 GRS  G17  71163687 25 F 23/10/2013 CSF  ? Meningitis Negative 131 Neg Positive 538
472 SCH7029858 GRS  C27  104881958 45 M 24/10/2013 CSF  Laboratory investigation Negative 96 14.1 Neg
473 SCH7030180 SOM  CAS  136652344 30 F 24/10/2013 CSF  Investigation Negative 130 Neg Positive
474 SCH7030373 SOM       18179614 29 M 24/10/2013 CSF  Tuberculous meningitis Negative 123 Neg Positive 4 107
475 SCH7037004 RED  B1   133083238 8m M 28/10/2013 CSF  Meningitis ? Negative 115 Neg Neg
476 SCH7038188 SOM       38482840 38 F 29/10/2013 CSF  Meningitis Negative 125 Positive 263 <LoD
477 SCH7044990 GRS  C15  137413340 29 M 31/10/2013 CSF  Laboratory investigation Negative 125 Neg
478 SCH7045876 RED  B1   121250344 3 F 31/10/2013 CSF  No diagnosis supplied Negative 124 Neg
479 SCH7050134 RED  S11  136002888 70d M 02/11/2013 CSF  Meningitis ? Negative 118 Neg
480 SCH7052132 SOM  CAS  136498268 49 F 04/11/2013 CSF  Investigation Positive for AFB MTB - 30 days 110 Neg Positive <LoD
481 SCH7054568 SOM  CAS  137537189 F 05/11/2013 CSF  Investigation Negative 125
482 SCH7055600 VAL       14129175 36 F 05/11/2013 CSF  Retroviral Disease Negative 133 Neg Positive 452 <LoD
483 SCH7056091 SOM  ANC  113071021 15 F 05/11/2013 CSF  Pyelonephritis ? Negative 117 Neg Positive 221
484 SCH7059672 GRS  C15  137352852 35 M 07/11/2013 CSF  No clinical details supplied Negative 114 191
485 SCH7062712 GRS  C15  78531704 21 F 07/11/2013 CSF  Illegible diagnosis/ICD10 Negative 125 Neg
486 SCH7064927 GRS  G17  137567251 44 F 08/11/2013 CSF  Laboratory investigation Negative 118 Neg Positive 534
487 SCH7066551 GEO  B2   109831008 42 M 09/11/2013 CSF  Laboratory investigation Negative 135 1.9 Neg
488 SCH7067319 RED  B2   129170684 1 F 10/11/2013 CSF  Tuberculous meningitis Negative 119 Neg Positive
489 SCH7067365 GRS  C15  137638433 37 M 10/11/2013 CSF  Investigation Negative 143 2.2 Neg 81
490 SCH7068163 RED  B2   108806613 8 M 11/11/2013 CSF  Tuberculous meningitis ? Negative 121 Neg
491 SCH7068176 FAL  CAS  89343115 14 M 11/11/2013 CSF  Laboratory investigation after request Negative 122 Neg
492 SCH7077264 GRS  E32  32062986 49 F 14/11/2013 CSF  ?Meningitis Negative 109 Neg 476
493 SCH7077851 GRS  D13  16035172 32 F 14/11/2013 CSF  Meningitis Negative 115 Neg Positive 142
494 SCH7077941 GRS  G16  89034771 49 M 14/11/2013 CSF  YOUNG STROKE NO RISK FACTOR Negative 120 Neg Neg
495 SCH7078742 GRS  C15  15985989 40 M 14/11/2013 CSF  Meningitis Positive for AFB MTB - 25 days 116 Neg 269
496 SCH7088435 GRS  C15M 138802079 31 F 19/11/2013 CSF  Laboratory investigation Negative 123 Neg Positive 803 14 531
497 SCH7093673 GRS  C15  125357368 38 F 21/11/2013 CSF  Laboratory investigation Positive for AFB MTB - 15 days 121 Neg Positive 29 45
498 SCH7094382 GRS  G17  43572122 49 F 21/11/2013 CSF  Laboratory investigation Negative 127 Neg Positive 54 511 110
499 SCH7104389 GRS  C27  35969427 36 F 26/11/2013 CSF  Laboratory investigation Negative 122 1.5 Neg Positive 156
500 SCH7104658 GRS  C15  35157197 42 M 26/11/2013 CSF  Laboratory investigation Negative 124 Neg Positive
501 SCH7106454 GRS  C14  71170617 25 M 27/11/2013 CSF  Meningitis ? Negative 89 Neg Neg
502 SCH7113098 GRS  G25  134996156 54 M 29/11/2013 CSF  Investigation Negative 123 Neg Neg
503 SCH7115750 GRS  C15  67940155 65 F 30/11/2013 CSF  Retroviral Disease + Negative 129 Neg
504 SCH7120380 GRS  C23  80532179 19 F 03/12/2013 CSF  Laboratory investigation Negative 126 Neg
505 SCH7126586 GRS  E16  33466624 28 F 05/12/2013 CSF  Laboratory investigation Negative 123 Neg Positive 142
506 SCH7129469 GRS  C15  119183861 33 F 06/12/2013 CSF  Laboratory investigation Negative 117 Neg
507 SCH7135416 RED  S12  124828732 1 F 10/12/2013 CSF  Pyrexia ?meningitis Negative 127 Neg
508 SCH7135417 RED  MREG 96271564 M 10/12/2013 CSF  No clinical details supplied Negative 120 Neg
509 SCH7136651 RED  ICU  105414437 4 M 10/12/2013 CSF  Meningitis ? Negative 134 Neg Neg
510 SCH7145141 GRS  G25  137656682 34 M 13/12/2013 CSF  Laboratory investigation Negative 117 Neg 91
511 SCH7146937 GRS  G25  29742848 39 M 14/12/2013 CSF  ?MENINGITIS Negative 129 Neg Neg
512 SCH7147561 GRS  C15  139228514 33 M 15/12/2013 CSF  No clinical details supplied Negative 125 Neg
513 SCH7148762 SOM  CAS  139233498 33 M 17/12/2013 CSF  Laboratory investigation ? Meningitis Negative 117 Neg Neg
514 SCH7150195 GRS  G17  139208342 24 M 17/12/2013 CSF  Laboratory investigation Negative 128 Neg Neg
515 SCH7152432 RED  D1   137150686 64d M 18/12/2013 CSF  Hydrocephalus Negative 110 Neg
516 SCH7161952 RED  ICU  40495624 5 M 24/12/2013 CSF  No clinical details supplied Negative 118 Neg Neg
517 SCH7162343 RED  E2   29544178 7 F 24/12/2013 CSF  Guillian Syndrome Negative 127 Neg Neg
518 SCH7167653 GRS  C15  20394789 39 M 30/12/2013 CSF  ?tb menengitis Negative 124 Neg Neg
519 SCH7169815 GRS  G8   60964251 60 M 31/12/2013 CSF  Illegible diagnosis/ICD10 Negative 116 Neg Neg
520 SCH7171924 KNY  2 21001656 37 M 02/01/2014 CSF  Meningitis Negative 120 36
521 SCH7172126 GRS  E7   108757618 26 F 02/01/2014 CSF  Cerebro-vascular accident Negative 122 Neg Positive 289
522 SCH7182393 GRS  G25  117590331 41 F 08/01/2014 CSF  No clinical details supplied Negative 127 Neg
523 SCH7190254 GRS  C15  113169866 32 F 12/01/2014 CSF  Investigation Negative 117 Neg Positive 321
524 SCH7196991 GRS  D13  122507965 40 M 15/01/2014 CSF  infection Negative 119 Neg 140
525 SCH7208310 RED  S11  113347488 3 M 20/01/2014 CSF  Meningitis ? Negative 113 Neg
526 SCH7212592 RED  MREG 122257645 2 M 22/01/2014 CSF  Meningitis ? Negative 122 Neg
527 SCH7216114 RED  S12  123513186 2 M 23/01/2014 CSF  Meningitis Negative 120 Neg Neg
80
528 SCH7219467 GRS  G17  114727084 46 M 24/01/2014 CSF  No clinical details supplied Negative 145 Positive 59
529 SCH7227603 GRS  C22  31100191 35 M 28/01/2014 CSF  Psychosis Negative 120 Neg Positive 137 62 023
530 SCH7231668 GRS  C15  46774642 43 F 29/01/2014 CSF  Meningitis Negative 129 2.4 Neg Positive 514 22 006
531 SCH7232541 GRS  C15  14846851 41 M 30/01/2014 CSF  Meningitis Negative 104 Neg
532 SCH7243382 RED  MREG 111454427 3 M 04/02/2014 CSF  No clinical details supplied Negative 102 Neg Neg
533 SCH7257507 RED  S12  135853216 7m M 09/02/2014 CSF  Tuberculous meningitis ? Negative 104 Neg Neg
534 SCH7259904 GRS  C15  48030712 47 M 10/02/2014 CSF  No clinical details supplied Negative 121 Neg Positive 17 73 038
535 SCH7265827 GRS  G25  139712210 26 F 12/02/2014 CSF  Meningitis Negative 116 Neg 308
536 SCH7268749 GRS  C15  74407305 54 M 13/02/2014 CSF  No clinical information Negative 127 Neg
537 SCH7271582 GRS  C15  140541756 22 F 14/02/2014 CSF  Laboratory investigation Negative 126 Neg 510
538 SCH7273992 RED  D1   139313126 54d M 15/02/2014 CSF  No clinical details supplied Negative 138 Neg Neg
539 SCH7274169 GRS  G12  84445527 45 F 15/02/2014 CSF  Laboratory investigation Negative 131 Neg Positive 167 <20
540 SCH7281835 RED  ICU  115655243 3 F 19/02/2014 CSF  Tuberculous meningitis ? Negative 113 Neg
541 SCH7286029 GRS  G16  140382474 24 M 20/02/2014 CSF  Tuberculosis ?meningitis Negative 108 Neg Neg
542 SCH7292952 GRS  G17  82578071 71 M 24/02/2014 CSF  Meningitis Negative 127 Neg Neg
543 SCH7304690 RED  B1   139354427 63d F 28/02/2014 CSF  Tuberculous meningitis tbm Negative 114 Neg Neg
544 SCH7308916 SOM  CAS  133785774 35 F 03/03/2014 CSF  Headache Negative 128 Neg Neg
545 SCH7316428 GRS  G17  84948421 54 M 05/03/2014 CSF  Meningitis ? Negative 126 Neg
546 SCH7322448 GRS  C12  82837758 44 F 07/03/2014 CSF  ? RVD Negative 132 Neg Positive 127 <LoD
547 SCH7324490 RED  MREG 139020143 3m M 08/03/2014 CSF  Sepsis Negative 159 Neg
548 SCH7324659 GRS  C15  39641642 52 F 08/03/2014 CSF  TB MENENGITIS Negative 105 Neg 25
549 SCH7327273 GRS  C15  107955064 53 M 10/03/2014 CSF  LOWER LIMB WEAKNESS Negative 121 Neg
550 SCH7339560 GRS  C12  23741598 79 F 14/03/2014 CSF  ?MENINGITIS Negative 126 Neg
551 SCH7342523 GRS  C14  141947671 16 M 16/03/2014 CSF  No clinical details supplied Negative 124 3.3 Neg Neg
552 SCH7350078 GRS  E26  33161373 47 F 19/03/2014 CSF  Tuberculosis ? MENINGITIS Negative 121 Neg Positive 664
553 SCH7359135 RED  MREG 134884063 10m F 24/03/2014 CSF  Tuberculous meningitis ? Negative 119 Neg Positive 2 188 2 165
554 SCH7359188 GRS  G17  122331309 20 F 24/03/2014 BCSF Illegible diagnosis/ICD10 Negative 120 Neg
555 SCH7367821 GRS  C22  131289506 27 M 27/03/2014 CSF  Retrovirus positive Negative 126 Positive 197
556 SCH7371136 GRS  G25  66605114 45 F 28/03/2014 CSF  No clinical details supplied Negative 140 Neg 27
557 SCH7377128 GRS  K41  57466591 34 F 01/04/2014 CSF  No clinical details supplied Negative 118 Neg Neg
558 SCH7386472 RED  B2   137351755 5m M 04/04/2014 CSF  No clinical details supplied Negative 113 Neg Positive 359 173 814
559 SCH7387807 GRS  C15  69115558 27 F 04/04/2014 CSF  CRANIAL NERVE Negative 128 Neg Neg
560 SCH7390344 RED  MREG 113031264 3 F 06/04/2014 CSF  Meningitis ?, seizures Negative 116 Neg
561 SCH7391018 GRS  C15  112820915 29 M 07/04/2014 CSF  No clinical details supplied Negative 117 Neg Positive 9
562 SCH7391985 GRS  C15  142456573 43 M 07/04/2014 CSF  No clinical details supplied Negative 148 Neg Neg
563 SCH7396816 GRS  C15  45484151 39 M 09/04/2014 CSF  No clinical details supplied Positive for AFB MTB - 15 days 93 Neg
564 SCH7398072 GRS  G17  122693021 28 F 09/04/2014 CSF  No clinical information Negative 113 Neg Neg
565 SCH7407299 GRS  C15  26321083 31 F 12/04/2014 CSF  Laboratory investigation Negative 123 Neg 652
566 SCH7409529 GRS  D13  14068043 17 M 14/04/2014 CSF  ?Ventriculitis Negative 121 Neg Neg
567 SCH7412228 RED  B1   142577014 11 M 15/04/2014 CSF  Tuberculous meningitis ? Negative 119 Neg Neg
568 SCH7414963 RED  D1   45528916 5 F 16/04/2014 CSF  Tuberculous meningitis Negative 107 Neg Neg
569 SCH7419461 GRS  F12  109300517 23 F 17/04/2014 CSF  Meningitis ? TB Negative 124 Neg Neg
570 SCH7421064 GRS  G25  115463572 26 M 18/04/2014 CSF  Illegible diagnosis/ICD10 Negative 119 Neg Positive 306 1 296 398
571 SCH7429730 RED  S11  36368769 8 M 24/04/2014 CSF  Tuberculous meningitis ? Negative 102 Neg Neg
572 SCH7430598 RED  D1   103823613 5 F 24/04/2014 CSF  Patient with ventriculitis Negative 123 Neg
573 SCH7433914 RED  S11  130319916 1 F 25/04/2014 CSF  Tuberculous meningitis vs JC virus Negative 115 Positive 3 509 1 793
574 SCH7436369 SOW       30575724 32 M 27/04/2014 CSF  Delirium Negative 122 Positive 888
575 SCH7436461 GRS  G17  142607837 42 M 27/04/2014 CSF  No clinical information Negative 119 Neg Positive 7
576 SCH7437259 GRS  C13  142769918 39 M 28/04/2014 CSF  Illegible diagnosis/ICD10 Negative 125 Positive 195
577 SCH7437455 RED  D1   132141177 1 M 28/04/2014 CSF  Tuberculous meningitis hydrocephalus Negative 114 Neg Neg
578 SCH7442180 RED  ICU  142783919 1 M 30/04/2014 CSF  Tuberculous meningitis Negative 129 Neg
579 SCH7442217 GRS  G16  141960021 29 F 30/04/2014 CSF  Meningitis Negative 128 20
580 SCH7476313 RED       116132887 3 M 16/05/2014 CSF  Laboratory investigation Negative 124 Neg Neg
581 SCH7476315 RED  S12  121853659 2 M 16/05/2014 CSF  Laboratory investigation Negative 123 Neg Neg
582 SCH7476318 GRS  G16  130711336 26 F 16/05/2014 CSF  Laboratory investigation Negative 141 Neg Positive 6
583 SCH7477520 RED  S11  122844491 2 F 16/05/2014 CSF  Tuberculosis + Negative 124 Neg
584 SCH7487819 GRS  G12  142949460 55 F 21/05/2014 CSF  Meningitis Negative 109 Neg Positive 409
585 SCH7493302 GRS  G25  87939336 69 F 23/05/2014 CSF  No clinical details supplied Negative 122 <1.0 Neg Neg Neg
586 SCH7497872 RED  D1   142797026 27d M 26/05/2014 CSF  No clinical details supplied Positive for AFB AFB - 7 days 115 Neg
587 SCH7500692 GRS  G16  32827271 33 F 27/05/2014 CSF  No clinical information Negative 115 Neg Positive 157 <20
588 SCH7503046 GEO  TR   25806738 33 F 28/05/2014 CSF  No diagnosis supplied Negative 123
589 SCH7503299 GRS  C15  54199369 38 M 28/05/2014 CSF  Laboratory investigation Negative 122 Neg Neg Neg
590 SCH7516004 GRS  E7   138797360 41 F 03/06/2014 CSF  Investigation Negative 45 Neg Neg
591 SCH7516313 GRS  G25  34806182 30 F 03/06/2014 CSF  No clinical details supplied Negative 119 Neg Positive 3 449 862
592 SCH7519316 GRS  C15  17138058 62 F 04/06/2014 CSF  Illegible diagnosis/ICD10 Negative 127 Neg
593 SCH7521120 GRS  D13  78792116 21 M 05/06/2014 CSF  Illegible diagnosis/ICD10 Negative 124 Neg Neg
81
594 SCH7525081 GRS  G16  35779602 54 F 06/06/2014 CSF  Tuberculous meningitis ? Negative 121 Neg Positive 383 <LoD
595 SCH7525390 GRS  G8   139570881 79 M 06/06/2014 CSF  Illegible diagnosis/ICD10 Negative 116 Neg Neg
596 SCH7526092 GRS  G16  72470248 29 M 06/06/2014 CSF  Meningitis Negative 116 Neg Positive
597 SCH7528103 RED  MREG 111886099 4 M 08/06/2014 CSF  No clinical details supplied Positive for AFB MTB - 29 days 108 Neg Neg
598 SCH7528994 GRS  G12  81878472 38 M 09/06/2014 CSF  No clinical details supplied Negative 121 Neg Positive 234 5 610
599 SCH7534994 GRS  C12  85679603 47 F 11/06/2014 CSF  ? TBM Negative 118 Neg Neg
600 SCH7541540 GRS  G17  29110210 31 F 13/06/2014 CSF  No clinical details supplied Negative 104 Neg Positive 351 53
601 SCH7543369 GRS  C15  15138399 57 M 14/06/2014 CSF  Laboratory investigation Negative 119 Neg
602 SCH7545642 GRS  G16  54347125 68 F 17/06/2014 CSF  Investigation Negative 121 Neg
603 SCH7549208 GRS  G16  28326270 32 F 18/06/2014 CSF  Cryptococcal meningitis Negative 124 Neg Positive 31
604 SCH7551429 RED  S12  143517670 2 M 19/06/2014 CSF  Hydrocephalus Negative 122 Neg Neg
605 SCH7552492 RED  S12  118909464 3 M 19/06/2014 CSF  Meningitis Negative 115 Neg Positive
606 SCH7557162 RED  S11  143142750 61d M 21/06/2014 CSF  Tuberculous meningitis ?,meningitis Negative 120 Neg Neg
607 SCH7559088 GRS  C15  144089869 25 F 23/06/2014 CSF  ?MENINGITIS Negative 121 Neg Positive 3 228 628
608 SCH7560103 RED  S12  139295471 7m F 23/06/2014 CSF  Meningitis ? Negative 124 Neg Neg
609 SCH7561696 RED  B2   142359348 82d F 24/06/2014 CSF  FTT vomiting Negative 112 Neg
610 SCH7571797 RED  B1   143533578 26d M 27/06/2014 CSF  Sepsis Negative 123 Neg Neg
611 SCH7573545 RED  D1   125909176 2 M 28/06/2014 CSF  VP shunt dysfunction Negative 105 Neg
612 SCH7577781 RED  S12  134702687 2 M 01/07/2014 CSF  No diagnosis supplied Positive for AFB MTB - 20 days 111 Neg Neg
613 SCH7581283 GRS  G12  144185246 42 F 02/07/2014 CSF  Stroke young Negative 124 Neg Positive 124
614 SCH7581596 GRS  C15  17413576 17 M 02/07/2014 CSF  No clinical details supplied Negative 114 Neg Neg
615 SCH7584829 GRS  G25  78827839 52 M 03/07/2014 CSF  No clinical information Negative 123 Neg Neg
616 SCH7584889 RED  S11  144239282 2 M 03/07/2014 CSF  Tuberculous meningitis Negative 110 Neg
617 SCH7592121 RED  D1   107272171 4 M 07/07/2014 CSF  Hydrocephalus Negative 111 Neg Neg
618 SCH7597985 GRS  G16  20606679 34 F 09/07/2014 CSF  Tuberculosis Negative 140 Neg
619 SCH7613434 RED  D1   43819101 7 M 16/07/2014 CSF  Tuberculous meningitis ventricular Negative 113 Neg Neg
620 SCH7619696 GRS  G12  144261765 41 F 18/07/2014 CSF  No clinical information Negative 109 Neg Neg
621 SCH7622783 RED  ICU  46528006 12 F 20/07/2014 CSF  Tuberculosis disseminated Negative 114 Neg Neg
622 SCH7627393 GRS  G25  86257417 42 M 22/07/2014 CSF  Laboratory investigation Negative 117 Neg Positive 34 182 400
623 SCH7627661 GRS  G12  24782344 34 F 22/07/2014 CSF  No clinical details supplied Negative 119 Neg Neg
624 SCH7638321 GRS  C15  86267705 49 F 26/07/2014 CSF  Laboratory investigation RVD POSITIVE AND HEADACHESNegative 120 Neg Positive
625 SCH7641992 GRS  C15  124907205 18 F 29/07/2014 CSF  Meningitis ? Positive for AFB MTB - 13 days 101 Neg Neg
626 SCH7643971 GRS  C15  15293491 71 F 29/07/2014 CSF  Laboratory investigation Negative 127 Neg Neg
627 SCH7649869 GRS  G25  16223802 38 M 31/07/2014 CSF  No clinical details supplied Negative 118 Neg Positive 299
628 SCH7652950 GRS  F7   56070964 61 M 01/08/2014 CSF  No clinical details supplied Negative 112
629 SCH7655540 GRS  G22  116896424 24 F 03/08/2014 CSF  Encephalitis Negative 121 Neg Neg Positive 4
630 SCH7668941 RED  D1   115376352 3 M 08/08/2014 CSF  No clinical details supplied Negative 119 Neg
631 SCH7671372 SOM  CAS  116480559 29 F 09/08/2014 CSF  Tuberculous meningitis Suspect Positive for AFB MTB - 16 days 119 Neg Neg Neg
632 SCH7672215 GRS  D12  68080829 28 M 09/08/2014 CSF  Meningitis ? Negative 109 15.1 Neg Neg
633 SCH7672668 GRS  C13  55689699 67 F 10/08/2014 CSF  Headache Fever, neck stiffness Negative 126
634 SCH7673022 GRS  C15  108824376 29 M 11/08/2014 CSF  Meningitis Negative 132 Neg Neg Neg
635 SCH7674395 RED  S11  119086197 3 M 11/08/2014 CSF  Tuberculous meningitis ? Negative 123 Neg Positive 933 <20
636 SCH7679117 KNY  2 20622940 41 M 13/08/2014 CSF  Diagnosis not stated Negative 135 Neg
637 SCH7683886 RED  ICU  135536795 1 M 14/08/2014 CSF  No clinical details supplied Negative 123 Neg
638 SCH7686671 MIT  EC   144542438 33 F 15/08/2014 CSF  Investigation FACIAL PALSY Negative 122 Neg Positive 82
639 SCH7688239 RED  MOPD 108298266 4 M 16/08/2014 CSF  Tuberculosis Negative 114 Neg Neg
640 SCH7688241 RED  MREG 40018954 7 F 16/08/2014 CSF  Meningitis hydrochapalus Negative 110 Neg
641 SCH7700440 RED  B2   131431165 1 F 21/08/2014 CSF  Tuberculosis disseminated Negative 124 Neg Positive 626
642 SCH7705355 RED  ICU  133932079 1 M 24/08/2014 CSF  No clinical details supplied Negative 121 Neg
643 SCH7718098 GRS  D15  75071936 23 M 29/08/2014 CSF  ? MENINGITIS Negative 119 Neg Neg
644 SCH7721382 GRS  C15  60595899 48 M 31/08/2014 CSF  Meningitis Negative 119 Neg Neg
645 SCH7722589 GRS  G16  115840324 26 M 01/09/2014 CSF  Cryptococcal meningitis ? Negative 110 Neg Positive
646 SCH7722910 RED  D1   13393079 1 M 01/09/2014 CSF  Meningitis ? Negative 123 Neg Neg
647 SCH7727279 RED  MREG 113444830 4 F 03/09/2014 CSF  Hydrocephalus TBM Negative 102 Neg Neg Neg
648 SCH7728996 RED  B2   144810611 69d M 03/09/2014 CSF  Meningitis Negative 129 Neg Positive 1 024 6 436
649 SCH7730356 GRS  C15  57077232 57 F 04/09/2014 CSF  No clinical information Positive for AFB MTB - 32 days 110 7.3 Neg Neg Positive 390
650 SCH7734173 GRS  C15  125570374 36 F 05/09/2014 CSF  Meningitis Negative 119 8 Neg Neg Positive 414
651 SCH7755356 GRS  C15  40327173 39 F 15/09/2014 CSF  Tuberculous meningitis ? Negative 120 Neg
652 SCH7767779 GRS  G8   145596342 44 M 19/09/2014 CSF  Burkitt's lymphoma Negative 115 Neg
653 SCH7769751 RED  S11  135231462 1 M 20/09/2014 CSF  Pulmonary tuberculosis Negative 120 Neg Neg
654 SCH7776964 GRS  C15  10437143 55 M 24/09/2014 CSF  No clinical details supplied Negative 123 Neg Positive 155
655 SCH7780386 RED  ICU  130104052 2 M 26/09/2014 CSF  Meningitis ? Negative 138 Neg
656 SCH7783533 RED  A9   131561862 1 M 27/09/2014 CSF  Sepsis ? Negative 119 Neg Neg Positive 1 302 112 291
657 SCH7791790 GRS  C15  29163599 31 F 01/10/2014 CSF  No clinical details supplied Negative 124 <1.0 Neg Positive 154
658 SCH7796981 GEO  TR   145783759 64 M 03/10/2014 CSF  Laboratory investigation Negative 121 Positive 189 467
659 SCH7797139 GEO  TR   25638495 28 F 03/10/2014 CSF  Laboratory investigation Negative 119 72
82
660 SCH7797564 RED  ICU  145772620 3 M 03/10/2014 CSF  Encephalitis SUSPECTED Negative 127 Neg
661 SCH7799431 GRS  C15  74732744 48 M 04/10/2014 CSF  Meningitis Negative 109 Neg Positive 107
662 SCH7800770 GRS  G25  142820570 30 F 06/10/2014 CSF  ? TB MENINGITIS Negative 118 2.6 Neg Neg Neg
663 SCH7806289 RED  D1   132044520 1 F 08/10/2014 CSF  Tuberculous meningitis Negative 112 Neg
664 SCH7806293 RED  B1   106341308 4 F 08/10/2014 CSF  Tuberculous meningitis Negative 107 Neg Positive 346 <LoD
665 SCH7813315 GRS  G16  73311755 63 F 10/10/2014 CSF  Delirium septic workup Negative 121 Neg
666 SCH7822989 GRS  G8   145639605 41 M 15/10/2014 CSF  No clinical information Negative 111 Neg Positive 595
667 SCH7827136 RED  D1   131870354 1 M 16/10/2014 CSF  ventriculitis Negative 109 Neg Neg
668 SCH7830246 RED  D1   144427515 3m M 17/10/2014 CSF  No clinical details supplied Negative 110 Neg
669 SCH7830436 RED  B1   137446191 1 F 17/10/2014 CSF  Meningitis ? Negative 127 Neg Neg
670 SCH7839384 RED  D1   143308732 4m M 22/10/2014 CSF  Tuberculous meningitis hcp Negative 114 Neg Neg
671 SCH7843311 GRS  G25  51662021 38 M 23/10/2014 CSF  Laboratory investigation Negative 121 Neg Neg
672 SCH7845892 RED  D1   142539113 1 M 24/10/2014 CSF  No clinical details supplied Negative 123 Neg 1 806
673 SCH7846283 GRS  G16  83194084 39 F 24/10/2014 CSF  No clinical details supplied Negative 115 Neg Neg
674 SCH7847633 RED  B1   29741311 9 M 25/10/2014 CSF  Tuberculous meningitis ? Positive for AFB MTB - 27 days 113 Neg Neg
675 SCH7857707 RED  S12  103801502 5 M 30/10/2014 CSF  Meningitis Negative 121 Neg Neg
676 SCH7858914 GRS  G7   36450518 57 F 30/10/2014 CSF  No clinical details supplied Negative 112 Neg Neg
677 SCH7859564 RED  B2   133898718 1 F 30/10/2014 CSF  Meningitis ? Negative 127 Neg Neg Positive 55 10 000 000
678 SCH7859570 RED  S11  29487758 7 M 30/10/2014 CSF  Meningitis ? Negative 120 Neg Neg
679 SCH7863980 GRS  G16  119270312 37 F 01/11/2014 CSF  Meningitis CRYPTOCOCCAL Negative 108 Neg Positive 47
680 SCH7864090 GRS  C15  52512415 51 M 01/11/2014 CSF  Tuberculosis ?/ Negative 122 Neg Neg
681 SCH7873237 WYN  CAS  139347934 14 F 06/11/2014 CSF  Meningitis Negative 120 3.6 Neg
682 SCH7884276 RED  S12  123110280 2 F 11/11/2014 CSF  Tuberculous meningitis ? Negative 106 Neg Neg
683 SCH7885155 GRS  C13  54827605 40 M 11/11/2014 BCSF Meningitis ? Negative 126 Neg Neg
684 SCH7885484 GRS  G12  50034214 53 F 11/11/2014 CSF  No clinical details supplied Negative 128 Neg Positive 509
685 SCH7887315 RED  E2   85647618 15 M 12/11/2014 CSF  Liver transplant Negative 119 Neg
686 SCH7887389 RED  ICU  116895491 3 M 12/11/2014 CSF  No clinical details supplied Positive for AFB MTB - 19 days 104 Neg
687 SCH7899361 RED  D1   146595715 3m M 17/11/2014 CSF  Hydrocephalus Negative 114 Neg
688 SCH7899362 RED  D1   145845848 43d F 17/11/2014 CSF  Hydrocephalus meningitis Negative 119 Neg
689 SCH7901903 RED  ICU  115362899 4 F 18/11/2014 CSF  Encephalitis Negative 127 Neg Neg
690 SCH7914300 GRS  D13  86159712 18 M 24/11/2014 CSF  No clinical details supplied Negative 110 Neg Neg
691 SCH7915118 GRS  C5   146531405 39 M 24/11/2014 CSF  ?IRIS Negative 129 1.8 Neg Positive 27
692 SCH7915333 GRS  E7   140913120 33 F 24/11/2014 CSF  Laboratory investigation Negative 124 Neg Positive 312
693 SCH7918077 RED  S12  132890419 1 F 25/11/2014 CSF  Tuberculous meningitis ? Negative 123 Neg Neg
694 SCH7921840 GRS  G16  147822159 75 M 26/11/2014 CSF  No clinical details supplied Negative 134 Neg Neg
695 SCH7927742 RED  S12  32030223 7 F 28/11/2014 CSF  No clinical details supplied Negative 108 Neg Neg
696 SCH7932632 GRS  C15  103318176 23 F 02/12/2014 CSF  Retroviral Disease Negative 122 Neg Positive 222
697 SCH7941745 GRS  C15  137531174 43 M 05/12/2014 CSF  Meningitis ? Negative 121 Neg
698 SCH7941901 RED  B1   119579050 3 M 05/12/2014 CSF  Tuberculosis ?Disseminated Negative 122 Neg Positive 827 1 557
699 SCH7943856 GRS  C15  19886597 30 F 06/12/2014 CSF  Meningitis ? Negative 122 Neg 338
700 SCH7952998 GRS  G17  137621272 45 F 10/12/2014 CSF  No clinical details supplied Negative 119 Neg
701 SCH7953281 GRS  C15  145300562 33 M 10/12/2014 CSF  No clinical details supplied Negative 123 Neg Positive 17
702 SCH7954543 RED  S12  140658808 11m F 11/12/2014 CSF  Tuberculous meningitis ? Negative 124 Neg Positive 649 10 000 000
703 SCH7957605 GRS  E7   147965800 43 F 12/12/2014 CSF  Negative 126 Neg Neg
704 SCH7964078 RED  B2   16027484 9 F 16/12/2014 CSF  No clinical details supplied Negative 113 Neg Positive 335 553
705 SCH7965423 GRS  G17  139570261 18 F 17/12/2014 CSF  Meningitis Negative 120 Neg Neg
706 SCH7967630 GRS  C5   69738482 34 M 18/12/2014 CSF  No clinical details supplied Negative 108 <1.0 Neg
707 SCH7977214 GRS  E7   146707070 40 F 24/12/2014 CSF  No clinical information Negative 125 Neg Neg
708 SCH7978225 KNY  5 140910696 10m M 25/12/2014 CSF  Meningitis Negative 118 <1.0
709 SCH7979079 RED  E2   136181302 3 M 26/12/2014 CSF  Tuberculous meningitis Positive for AFB MTB - 24 days 116 Neg
710 SCH7979903 HEIEC EC   148272198 34 F 28/12/2014 CSF  Meningitis Negative 125 Neg Positive 499
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Number Labno Locn Ward PatID Age Sex Specimen Date Specimen Clinical Data TB Culture ID and TTP CSF Cl CSF ADA ZN Stain GeneXpert HIV CD4 Viral Load
1 SCH5647192 GRS  G12  20804035 28 F 16/01/2012 CSF  Investigation Negative <1.0 Neg
2 SCH5692856 GRS       81212219 49 F 06/02/2012 CSF  Negative 1.2 Neg Neg
3 SCH5729919 GRS  E7   37056041 35 M 22/02/2012 CSF  Dementia Negative 129 2.6 Neg Positive
4 SCH5734708 GRS  G17  65425001 32 F 24/02/2012 CSF  Negative 144 <1.0 Neg
5 SCH5764180 GRS  E7   17079278 35 F 09/03/2012 CSF  Investigation Positive for AFB MTB - 17 days 48.3 Neg
6 SCH5778460 GRS  C15  29314093 36 F 16/03/2012 CSF  Tuberculous meningitis Negative 126 <1.0 Neg Neg
7 SCH5796304 GRS  C12  57908469 60 M 26/03/2012 CSF  Investigation Negative 1.1 Neg
8 SCH5799740 GRS  G17  124179730 52 F 27/03/2012 CSF  Sepsis Negative <1.0 Neg Positive 5
9 SCH5806967 GRS  G16  80670524 44 M 30/03/2012 CSF  Laboratory investigation Negative 1.5 Neg Positive 108 628
10 SCH5815360 GRS  C15  15255979 35 F 03/04/2012 CSF  No clinical details supplied Negative <1.0 Neg
11 SCH5823405 GRS  G16  62070685 38 M 08/04/2012 CSF  Laboratory investigation Negative 124 <1.0 Neg Neg
12 SCH5857402 GRS  C15  13736186 70 M 25/04/2012 CSF  Investigation Negative <1.0 Neg
13 SCH5891194 WYN  CAS  108169301 25 F 12/05/2012 CSF  Investigation Positive for AFB MTB - 19 days 9.6 Neg Positive 52
14 SCH5898314 GRS  C15  73173122 28 M 16/05/2012 CSF  Meningitis Negative 7 Neg Neg
15 SCH5936346 WYN  CAS  65206732 38 F 03/06/2012 CSF  Meningitis Negative <1.0 Neg
16 SCH5975757 GRS  C15  78464484 21 M 21/06/2012 CSF  Free text diagnosis ?meningitis Negative <1.0 Neg Neg
17 SCH5979512 GRS  G17  125750406 66 M 24/06/2012 CSF  Investigation Negative <1.0 Neg
18 SCH5992159 GRS  C15  22805857 27 F 29/06/2012 CSF  ?sepsis Negative <1.0 Neg Positive 662
19 SCH5992251 WYN  SMM  115836736 55 M 29/06/2012 CSF  CONFUSION Negative <1.0 Neg Neg
20 SCH6001006 GRS  C15  75615351 45 F 05/07/2012 CSF  ACUTE CONFUSIONAL STATE Positive for AFB MTB - 26 days 6.4 Neg Neg
21 SCH6021902 GRS  C15  117621664 52 M 15/07/2012 CSF  Tuberculosis Negative <1.0 Neg
22 SCH6034665 GRS  C15  111024204 32 F 20/07/2012 CSF  Laboratory investigation Positive for AFB MTB - 18 days 6.3 Neg Positive
23 SCH6049806 GRS  C15  84893437 15 M 27/07/2012 CSF  Meningitis ? Negative 2.3 Neg
24 SCH6061693 WYN  CAS  30169502 20 F 03/08/2012 CSF  Suspect TB Negative <1.0 Neg Neg
25 SCH6082419 GFJ       70883343 33 F 14/08/2012 CSF  No clinical details supplied Positive for AFB MTB - 23 days 24.5 Neg
26 SCH6084480 SOM  KING 19744903 38 M 15/08/2012 CSF  Meningitis Negative 128 1.5 Neg Neg
27 SCH6088786 SOM  CAS  129615423 19 F 16/08/2012 CSF  Pneumonia Negative 1.1 Neg
28 SCH6088914 SOM  BICK 33226879 23 F 16/08/2012 CSF  Laboratory investigation Negative 2.4 Neg Positive 1 530
29 SCH6092224 WYN  CAS  117432682 35 M 18/08/2012 CSF  Meningitis Negative 9.7 Neg Positive 27
30 SCH6098390 GRS  C15  52334711 52 M 21/08/2012 CSF  Investigation Negative 3 Neg Neg
31 SCH6099513 GRS  C15  40509077 24 F 22/08/2012 CSF  Investigation Negative 3.3 Neg Positive 12
32 SCH6101017 SOM  BICK 74287210 44 F 22/08/2012 CSF  Laboratory investigation Negative 10.5 Neg
33 SCH6109018 SOM  CAS  126022995 38 M 25/08/2012 CSF  Investigation Negative 127 <1.0 Neg
34 SCH6110736 GRS  C15  103127023 34 F 27/08/2012 CSF  Laboratory investigation Negative 142 <1.0 Neg Positive 188
35 SCH6123534 GRS  D15  123131450 31 M 31/08/2012 CSF  Laboratory investigation Positive for AFB MTB - 38 days 3.6 Neg Positive 60
36 SCH6125833 GRS  C15  43147776 44 M 02/09/2012 CSF  Laboratory investigation Positive for AFB MTB - 15 days 4.3 Neg Positive 51
37 SCH6126727 SOM  KING 27949338 42 M 03/09/2012 CSF  Investigation Negative <1.0 Neg
38 SCH6130014 GFJ       13518030 60 M 04/09/2012 CSF  Sepsis Positive for AFB MTB - 21 days 5.7 Neg
39 SCH6134695 SOM  CAS  71108435 46 M 06/09/2012 CSF  Laboratory investigation Negative <1.0
40 SCH6139709 GRS  C15  72089360 50 F 07/09/2012 CSF  Laboratory investigation Negative 7 Neg Positive 352
41 SCH6143741 GRS  G7   32358798 64 M 10/09/2012 CSF  Investigation Negative 1.2 Neg Positive 20 123
42 SCH6147546 BROCH D    113683643 31  11/09/2012 CSF  Investigation Negative <1.0 Neg Positive 132
43 SCH6157286 GRS  C15  37430766 28 F 15/09/2012 CSF  No clinical information Negative 120 <1.0 Neg
44 SCH6189979 WYN  CAS  103596383 57 M 01/10/2012 CSF  Investigation Negative <1.0 Neg
45 SCH6201701 SOM  BICK 88044854 64 F 05/10/2012 CSF  Investigation Negative 141 <1.0 Neg Neg
46 SCH6202306 GRS  K41  58004508 32 F 06/10/2012 CSF  No clinical details supplied Negative 8.8 Neg Neg
47 SCH6218089 GRS  G16  31502461 60 M 12/10/2012 CSF  Laboratory investigation Negative 124 <1.0 Neg Neg
48 SCH6236480 SOM  KING 55062285 53 M 20/10/2012 CSF  Laboratory investigation Negative 132 <1.0 Neg
49 SCH6236485 SOW  CAS  81992778 37 F 20/10/2012 CSF  Laboratory investigation Positive for AFB MTB - 24 days 2.7 Neg
50 SCH6241751 SOM  KING 130676836 44 M 23/10/2012 CSF  Investigation Negative 140 1.8 Neg
51 SCH6244002 KNY  2 20155487 32 M 24/10/2012 CSF  ?MENINGITIS Negative 120 <1.0 Neg Positive 40
52 SCH6246954 KNY       21561451 57 F 25/10/2012 CSF  Cerebro-vascular accident Negative 121 <1.0
53 SCH6256333 GRS  C15  130219991 39 M 30/10/2012 CSF  Investigation Negative 1.1 Neg Positive 11
54 SCH6272304 WYN  CAS  56194657 50 M 06/11/2012 CSF  Laboratory investigation Positive for AFB MTB - 20 days 6.8 Positive AFB Neg 462
55 SCH6295461 GRS  C15  70908645 24 M 15/11/2012 CSF  Meningitis ? Negative <1.0 Neg Neg
56 SCH6303940 GRS  E7   119272912 22 F 20/11/2012 CSF  Laboratory investigation Negative 125 <1.0 Neg
57 SCH6315745 GRS  C15  116744947 31 F 26/11/2012 CSF  No clinical details supplied Negative 109 3.4 Neg Positive
58 SCH6325215 GRS  G22  33490913 44 F 29/11/2012 CSF  Psychosis Negative 123 <1.0 Neg Positive 245
59 SCH6326844 GRS  C15  43789718 27 F 30/11/2012 CSF  Meningitis TB? Negative 121 <1.0 Neg Positive 36
60 SCH6347186 GRS  C15  33513102 53 M 10/12/2012 CSF  Laboratory investigation Negative 121 5.8 Neg Positive 123
61 SCH6348863 GRS  F5   41090390 37 F 11/12/2012 CSF  Laboratory investigation Negative 128 <1.0 Neg Positive 545
62 SCH6365877 GRS  C15  10617280 33 M 20/12/2012 CSF  Investigation Negative 118 <1.0 Neg Neg 128
63 SCH6372219 KNY  4 21103049 29 F 25/12/2012 CSF  ENCEPHILITIS? Negative <1.0
64 SCH6380829 WYN       131910531 33 M 02/01/2013 CSF  Meningitis Negative 1.7 Positive 210 204 600
65 SCH6382663 GRS  C15  44138691 40 M 04/01/2013 CSF  Negative 1.6 Neg
66 SCH6386938 SOM  CAS  89395859 39 F 07/01/2013 CSF  Meningitis Negative 2.4 Neg
67 SCH6439283 WEF  ARV  46557765 37 F 31/01/2013 CSF  Investigation Negative 124 <1.0
68 SCH6469149 SOM  CAS  40632697 35 F 13/02/2013 CSF  No clinical details supplied Negative 5.5 Neg Positive 250 40
69 SCH6510418 GRS  C15  34663476 43 M 02/03/2013 CSF  Delirium Negative 1.4 Neg Neg
70 SCH6528001 GRS  G17  65696940 28 F 11/03/2013 CSF  Laboratory investigation Negative 118 2.1 Neg Neg
71 SCH6561871 GRS  G25  59973560 47 F 26/03/2013 CSF  Laboratory investigation Negative 122 1.2 Neg Neg
72 SCH6592891 GRS  C15  86869781 53 F 10/04/2013 CSF  Investigation Negative 125 <1.0 Neg Positive 159 84
73 SCH6602527 GRS  C15  84631019 37 F 15/04/2013 CSF  No clinical information Negative 125 <1.0 Neg
74 SCH6621477 KNY  2 20060083 63 M 23/04/2013 CSF  Negative 119 2.5 Positive
75 SCH6628759 GRS  C15  38086740 62 M 25/04/2013 CSF  No clinical details supplied Positive for AFB MTB - 18 days 48.1 Neg Neg
76 SCH6630695 GRS  G17  56104284 33 M 26/04/2013 CSF  Pulmonary tuberculosis Negative 122 <1.0 Neg Neg
85
77 SCH6640324 KNY  2 20614491 32 M 02/05/2013 CSF  Pulmonary tuberculosis Positive for AFB MTB - 18 days 111 4.1 Neg
78 SCH6701224 GRS  G12  73418113 33 F 29/05/2013 CSF  Laboratory investigation Negative <1.0 Neg Positive 7
79 SCH6730014 GRS  K41  129099842 24 F 11/06/2013 CSF  Investigation Negative 2.1 Neg
80 SCH6796673 SOM  BAIL 132461567 41 M 12/07/2013 CSF  Laboratory investigation Negative 1.3 Neg
81 SCH6810263 GRS  G5   76209139 50 F 18/07/2013 CSF  Investigation Negative <1.0 Neg Positive
82 SCH6881350 MOS  CAS  2205045 28 F 20/08/2013 CSF  Meningitis Negative 122 <1.0 Positive
83 SCH6916489 SOM  KING 103267118 40 M 04/09/2013 CSF  No clinical details supplied Negative 1.1 Neg Positive
84 SCH6922532 DPMSA 4A   54909791 34 M 06/09/2013 CSF  Pulmonary tuberculosis seizers Negative 2.3 Neg Positive 189
85 SCH6924288 WYN       73936866 44 F 07/09/2013 CSF  Investigation Negative 2.8 Neg Positive 67
86 SCH6939302 SOM  BAIL 131399792 31 M 13/09/2013 CSF  No clinical information Negative 7.8 Neg Positive
87 SCH6948665 GRS  F26  85621431 45 F 18/09/2013 CSF  No clinical information Negative 9.4 Neg Positive 10 000 000
88 SCH7029858 GRS  C27  104881958 45 M 24/10/2013 CSF  Laboratory investigation Negative 96 14.1 Neg
89 SCH7066551 GEO  B2   109831008 42 M 09/11/2013 CSF  Laboratory investigation Negative 135 1.9
90 SCH7067365 GRS  C15  137638433 37 M 10/11/2013 CSF  Investigation Negative 143 2.2 Neg Positive 81
91 SCH7104389 GRS  C27  35969427 36 F 26/11/2013 CSF  Laboratory investigation Negative 122 1.5 Neg Positive 156
92 SCH7160344 SOM  CAS  139303838 22 F 23/12/2013 CSF  No clinical details supplied Negative 4.4 Neg Neg
93 SCH7163009 WYN  CAS  117966564 29 F 24/12/2013 CSF  Meningitis Negative 2.4 Neg Positive
94 SCH7163445 SOM  CAS  119239499 28 M 25/12/2013 CSF  No clinical details supplied Negative <1.0 Neg Neg
95 SCH7168120 SOM  CAS  139366348 33 M 30/12/2013 CSF  NEW ONSET SEIZURES Negative <1.0 Neg Neg
96 SCH7173446 SOM  CAS  73745325 57 F 03/01/2014 CSF  Laboratory investigation Arachnoiditis Negative 44.7 Neg Neg
97 SCH7179954 GRS  F8   19580760 45 M 07/01/2014 CSF  Investigation Negative <1.0 Neg Positive 174
98 SCH7187161 GRS  D12  132443763 39 F 10/01/2014 CSF  No clinical details supplied Negative 1.6 Neg Positive 208 40
99 SCH7187494 GRS  C15  61094116 44 M 10/01/2014 CSF  Investigation Negative 4.5 Neg Positive 215 40
100 SCH7202389 SOM  CAS  117212951 33 M 17/01/2014 CSF  Meningitis ? Negative <1.0 Neg
101 SCH7213862 WYN  SMM  119836955 24 M 22/01/2014 CSF  Investigation Positive for AFB MTB - 8 days 8.5 Positive AFB Positive 4
102 SCH7231668 GRS  C15  46774642 43 F 29/01/2014 CSF  Meningitis Negative 129 2.4 Neg Positive 514 22 006
103 SCH7236812 SOM  CAS  88741111 40 F 31/01/2014 CSF  No clinical details supplied Negative 2.3 Neg
104 SCH7288743 GRS  C15  136013901 49 M 21/02/2014 CSF  Laboratory investigation Negative 2.9 Neg Positive 88
105 SCH7308719 WYN       72312689 46 M 02/03/2014 BCSF Meningitis ? Positive for AFB MTB - 16 days 7.5 Neg Positive 157
106 SCH7342523 GRS  C14  141947671 16 M 16/03/2014 CSF  No clinical details supplied Negative 124 3.3 Neg Neg
107 SCH7447878 GRS  C15  142854553 18 F 03/05/2014 CSF  Meningitis Negative 4.4 Neg Positive 68
108 SCH7463442 GRS  C15  57835860 68 F 12/05/2014 CSF  No clinical details supplied Negative 19.3 Neg
109 SCH7470440 GRS  D13  85369601 17 M 14/05/2014 CSF  Laboratory investigation Positive for AFB MTB - 12 days 5.9 Neg Positive 554
110 SCH7479831 GRS  C15  25652215 27 F 18/05/2014 CSF  Illegible diagnosis/ICD10 Negative 2.5 499
111 SCH7493302 GRS  G25  87939336 69 F 23/05/2014 CSF  No clinical details supplied Negative 122 <1.0 Neg Neg Neg
112 SCH7503148 FAL  CAS  142364421 53 F 28/05/2014 CSF  ?Meningitis Negative 2.3 Neg 209
113 SCH7519957 GRS  C15  135182921 68 M 04/06/2014 CSF  CEREBRILE Negative 1.1 Neg Neg
114 SCH7557918 GRS  C15  144082948 45 M 22/06/2014 CSF  ?MENINGITIS Positive for AFB MTB  - 19 days 7.6 Neg
115 SCH7561405 MOS  C    1105022 34 F 24/06/2014 CSF  Retroviral Disease Negative 4.1 Positive 3 834
116 SCH7562978 WYN  SMM  87330486 13 M 24/06/2014 CSF  Tuberculous meningitis Negative 70.6 Neg Neg
117 SCH7576168 WYN  SMF  64880222 30 F 30/06/2014 CSF  Gastro Enteritis HIV Negative 2 Neg Positive 162
118 SCH7590134 GRS  C15  124638024 38 M 06/07/2014 CSF  Pyrexia of unknown origin Negative <1.0 Neg Positive 193 40
119 SCH7590306 GRS  C15  26863357 36 M 06/07/2014 CSF  No clinical details supplied Positive for AFB MTB - 15 days 7.9 Neg
120 SCH7590496 GRS  C15  45232287 24 M 06/07/2014 CSF  Tuberculous meningitis Positive for AFB MTB - 15 days 25.3 Positive
121 SCH7612489 GRS  C15  144445368 32 F 16/07/2014 CSF  ?MENINGITIS Negative <1.0 Neg Positive
122 SCH7627110 2MIL LAB  94875549PE 41 M 22/07/2014 CSF  Tuberculosis Negative 3.2 Neg Positive 83 612
123 SCH7639139 SOM  CAS  103309910 27 F 27/07/2014 CSF  Meningism / Confusion Negative 1.7 Neg Positive 1 902 683
124 SCH7646819 GRS  G8   39837505 28 M 30/07/2014 CSF  Illegible diagnosis/ICD10 Negative 1.6 Neg Positive 215
125 SCH7647072 GRS  G8   112351739 50 F 30/07/2014 CSF  BURKITTIS LYMPHOMA Negative 2.5 Neg Positive 160
126 SCH7669531 GRS  C15  144618097 33 M 08/08/2014 CSF  Tuberculosis Negative 1.6 Neg Neg
127 SCH7672215 GRS  D12  68080829 28 M 09/08/2014 CSF  Meningitis ? Negative 109 15.1 Neg Neg
128 SCH7696765 GRS  E7   37610995 31 F 20/08/2014 CSF  Tuberculous meningitis ? Negative <1.0 Neg Positive 735
129 SCH7705030 SOW  C2   21924402 41 M 23/08/2014 CSF  Meningitis Negative 4.7 Neg Positive 353
130 SCH7730356 GRS  C15  57077232 57 F 04/09/2014 CSF  No clinical information Positive for AFB MTB - 32 days 110 7.3 Neg Neg Positive
131 SCH7734173 GRS  C15  125570374 36 F 05/09/2014 CSF  Meningitis Negative 119 8 Neg Neg Positive 414
132 SCH7734771 SOM  ICU  144547833 40 M 05/09/2014 CSF  Cerebro-vascular accident Pulmonary oedema / hpt / illeg. diag.Negative 1.2 Positive
133 SCH7738449 2MIL SURG 86752508DB 8 M 08/09/2014 CSF  Laboratory investigation Negative <1.0 Neg
134 SCH7745366 GRS  C15  46336954 26 F 10/09/2014 CSF  Meningitis Negative 3 Neg 614
135 SCH7766156 GRS  C15  23627078 39 M 19/09/2014 CSF  Illegible diagnosis/ICD10 Negative 4.4 Neg Positive 285 40
136 SCH7768857 WYN       14417414 37 F 20/09/2014 CSF  Tuberculous meningitis Negative <1.0 Neg Positive 260
137 SCH7791790 GRS  C15  29163599 31 F 01/10/2014 CSF  No clinical details supplied Negative 124 <1.0 Neg Positive 154
138 SCH7800770 GRS  G25  142820570 30 F 06/10/2014 CSF  ? TB MENINGITIS Negative 118 2.6 Neg Neg Neg
139 SCH7817731 2MIL LAB  98141062MC 36 F 13/10/2014 CSF  Delirium Negative 1.3 Neg Positive 12 902
140 SCH7866147 GRS  C15  146441845 66 F 03/11/2014 CSF  Meningitis Negative 5.6 Neg Positive 289 40
141 SCH7873237 WYN  CAS  139347934 14 F 06/11/2014 CSF  Meningitis Negative 120 3.6 Neg
142 SCH7876812 WYN       102879392 24 F 07/11/2014 CSF  Laboratory investigation Negative 2.1 Neg
143 SCH7882290 WYN  SMF  146514518 42 F 10/11/2014 CSF  Negative 2.3 Neg Positive 620
144 SCH7894798 2MIL DERM 94845377DA 43 F 14/11/2014 CSF  Laboratory investigation ?meningitis Negative 1.1 Neg Positive 10 000 000
145 SCH7897178 FAL  CAS  124813387 29 M 15/11/2014 CSF  Meningitis ? Negative 8.6 Neg 134
146 SCH7905071 2MIL LAB  99040057MC 31 M 19/11/2014 CSF  Headache Negative 1.5 Neg
147 SCH7915118 GRS  C5   146531405 39 M 24/11/2014 CSF  ?IRIS Negative 129 1.8 Neg Positive 27
148 SCH7926079 SOM  BICK 147879332 62 M 28/11/2014 CSF  No clinical details supplied Negative <1.0 Neg Neg
149 SCH7926792 WYN  CAS  75749176 29 F 28/11/2014 CSF  Laboratory investigation Negative 2.7 Neg Positive 395 407 656
150 SCH7967630 GRS  C5   69738482 34 M 18/12/2014 CSF  No clinical details supplied Negative 108 <1.0 Neg
151 SCH7978225 KNY  5 140910696 10m M 25/12/2014 CSF  Meningitis Negative 118 <1.0
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100-user Stata network perpetual license:       Serial number:  30120560105         Licensed to:  Hendre Swanepoel                       UCT_HS
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . diagti 20 0 115 141
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal        141        115        256   Abnormal          0         20         20 
     Total        141        135        276 
                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      7.2%      4.5%        11%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%     83.2%      100%Specificity                      Pr(-|N)     55.1%     48.8%     61.3%ROC area               (Sens. + Spec.)/2      .775      .745      .806 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.23      1.94      2.55 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .      6.33         . Positive predictive value        Pr(A|+)     14.8%     9.29%     21.9% Negative predictive value        Pr(N|-)      100%     97.4%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
6 . diagti 1 0 16 22
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal         22         16         38   Abnormal          0          1          1 
     Total         22         17         39 
CSF chloride diagnostic accuracy in 0-12 year age group: All patients / HIV+ / HIV-
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                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      2.6%     .065%      13.5%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%      2.5%      100%Specificity                      Pr(-|N)     57.9%     40.8%     73.7%ROC area               (Sens. + Spec.)/2      .789         .         1 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.38      1.64      3.45 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .         0         . Positive predictive value        Pr(A|+)     5.88%     .149%     28.7% Negative predictive value        Pr(N|-)      100%     84.6%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
7 . diagti 6 0 54 73
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal         73         54        127   Abnormal          0          6          6 
     Total         73         60        133 
                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      4.5%      1.7%      9.56%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%     54.1%      100%Specificity                      Pr(-|N)     57.5%     48.4%     66.2%ROC area               (Sens. + Spec.)/2      .787      .744      .831 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.35      1.92      2.88 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .      2.05         . Positive predictive value        Pr(A|+)       10%     3.76%     20.5% Negative predictive value        Pr(N|-)      100%     95.1%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
8 . 
CSF chloride diagnostic accuracy in 0-12 year age group: All patients / HIV+ / HIV-
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 ___  ____  ____  ____  ____ (R) /__    /   ____/   /   ____/___/   /   /___/   /   /___/   12.0   Copyright 1985-2011 StataCorp LP  Statistics/Data Analysis            StataCorp                                      4905 Lakeway DriveCollege Station, Texas 77845 USA800-STATA-PC        http://www.stata.com979-696-4600      stata@stata.com979-696-4601 (fax)
100-user Stata network perpetual license:       Serial number:  30120560105         Licensed to:  Hendre Swanepoel              UCT_HS
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . diagti 21 3 136 275
   Truedisease  Test result status  Neg.       Pos.  Total
  Normal 275 136 411Abnormal   3  21  24
 Total  278  157  435 
                                                 [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      5.5%      3.6%       8.1%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)     87.5%     67.6%     97.3%Specificity                      Pr(-|N)     66.9%     62.1%     71.4%ROC area               (Sens. + Spec.)/2      .772      .701      .843 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.64      2.16      3.24 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .187     .0647       .54 Odds ratio                   LR(+)/LR(-)      14.2      4.41      45.2 Positive predictive value        Pr(A|+)     13.4%     8.47%     19.7% Negative predictive value        Pr(N|-)     98.9%     96.9%     99.8% ---------------------------------------------------------------------------
6 . diagti 10 3 58 105
   True disease       Test result status       Neg.       Pos.  Total
  Normal 105 58 163Abnormal   3 10  13
 Total  108  68  176 
CSF chloride diagnostic accuracy in 13+ year age group: All patients / HIV+ / HIV-
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                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      7.4%        4%      12.3%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)     76.9%     46.2%       95%Specificity                      Pr(-|N)     64.4%     56.6%     71.7%ROC area               (Sens. + Spec.)/2      .707      .582      .831 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.16       1.5      3.11 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .358      .132      .973 Odds ratio                   LR(+)/LR(-)      6.03      1.71      21.1 Positive predictive value        Pr(A|+)     14.7%     7.28%     25.4% Negative predictive value        Pr(N|-)     97.2%     92.1%     99.4% ---------------------------------------------------------------------------
7 . diagti 5 0 39 81
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal         81         39        120   Abnormal          0          5          5 
     Total         81         44        125 
                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)        4%      1.3%      9.09%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%     47.8%      100%Specificity                      Pr(-|N)     67.5%     58.3%     75.8%ROC area               (Sens. + Spec.)/2      .838      .795       .88 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      3.08      2.38      3.98 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .      2.61         . Positive predictive value        Pr(A|+)     11.4%     3.79%     24.6% Negative predictive value        Pr(N|-)      100%     95.5%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
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 ___  ____  ____  ____  ____ (R) /__    /   ____/   /   ____/___/   /   /___/   /   /___/   12.0   Copyright 1985-2011 StataCorp LP  Statistics/Data Analysis            StataCorp                                      4905 Lakeway DriveCollege Station, Texas 77845 USA800-STATA-PC        http://www.stata.com979-696-4600      stata@stata.com979-696-4601 (fax)
100-user Stata network perpetual license:       Serial number:  30120560105         Licensed to:  Hendre Swanepoel              UCT_HS
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . diagti 41 3 251 416
   Truedisease  Test result status  Neg.       Pos.  Total
  Normal 416 251 667Abnormal   3  41  44
 Total  419  292  711 
                                                 [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      6.2%      4.5%      8.22%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)     93.2%     81.3%     98.6%Specificity                      Pr(-|N)     62.4%     58.6%     66.1%ROC area               (Sens. + Spec.)/2      .778      .736       .82 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.48      2.18      2.81 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .109     .0366      .326 Odds ratio                   LR(+)/LR(-)      22.7      7.36      69.7 Positive predictive value        Pr(A|+)       14%     10.3%     18.6% Negative predictive value        Pr(N|-)     99.3%     97.9%     99.9% ---------------------------------------------------------------------------
6 . diagti 11 3 74 127
   True disease       Test result status       Neg.       Pos.  Total
  Normal 127 74 201Abnormal   3 11  14
 Total  130  85  215 
CSF chloride diagnostic accuracy among all ages: All patients / HIV+ / HIV-
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                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      6.5%      3.6%      10.7%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)     78.6%     49.2%     95.3%Specificity                      Pr(-|N)     63.2%     56.1%     69.9%ROC area               (Sens. + Spec.)/2      .709      .592      .825 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.13      1.54      2.96 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .339      .124       .93 Odds ratio                   LR(+)/LR(-)      6.29      1.82      21.6 Positive predictive value        Pr(A|+)     12.9%     6.64%       22% Negative predictive value        Pr(N|-)     97.7%     93.4%     99.5% ---------------------------------------------------------------------------
7 . diagti 11 0 93 154
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal        154         93        247   Abnormal          0         11         11 
     Total        154        104        258 
                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      4.3%      2.1%       7.5%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%     71.5%      100%Specificity                      Pr(-|N)     62.3%       56%     68.4%ROC area               (Sens. + Spec.)/2      .812      .781      .842 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)      2.66      2.26      3.12 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .      4.68         . Positive predictive value        Pr(A|+)     10.6%      5.4%     18.1% Negative predictive value        Pr(N|-)      100%     97.6%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
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 ___  ____  ____  ____  ____(R) /__    /   ____/   /   ____/   ___/   /   /___/   /   /___/      Statistics/Data Analysis  
 ___  ____  ____  ____  ____ (R) /__    /   ____/   /   ____/___/   /   /___/   /   /___/   12.0   Copyright 1985-2011 StataCorp LP  Statistics/Data Analysis            StataCorp                                      4905 Lakeway DriveCollege Station, Texas 77845 USA800-STATA-PC        http://www.stata.com979-696-4600      stata@stata.com979-696-4601 (fax)
100-user Stata network perpetual license:       Serial number:  30120560105         Licensed to:  Hendre Swanepoel              UCT_HS
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . diagti 14 6 14 118
   Truedisease  Test result status  Neg.       Pos.  Total
  Normal 118 14 132Abnormal   6 14  20
 Total  124  28  152 
                                                 [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)       13%      8.2%      19.6%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)       70%     45.7%     88.1%Specificity                      Pr(-|N)     89.4%     82.8%     94.1%ROC area               (Sens. + Spec.)/2      .797      .691      .903 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)       6.6      3.72      11.7 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .336      .171      .657 Odds ratio                   LR(+)/LR(-)      19.7      6.66      57.9 Positive predictive value        Pr(A|+)       50%     30.6%     69.4% Negative predictive value        Pr(N|-)     95.2%     89.8%     98.2% ---------------------------------------------------------------------------
6 . diagti 7 3 5 55
   Truedisease  Test result status  Neg.       Pos.  Total
  Normal 55 5 60Abnormal  3 7 10
 Total  58  12  70 
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                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)       14%      7.1%      24.7%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)       70%     34.8%     93.3%Specificity                      Pr(-|N)     91.7%     81.6%     97.2%ROC area               (Sens. + Spec.)/2      .808      .655      .962 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)       8.4      3.31      21.3 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)      .327      .127      .846 Odds ratio                   LR(+)/LR(-)      25.7      5.34       123 Positive predictive value        Pr(A|+)     58.3%     27.7%     84.8% Negative predictive value        Pr(N|-)     94.8%     85.6%     98.9% ---------------------------------------------------------------------------
7 . diagti 3 0 5 25
      True    disease       Test result    status       Neg.       Pos.      Total
    Normal         25          5         30   Abnormal          0          3          3 
     Total         25          8         33 
                                                  [95% Confidence Interval]---------------------------------------------------------------------------Prevalence                         Pr(A)      9.1%      1.9%      24.3%---------------------------------------------------------------------------Sensitivity                      Pr(+|A)      100%     29.2%      100%Specificity                      Pr(-|N)     83.3%     65.3%     94.4%ROC area               (Sens. + Spec.)/2      .917      .849      .984 ---------------------------------------------------------------------------Likelihood ratio (+)     Pr(+|A)/Pr(+|N)         6       2.7      13.4 Likelihood ratio (-)     Pr(-|A)/Pr(-|N)         0         .         . Odds ratio                   LR(+)/LR(-)         .      3.18         . Positive predictive value        Pr(A|+)     37.5%     8.52%     75.5% Negative predictive value        Pr(N|-)      100%     86.3%      100% ---------------------------------------------------------------------------
  Missing values or confidence intervals may be estimated  using the -sf- or -sf0- options.
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___  ____  ____  ____  ____(R)
/__    /   ____/   /   ____/   
___/   /   /___/   /   /___/    
Statistics/Data Analysis
 ___  ____  ____  ____  ____ (R)
 /__  /  ____/  /  ____/
___/   /  /___/  /  /___/  12.0   Copyright 1985-2011 StataCorp LP
  Statistics/Data Analysis StataCorp
4905 Lakeway Drive
College Station, Texas 77845 USA
800-STATA-PC        http://www.stata.com
979-696-4600 stata@stata.com
979-696-4601 (fax)
100-user Stata network perpetual license:
Serial number:  30120560105
Licensed to:  Hendre Swanepoel
University of Cape Town
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF Cl - Stata import.xl
6 . gen NCSFCl=-CSFCl
7 . roctab TBCUL NCSFCl, binomial detail table graph summary
TBCUL
    NCSFCl          0          1      Total
-159  1  0  1 
-151  2  0  2 
-148  2  0  2 
-145  2  0  2 
-144  2  0  2 
-143  1  0  1 
-142  3  0  3 
-141  3  0  3 
-140  4  0  4 
-139  1  0  1 
-138  4  0  4 
-136  2  0  2 
-135  3  0  3 
-134  3  0  3 
-133  3  0  3 
-132  6  0  6 
-131  10  0  10 
-130  7  0  7 
-129  13  0  13 
-128  18  1  19 
-127  29  0  29 
-126  23  0  23 
-125  31  1  32 
-124  38  0  38 
-123  47  0  47 
-122  57  0  57 
-121  49  1  50 
-120  52  0  52 
-119  42  1  43 
-118  28  0  28 
-117  22  0  22 
-116  18  3  21 
-115  20  2  22 
-114  13  0  13 
-113  12  3  15 
-112  12  2  14 
-111  10  4  14 
-110  12  4  16 
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      -109         11          1         12 
      -108          6          3          9 
      -107          6          4         10 
      -106          4          3          7 
      -105          8          0          8 
      -104          6          2          8 
      -103          3          3          6 
      -102          5          0          5 
      -101          4          1          5 
      -100          1          1          2 
       -98          2          0          2 
       -96          1          2          3 
       -95          0          1          1 
       -94          1          0          1 
       -93          0          1          1 
       -89          1          0          1 
       -85          1          0          1 
       -62          1          0          1 
       -45          1          0          1 
     Total        667         44        711 
Detailed report of sensitivity and specificity
                                           Correctly
Cutpoint      Sensitivity   Specificity   Classified          LR+          LR-
( >= -159 )       100.00%         0.00%        6.19%       1.0000     
( >= -151 )       100.00%         0.15%        6.33%       1.0015       0.0000
( >= -148 )       100.00%         0.45%        6.61%       1.0045       0.0000
( >= -145 )       100.00%         0.75%        6.89%       1.0076       0.0000
( >= -144 )       100.00%         1.05%        7.17%       1.0106       0.0000
( >= -143 )       100.00%         1.35%        7.45%       1.0137       0.0000
( >= -142 )       100.00%         1.50%        7.59%       1.0152       0.0000
( >= -141 )       100.00%         1.95%        8.02%       1.0199       0.0000
( >= -140 )       100.00%         2.40%        8.44%       1.0246       0.0000
( >= -139 )       100.00%         3.00%        9.00%       1.0309       0.0000
( >= -138 )       100.00%         3.15%        9.14%       1.0325       0.0000
( >= -136 )       100.00%         3.75%        9.70%       1.0389       0.0000
( >= -135 )       100.00%         4.05%        9.99%       1.0422       0.0000
( >= -134 )       100.00%         4.50%       10.41%       1.0471       0.0000
( >= -133 )       100.00%         4.95%       10.83%       1.0521       0.0000
( >= -132 )       100.00%         5.40%       11.25%       1.0571       0.0000
( >= -131 )       100.00%         6.30%       12.10%       1.0672       0.0000
( >= -130 )       100.00%         7.80%       13.50%       1.0846       0.0000
( >= -129 )       100.00%         8.85%       14.49%       1.0970       0.0000
( >= -128 )       100.00%        10.79%       16.32%       1.1210       0.0000
( >= -127 )        97.73%        13.49%       18.71%       1.1297       0.1684
( >= -126 )        97.73%        17.84%       22.78%       1.1895       0.1274
( >= -125 )        97.73%        21.29%       26.02%       1.2416       0.1068
( >= -124 )        95.45%        25.94%       30.24%       1.2888       0.1752
( >= -123 )        95.45%        31.63%       35.58%       1.3962       0.1437
( >= -122 )        95.45%        38.68%       42.19%       1.5567       0.1175
( >= -121 )        95.45%        47.23%       50.21%       1.8088       0.0962
( >= -120 )        93.18%        54.57%       56.96%       2.0512       0.1249
( >= -119 )        93.18%        62.37%       64.28%       2.4762       0.1093
( >= -118 )        90.91%        68.67%       70.04%       2.9013       0.1324
( >= -117 )        90.91%        72.86%       73.98%       3.3501       0.1248
( >= -116 )        90.91%        76.16%       77.07%       3.8136       0.1194
( >= -115 )        84.09%        78.86%       79.18%       3.9779       0.2017
( >= -114 )        79.55%        81.86%       81.72%       4.3849       0.2499
( >= -113 )        79.55%        83.81%       83.54%       4.9127       0.2441
( >= -112 )        72.73%        85.61%       84.81%       5.0530       0.3186
( >= -111 )        68.18%        87.41%       86.22%       5.4140       0.3640
( >= -110 )        59.09%        88.91%       87.06%       5.3262       0.4601
( >= -109 )        50.00%        90.70%       88.19%       5.3790       0.5512
( >= -108 )        47.73%        92.35%       89.59%       6.2420       0.5660
( >= -107 )        40.91%        93.25%       90.01%       6.0636       0.6337
( >= -106 )        31.82%        94.15%       90.30%       5.4417       0.7242
( >= -105 )        25.00%        94.75%       90.44%       4.7643       0.7915
( >= -104 )        25.00%        95.95%       91.56%       6.1759       0.7816
( >= -103 )        20.45%        96.85%       92.12%       6.4968       0.8213
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( >= -102 )        13.64%        97.30%       92.12%       5.0530       0.8876
( >= -101 )        13.64%        98.05%       92.83%       6.9965       0.8808
( >= -100 )        11.36%        98.65%       93.25%       8.4217       0.8985
( >= -98 )          9.09%        98.80%       93.25%       7.5795       0.9201
( >= -96 )          9.09%        99.10%       93.53%      10.1061       0.9173
( >= -95 )          4.55%        99.25%       93.39%       6.0636       0.9618
( >= -94 )          2.27%        99.25%       93.25%       3.0318       0.9847
( >= -93 )          2.27%        99.40%       93.39%       3.7898       0.9832
( >= -89 )          0.00%        99.40%       93.25%       0.0000       1.0060
( >= -85 )          0.00%        99.55%       93.39%       0.0000       1.0045
( >= -62 )          0.00%        99.70%       93.53%       0.0000       1.0030
( >= -45 )          0.00%        99.85%       93.67%       0.0000       1.0015
( >  -45 )          0.00%       100.00%       93.81%                    1.0000
                      ROC                     Binomial Exact 
           Obs       Area     Std. Err.      [95% Conf. Interval]
         
           711     0.8615       0.0280        0.83462     0.88666
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___  ____  ____  ____  ____(R)
/__    /   ____/   /   ____/   
___/   /   /___/   /   /___/    
Statistics/Data Analysis
 ___  ____  ____  ____  ____ (R)
 /__  /  ____/  /  ____/
___/   /  /___/  /  /___/  12.0   Copyright 1985-2011 StataCorp LP
  Statistics/Data Analysis StataCorp
4905 Lakeway Drive
College Station, Texas 77845 USA
800-STATA-PC        http://www.stata.com
979-696-4600 stata@stata.com
979-696-4601 (fax)
100-user Stata network perpetual license:
Serial number:  30120560105
Licensed to:  Hendre Swanepoel
University of Cape Town
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF ADA - Stata import.x
6 . roctab TBCUL CSFADA, binomial detail table graph summary
TBCUL
    CSFADA          0          1      Total
.9  54  0  54 
1.1  6  0  6 
1.2  4  0  4 
1.3  2  0  2 
1.4  1  0  1 
1.5  4  0  4 
1.6  4  0  4 
1.7  2  0  2 
1.8  2  0  2 
1.9  1  0  1 
2  1  0  1 
2.1  3  0  3 
2.2  1  0  1 
2.3  5  0  5 
2.4  4  0  4 
2.5  3  0  3 
2.6  2  0  2 
2.7  1  1  2 
2.8  1  0  1 
2.9  1  0  1 
3  2  0  2 
3.2  1  0  1 
3.3  2  0  2 
3.4  1  0  1 
3.6  1  1  2 
4.1  1  1  2 
4.3  0  1  1 
4.4  3  0  3 
4.5  1  0  1 
4.7  1  0  1 
5.5  1  0  1 
5.6  1  0  1 
5.7  0  1  1 
5.8  1  0  1 
5.9  0  1  1 
6.3  0  1  1 
6.4  0  1  1 
6.8  0  1  1 
7  2  0  2 
7.3  0  1  1 
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       7.5          0          1          1 
       7.6          0          1          1 
       7.8          1          0          1 
       7.9          0          1          1 
         8          1          0          1 
       8.5          0          1          1 
       8.6          1          0          1 
       8.8          1          0          1 
       9.4          1          0          1 
       9.6          0          1          1 
       9.7          1          0          1 
      10.5          1          0          1 
      10.8          0          1          1 
      14.1          1          0          1 
      15.1          1          0          1 
      19.3          1          0          1 
      24.5          0          1          1 
      25.3          0          1          1 
      44.7          1          0          1 
      48.1          0          1          1 
      48.3          0          1          1 
      70.6          1          0          1 
     Total        132         20        152 
Detailed report of sensitivity and specificity
                                           Correctly
Cutpoint      Sensitivity   Specificity   Classified          LR+          LR-
( >= .9 )         100.00%         0.00%       13.16%       1.0000     
( >= 1.1 )        100.00%        40.91%       48.68%       1.6923       0.0000
( >= 1.2 )        100.00%        45.45%       52.63%       1.8333       0.0000
( >= 1.3 )        100.00%        48.48%       55.26%       1.9412       0.0000
( >= 1.4 )        100.00%        50.00%       56.58%       2.0000       0.0000
( >= 1.5 )        100.00%        50.76%       57.24%       2.0308       0.0000
( >= 1.6 )        100.00%        53.79%       59.87%       2.1639       0.0000
( >= 1.7 )        100.00%        56.82%       62.50%       2.3158       0.0000
( >= 1.8 )        100.00%        58.33%       63.82%       2.4000       0.0000
( >= 1.9 )        100.00%        59.85%       65.13%       2.4906       0.0000
( >= 2 )          100.00%        60.61%       65.79%       2.5385       0.0000
( >= 2.1 )        100.00%        61.36%       66.45%       2.5882       0.0000
( >= 2.2 )        100.00%        63.64%       68.42%       2.7500       0.0000
( >= 2.3 )        100.00%        64.39%       69.08%       2.8085       0.0000
( >= 2.4 )        100.00%        68.18%       72.37%       3.1429       0.0000
( >= 2.5 )        100.00%        71.21%       75.00%       3.4737       0.0000
( >= 2.6 )        100.00%        73.48%       76.97%       3.7714       0.0000
( >= 2.7 )        100.00%        75.00%       78.29%       4.0000       0.0000
( >= 2.8 )         95.00%        75.76%       78.29%       3.9188       0.0660
( >= 2.9 )         95.00%        76.52%       78.95%       4.0452       0.0653
( >= 3 )           95.00%        77.27%       79.61%       4.1800       0.0647
( >= 3.2 )         95.00%        78.79%       80.92%       4.4786       0.0635
( >= 3.3 )         95.00%        79.55%       81.58%       4.6444       0.0629
( >= 3.4 )         95.00%        81.06%       82.89%       5.0160       0.0617
( >= 3.6 )         95.00%        81.82%       83.55%       5.2250       0.0611
( >= 4.1 )         90.00%        82.58%       83.55%       5.1652       0.1211
( >= 4.3 )         85.00%        83.33%       83.55%       5.1000       0.1800
( >= 4.4 )         80.00%        83.33%       82.89%       4.8000       0.2400
( >= 4.5 )         80.00%        85.61%       84.87%       5.5579       0.2336
( >= 4.7 )         80.00%        86.36%       85.53%       5.8667       0.2316
( >= 5.5 )         80.00%        87.12%       86.18%       6.2118       0.2296
( >= 5.6 )         80.00%        87.88%       86.84%       6.6000       0.2276
( >= 5.7 )         80.00%        88.64%       87.50%       7.0400       0.2256
( >= 5.8 )         75.00%        88.64%       86.84%       6.6000       0.2821
( >= 5.9 )         75.00%        89.39%       87.50%       7.0714       0.2797
( >= 6.3 )         70.00%        89.39%       86.84%       6.6000       0.3356
( >= 6.4 )         65.00%        89.39%       86.18%       6.1286       0.3915
( >= 6.8 )         60.00%        89.39%       85.53%       5.6571       0.4475
( >= 7 )           55.00%        89.39%       84.87%       5.1857       0.5034
( >= 7.3 )         55.00%        90.91%       86.18%       6.0500       0.4950
( >= 7.5 )         50.00%        90.91%       85.53%       5.5000       0.5500
( >= 7.6 )         45.00%        90.91%       84.87%       4.9500       0.6050
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( >= 7.8 )         40.00%        90.91%       84.21%       4.4000       0.6600
( >= 7.9 )         40.00%        91.67%       84.87%       4.8000       0.6545
( >= 8 )           35.00%        91.67%       84.21%       4.2000       0.7091
( >= 8.5 )         35.00%        92.42%       84.87%       4.6200       0.7033
( >= 8.6 )         30.00%        92.42%       84.21%       3.9600       0.7574
( >= 8.8 )         30.00%        93.18%       84.87%       4.4000       0.7512
( >= 9.4 )         30.00%        93.94%       85.53%       4.9500       0.7452
( >= 9.6 )         30.00%        94.70%       86.18%       5.6571       0.7392
( >= 9.7 )         25.00%        94.70%       85.53%       4.7143       0.7920
( >= 10.5 )        25.00%        95.45%       86.18%       5.5000       0.7857
( >= 10.8 )        25.00%        96.21%       86.84%       6.6000       0.7795
( >= 14.1 )        20.00%        96.21%       86.18%       5.2800       0.8315
( >= 15.1 )        20.00%        96.97%       86.84%       6.6000       0.8250
( >= 19.3 )        20.00%        97.73%       87.50%       8.8000       0.8186
( >= 24.5 )        20.00%        98.48%       88.16%      13.2000       0.8123
( >= 25.3 )        15.00%        98.48%       87.50%       9.9000       0.8631
( >= 44.7 )        10.00%        98.48%       86.84%       6.6000       0.9138
( >= 48.1 )        10.00%        99.24%       87.50%      13.2000       0.9069
( >= 48.3 )         5.00%        99.24%       86.84%       6.6000       0.9573
( >= 70.6 )         0.00%        99.24%       86.18%       0.0000       1.0076
( >  70.6 )         0.00%       100.00%       86.84%                    1.0000
                      ROC                     Binomial Exact 
           Obs       Area     Std. Err.      [95% Conf. Interval]
         
           152     0.9066       0.0242        0.85029     0.94873
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___  ____  ____  ____  ____(R)
/__    /   ____/   /   ____/   
___/   /   /___/   /   /___/    
Statistics/Data Analysis
 ___  ____  ____  ____  ____ (R)
 /__  /  ____/  /  ____/
___/   /  /___/  /  /___/  12.0   Copyright 1985-2011 StataCorp LP
  Statistics/Data Analysis StataCorp
4905 Lakeway Drive
College Station, Texas 77845 USA
800-STATA-PC        http://www.stata.com
979-696-4600 stata@stata.com
979-696-4601 (fax)
100-user Stata network perpetual license:
Serial number:  30120560105
Licensed to:  Hendre Swanepoel
University of Cape Town
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF Cl - Age 0 to 12 yea
6 . univar Age CD4 ViralLoad
-------------- Quantiles --------------
Variable       n     Mean     S.D. Min .25 Mdn .75 Max
-------------------------------------------------------------------------------
     Age     276     3.26     3.32  0.08  1.00  2.00  5.00  12.00
 CD4  31  748.26  783.43  28.00  184.00  463.00  1007.00  3509.00
ViralLoad  30  1.9e+06  3.7e+06  40.00  1793.00 91307.50  6.7e+05  1.0e+07
-------------------------------------------------------------------------------
7 . 
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___  ____  ____  ____  ____(R)
/__    /   ____/   /   ____/   
___/   /   /___/   /   /___/    
Statistics/Data Analysis
 ___  ____  ____  ____  ____ (R)
 /__  /  ____/  /  ____/
___/   /  /___/  /  /___/  12.0   Copyright 1985-2011 StataCorp LP
  Statistics/Data Analysis StataCorp
4905 Lakeway Drive
College Station, Texas 77845 USA
800-STATA-PC        http://www.stata.com
979-696-4600 stata@stata.com
979-696-4601 (fax)
100-user Stata network perpetual license:
Serial number:  30120560105
Licensed to:  Hendre Swanepoel
University of Cape Town
Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF Cl - Age 13 years an
> trow
6 . univar Age CD4 ViralLoad
-------------- Quantiles --------------
Variable       n     Mean     S.D. Min .25 Mdn .75 Max
-------------------------------------------------------------------------------
     Age  437  38.21  13.52  13.00  29.00  37.00  46.00  80.00
 CD4  177  221.69  193.33  3.00  59.00  171.00  333.00  1005.00
ViralLoad  46  4.2e+05  1.1e+06  40.00  40.00  1160.00  1.8e+05  5.7e+06
-------------------------------------------------------------------------------
7 . 
Median and IQRs for age, CD4, and viral load for CSF chloride group ages 13 and older
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1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF Cl - Ages recalculat
6 . univar Age CD4 ViralLoad
-------------- Quantiles --------------
Variable       n     Mean     S.D. Min .25 Mdn .75 Max
-------------------------------------------------------------------------------
     Age  713  24.68  20.16  0.08  3.00  26.00  39.00  80.00
 CD4  208  300.17  395.05  3.00  78.00  194.00  380.00  3509.00
ViralLoad  76  1.0e+06  2.6e+06  40.00  68.50 10508.00  2.2e+05  1.0e+07
-------------------------------------------------------------------------------
7 . 
Median and IQRs for age, CD4, and viral load for CSF chloride group all ages
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Notes:
1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL & CSF ADA - Ages recalcula
6 . univar Age CD4 ViralLoad
-------------- Quantiles --------------
Variable       n     Mean     S.D. Min .25 Mdn .75 Max
-------------------------------------------------------------------------------
     Age  152  38.12  13.14  0.83  29.50  36.50  45.00  70.00
 CD4  51  225.31  197.55  4.00  60.00  174.00  352.00  735.00
ViralLoad  23  9.9e+05  2.9e+06  40.00  40.00  189.00  1.1e+05  1.0e+07
-------------------------------------------------------------------------------
7 . 
Median and IQRs for age, CD4, and viral load for CSF ADA group all ages
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1 . capture log close
2 . clear
3 . clear matrix
4 . set more off
5 . import excel "C:\Users\Hendre\Dropbox\MMed 2015\Data\Processed Data\TBCUL all positives for TTP.xlsx
6 . univar TBCULTBPOL
-------------- Quantiles --------------
Variable       n     Mean     S.D.      Min      .25      Mdn      .75 Max
-------------------------------------------------------------------------------
TBCULTBPOL     182    20.88     7.88     7.00    15.00    19.00    25.00    45.00
-------------------------------------------------------------------------------
7 . 
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This document addresses processing of different categories of specimens: 
1. Urinary samples 
2. Faecal samples 
3. Cerebrospinal samples 
4. Fluids and tissue from sterile sites 
5. Respiratory samples 
6. Mycological samples 
7. Pus and pus swabs 
8. Gastric Biopsies for Helicobacter 
9. Hardware (e.g. Orthopeadic nails and screws) 
 
RESPONISIBILITY 
All technical staff must understand and apply the information of this document. 
 
TURNAROUND TIMES 
These are stipulated in SOP MIC 0762 
 
MATERIALS AND REAGENTS 
Anaerobic indicator strips 
Blotting paper 
Cell counting chamber 
Cell counting fluid 
Clostridium GeneXpert kit 
Commercial anarobic saches 
Cover slips 
Crushers pestle and mortars - sterile 
Cytospin funnels, filters and slide holders 
DNA extraction fluid 
Flat bottomed 96 well microtitre trays 
Flint 
Forceps and scalpel – sterile 
Formal saline 





Graduated and automatic pipettes 
Immersion oil 
KOH 30% 




Lysing reagent for Bordetella 
Microscope cleaning fluid 
Optochin and vancomycin antibiotic discs 
Petri dishes 
Pipette tips - sterile 
Pipettes – sterile, plastic and glass 
Plastic screw-topped tubes – sterile 
Plastic slide holders (Blue) 
Precipitating fluid 
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Saline tubes - sterile 
Scalpel blades 
Sodium hypochlorite 5% (Jik) 




Swabs – cotton, sterile 
Tissues 
Various culture media 
Various media – liquid and solid agar in plates, tubes and bottles 
Wax 
Racks – plastic, metal and wooden. 
 
EQUIPMENT 
Adjustable air-displacement pipette with sterile tips 
Anaerobic gas and cylinder 
Anaerobic jars 














CSF – Cerebrospinal fluid 
FTA – Flourescent Treponemal Antibody 
VDRL – Venereal Disease Research Laboratory 
CLAT – Cryptococcal Latex Agglutination Test 
CRAG – Cryptococcal Antigen 
ZN - Ziehl Neelsen 
LIS – Laboratory information system 
SNF – Supernatant fluid 
NG – No Growth 
MGEN.Y (After request outstanding list) 
MGEN.C (Cell count outstanding list) 
MTB.M (ZN outstanding list) 
MGEN.T (Clostridium outstanding list) 
MGEN.Q (Bordetella & PCR16s outstanding lists) 
 
RETENTION AND DISPOSAL OF SAMPLES 
1. All samples are kept for 6 days at 2-8ºC, excluding pus swabs which are kept at room 
temperature. These are then discarded into red plastic lined boxes. 
2. Urine microtitre trays for microscopy kept for ±2 days. 
3. All CSF samples are kept for two weeks. 
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HEALTH AND SAFETY 
Observe the general laboratory safety rules as set out in the NHLS safety manual. 
 
PROCEDURE 




1) Bench senior to allocate staff to sections as per roster on bench 
2) Allocated staff member is responsible for ensuring the allocated resposibilites are performed 
for the section. 
3) One processing staff member starts at 07H00. 
Priority is given to specimen in the UCTCL rack from C17 so that microscopy results are 
recorded on the LIS before 08H00. 
Thereafter sputum samples are labelled for processing so that samples can be sent for TB 
culture ASAP. 
4) Specimen receiving clerk to: 
 
· check and label urines first at 07H00. 
· check after request list and record details on Checking of after requests and cell counts 
FRM/GEN/14 
5) Stagger tea times and lunch times. 
 
General Sorting and Registration rules 
 
1. C17 registration clerk to be informed of the importance of pus swab and fluid specimen 
type and site when registering. 
2. Technologist checking the forms to indicate clearly the CORRECT specimen type code 
that should be used along with the site code or text if available. 
3. Clinical information should always be consulted as this may provide additional information 
about the type and site of the specimen. 
4. If no specimen type is indicated on the request form, a laboratory clerk will contact the 
clinician to confirm details. 
 
General household rules 
1. Keep lids on red lined boxes, except when discarding material. 
2. Keep biocide discard jars’ lids on at all times – to avoid fumes affecting staff. 
3. Tissue/hand towels needed at following stations: 
i. -On trolley 
ii. -For urines 
iii. -For washing of cell counting chambers 
4. Change 70% alcohol in coplin jar every morning. 
5. Record cleaning of benches and microscope at 15H30. 
6. Record cleaning of BSC after every use, and perform a smoke test once a week. 
7. Discard specimens and clean trays for the next day at 15H30. 
8. Stock bench with media ,stains, slides and tubes as to prepare for late shift at 15H30. 
9. Pre-reduce anaerobic plates after each delivery. 
10. Cut strips of parafilm. 
11.  Cut CSF filters for cytospin 
12. Change urine wire loops Monday and Thursday and indicate on the urine worksheet. 
13. Sign worksheets to indicate person responsible for processing. 
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General GLP (Good Laboratory Practice) 
1. Remove smears from hot tray as soon as they are dry – to avoid burning. 
2. Stack plates in numerical order when labeling. 
3. Pack slides in specific tray when labeling, leaving a gap to start. 
4. Record time of specimen arrival on bench on M/PROC/01 sheet. 
 
Anaerobic jars 
See general SOP no MIC 0738 
1. Anaerobic Indicator strips are used. 
2. Separate 2 day anaerobic plates (Nala & Brucella) from one day plates ( 4%). 
3. Always indicate the date to be opened on 2 day jars. 
4. Put up a 2 day anaerobic jar after every batch 
5. Always use the correct lid and bottom with the same number. 
6. Close Genboxes properly. See package insert. 
7. Put up the jars after every delivery. 
8. Pre-reduce anaerobic media after every delivery. 
9. Record details on the anaerobic worksheet FRM/proc/03/. 
 
Centrifuge and cytospin use 
1. Leave lids open when not in use. 
2. Always set timer when spinning. 
3. Unpack balances after spinning. 
4. Place balances in volumetric sequence when unloading: 
-Yellow together & 
-Green separate from yellow labeled tubes. 
 
QUALITY CONTROL 
1. All media is checked prior to being issued for routine use. 
2. Check and change loops to ensure that they remain round and are free of bends, dents, 
corrosion or incinerated material. 
3. All pipettes are calibrated 
4. Control slides for the Gram Stain and ZN stain are performed daily and recorded on Stains 
worksheet FRM/GEN/04 according to Internal Quality Control SOP GPL1863 
5. Logsheet for control of Reagents and Package Inserts FRM/GEN/12 is completed when 
opening a new batch / lot: 
Urine Antigen Test 
GeneXpert Closdridium Test 
Lysis Buffer 
Genbox Anaerobic 
Anaerobic indicator strips 
112
In the event of a dispute concerning this document, the electronic version stored on Q-Pulse will be deemed to 
be the correct version 
National Health Laboratory Service- All rights reserved 





SECTION 3: CSF PROCESSING 
 
Responsibilties 
1. Check MGEN.C for outstanding cell counts, record on FRM/GEN/14 
a) this must be performed after hours and on weekends at the end of the 20h00 shift 
2. Complete move order weekly 
3. Complete the Logsheet for control of Reagents and Package Inserts FRM/GEN/12 for new 
lots. 






a) Record details on 10% Microscopy IQC FRM/GEN/11 
5. Perform a Gram stain control and a ZN control daily 




CSF’s are processed as soon as possible, as the cell count is urgent. 
 
Receipt of sample: 
A guideline of a minimum of 2 ml of CSF is required for culture. 
1. Correlate CSF to request form 
2. Initial top left hand corner of request form 
3. Date stamp request form 
4. Comment on appearance of CSF according to flow diagram 1, 
5. Record on request form and initial. 






TURBID  (TUR) 
BLOODSTAINED(BLDY) 
-If  obviously  bloodstained 
CLEAR 
Comment 
on  colour  of  SNF 
if  BLDY  or  TUR  (due  to 
RBC’s) 
CLEAR  and 
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1) CSFs referred from ‘up-country’ labs will not require a cell count or culture as they are referred 




Unsuitable CSFS for cell counts include: 
· CSFs received in clot activating tubes 
· Heavily bloodstained CSFS 
Record and initial on the request form and enter on the LIS the reason the CSF was unsuitable for 
cell count. 
 
Cell Count Set Up: 
1) Perform cell counts on all CSFs including post mortem CSFs, clotted CSFs and referred CSFs 
where a cell count was NOT performed at the stat lab. 
2) Use the clearest CSF if more than 1 tube is received. 
3) Invert CSF 10-15 times. If conical tube is received, flick bottom of tube to mix cells. 
4) Pipette 0.1ml CSF using a sterile graduated glass pipette into a glass tube. 
5) Place cover slip on cell counting chamber 
NOTE: if performing more than one cell count, differentiate on the request form and cell 
chamber using numbers 1,2,3,4 etc. 
6) Pipette 10µl cell counting fluid in glass tube and mix with CSF. 
7) Pipette stained CSF on cell counting chamber, covering the mirrored surface. 
8) NOTE: unstained cellcounts are performed on small volume CSFs as follows: 
a) Pipette 20µl of CSF onto cell counting chamber 
b) Place counting chamber in moist chamber for 5-10 minutes. 




1) Register CSF on LIS 
2) Ensure all test requests are ordered, excluding TB, as this will await the cell count result. 
3) Routine culture – CSF, FCELL 
4) CLAT - CRYP 
5) Fungal – MYCO, CRYP 
6) FTA / TPHA / VDRL – FTA 
7) GeneXpert - PCRXC 
8) Add additional test requests to CSFs already registered in C17. 
9) Place form stickers on request form 
10) Scan form/s 
 
Perform Cell Count: 
1) Count the number of polymorphonuclear cells and lymphocytes in 5 large blocks 
2) Count the erythrocytes in 1 large block and multiply 5. 
3) If many white blood cells are observed, count only one large block and multiply by 5. 
4) If innumerable cells are observed, count only one small block and multiply by 80. 
5) If cells are unclassifiable, count cells and report as unidentifiable cells. 
6) Indicate on request form for clotted CSFs that a cell count was performed but may be 
inaccurate due to the presence of clots. 
7) Using the cell count and table 1 determine if a TB culture is required and if a comment is 
applicable. 
8) Record all results and comments on the request form and initial. 
9) Enter cell count results on LIS under FCELL. 
10) Order TB tests if required. 
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TB MC&S or GeneXpert on request is only performed on CSF’s with a cell count of 5 or more 
lymphocytes or if the specimen is from an immuno-compromised patient, irrespective of the 
cell count. If TB is requested and not performed due to laboratory criteria, add the comment 
TBCSF (Specimen not sent for TB culture) on the request form and LIS. 
 
11) Telephonically inform the requesting doctor or ward of cell count results from UCT Private 
Hosiptal patients. 
12) If a substantial number of unidentifiable cells are observed, contact the clinician and if it is 
significant prepare sample for cytology: 
a) Aliquot CSF into a labelled tube. 
b) Photocopy request form 







Fuschs-Rosenthal counting chamber was originally designed for counting cells in CSF specimens. 
The depth is 0.2mm and the ruled area consists of 16 x1mm squares divided by triple lines. These 
squares are subdivided to form 16 smaller squares, each with an area of 1/16th of mm². 
Calculation of cell counts = 1.0mm x 1.0mm x 0.2mm x 5 = cells/ mm³. 
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· Label all media and tubes with ‘SCH’ labels. 
· Label slides with SCH number, surname and bench 




1) Using a pipette separate SNF from deposit into sterile 
2) Resuspend deposit and inoculate: 
· At least 5-7 drops for a cytospin Gram Stain, if insufficient prepare a slide for a direct Gram 
stain 
· 2% BA CO2 at 35ºC 
· BBA CO2 at 35ºC 
Spin slide in cytospin for 2 minutes at 1000rpm 
 
Brain abcesses add: 
· Brucella agar – 2 day anaerobically 
Nala agar – 2 day anaerobically 
 
Post Mortem CSFs add: 
· NYC - CO2 at 35ºC 




1) Pipette appromixmately 100µl into a blue top tube 
2) Place in FTA container in the refrigerator 
 
Fungal culture: 
1) Inoculate 40µl of SNF into a glass tube and perform the CRAG Lateral Flow Assay. 
2) Inoculate 2 drops of deposit onto the PDA slope ONLY if the doctor specifically request Fungal 
culture, and incubate the slope at 30ºC O2 
 
TB Processing: 
1) Place red dots on tubes and form 
2) Cytospin at least 5-7 drops of deposit and prepare a ZN stain 
 If insufficient for a ZN stain, report on LIS: 
‘Regret, insufficient sample for TB microscopy’ 
3) In the case of a request for GeneXpert the remainder of the CSF is sent to the TB laboratory 
as soon as possible. No ZN stain is needed in this case. 
· Place a label on the Processing Audit Trail Form FRM/PROC/01 
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This protocol details the steps to be taken when processing and decontaminating clinical specimens 
to optimise the recovery of mycobacteria (particularly M. tuberculosis) while reducing the 
contamination rate as much as possible. 
 
PRINCIPLE 
Mycobacterial culture is an important facet of the laboratory diagnosis of tuberculosis. However, 
mycobacterial culture is complicated by the fact that some mycobacteria (such as M. tuberculosis) 
take longer to grow than other organisms. If there are any rapidly-growing organisms in the clinical 
sample, they can overgrow any mycobacteria present, contaminating the culture.  The 
decontamination process, if not carried out correctly, can also affect the viability of mycobacteria in 
the clinical sample. It is thus important that appropriate specimens are decontaminated to reduce the 
likelihood of bacterial contamination, while still allowing mycobacteria to survive. 
 
SCOPE 
This SOP applies to all specimens in the laboratory on which mycobacterial culture has been 
requested, or on which myobacterial culture is deemed necessary from the clinical data supplied. 
This SOP must be followed by any medical technologist / student medical technologist / technician / 
medical scientist / pathologist / pathology registrar who may be working in the laboratory and 
processing specimens for mycobacterial culture. 
 
ABBREVIATIONS 
The following abbreviations are used in this SOP: 
 
CSF Cerebrospinal fluid 
TB Tuberculosis 
MOTT Mycobacteria other than tuberculosis 
MGIT Mycobacterial Growth Indicator Tube 
LJ Lowenstein-Jensen medium 
AUR Auramine stain 
ZN Ziehl-Neelsen stain 
PB Phosphate buffer 
PANTA Polymixin B, Azlocillin, Nalidixic acid, Trimethoprim,   Amphotericin B 
OADC Oleic acid – albumin – dextrose – catalase 
NALC N-Acetyl-L-Cysteine 
NaOH Sodium hydroxide 
Na3C6H5O7 Sodium Citrate 
EQA External quality control 
LIS Laboratory information system 
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Specimens for TB culture 
 TB culture is performed on all specimens when requested by the clinician or as followed by 
GeneXpert algorithm. 
 Any specimen taken as part of an invasive procedure (e.g. sterile fluids and tissues) on which 
only TB microscopy has been requested will automatically get a TB culture even if not 
specifically requested by the clinician. 
 TB culture must be performed on all specimens where the clinical data raises the possibility of 
multi-drug resistant TB. 
 All EQA samples that require TB culture. 
For specimens considered unsuitable for TB culture follow the SOP no GPL1667 for rejected 
specimens. 
 Specimens (tissues) received in formalin are unsuitable for TB culture. MTEST and forward 
the specimen to Histology. 
 Notify requesting doctor of all rejected trial specimens. 
 
EQUIPMENT AND SUPPLIES 
Biosafety cabinet 
Refrigerated centrifuge 
30 or 50 ml sterile tubes 
Glass slides 









1. NALC / NaOH/ Na3C6H5O7 
 4% NaOH/2.9% Sodium citrate solution – supplied in 1L aliquots by the media laboratory at 
NHLS Green Point. 
 Add 0,5g NALC powder to 100ml NaOH/Sodium citrate. 
 Mix well, date and initial the bottle and ready for use. 
2. Phosphate buffer (PB) pH 6.8 is supplied in 20ml aliquots by the media laboratory. 
3. MGIT PANTA 
 Reconstitute lyophilised MGIT PANTA with 15ml MGIT OADC supplement. 
 Record on the box the date of reconstitution, the expiry date and your initials. 
 Reconstituted PANTA is stable for 5 days and stored at 2oC-8oC. 
 
FREQUENCY 
 Specimens are processed daily Monday to Friday. 
 No processing occurs over Saturdays, Sundays and public holidays. 
 Samples are processed in batches of maximum 30 specimens. 
 The cut-off time for the last batches of the day is 13H30. 
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M. tuberculosis is spread by the airborne route. Many laboratory procedures are accompanied by the 
formation of aerosols that may contain bacteria but most importantly, mycobacteria. The technologist 
must be aware of aerosol formation and the dangers thereof. Therefore all procedures, as far as 
possible, should be performed in the laminar flow cabinet. Refer to the NHLS Safety Manual for 
additional information regarding Health and Safety. 
 
NOTE: PROCESS ONE SPECIMEN AT A TIME INSIDE THE LAMINAR FLOW CABINET. 
Specimens broken in the centrifuge: 
i. Working under the laminar flow cabinet, decontaminate the buckets by using a suitable 
disinfectant. 
ii. Leave the buckets to soak under the hood for at least 15 minutes before removing any broken 
pieces with a pair of forceps and discarding them in the sharps container. Rinse the buckets in 
water and leave to dry before using again. 
iii. For specimens broken in the centrifuge send out a final report. 
 
Refer also to the NHLS Safety Manual, for additional information regarding protective personal 
equipment, and procedures to be followed in the case of suspected exposure to blood / body fluids. 
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Specimen received and checked for 
suitability for culture 
 
SUMMARY 
The following flow chart and table provide a summary of specimen processing for mycobacterial 
culture, as well as which stains / media are used for different specimen types. Details will be found in 








Nature of specimen 
Cultured in routine 
lab? 
Inoculate MGIT +/- 
LJ (Gxpert, Store) 
Specimen from non- 
sterile site 
 Resp tract 
 Gastric asp / wash 
 Urine, Stool 
 Pus swab / Pus 
 Non-sterile tissue 
Specimen from normally 
sterile site 
 CSF 
 Sterile body Fluid 
 Sterile tissue 
 Pus swab / Pus 
No Yes 
Inoculate 2% BA 
Decontaminate Growth No growth 
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SPECIMEN TYPE Microscopy Decontam Culture Media 
Urines, Respiratory specs, 
Gastric washings 
Auramine Yes Yes MGIT 
CSF ZN No* Yes MGIT 
Fluids, curretings, pus swabs ZN No* yes MGIT 
Tissue ZN No* Yes MGIT 
Bone Marrow & Blood Cultures None No* Yes Myco F/Lytic 
inoculated at bedside 
Bone Biopsies None No* Yes MGIT, tube size 
depending on the size 
of the tissue 
EQA samples for culture None Yes Yes MGIT and LJ in 37oC 
incubator 
*Decontaminate if routine culture has yielded growth 
*Rectal Tissue must be decontaminated. 
Table 1: Summary of processing requirements for different specimen types. Please refer to the text 
for full details. 
 
Stool specimens for TB microscopy and culture: 
 
Do direct TB microscopy. 
Add coded comment “tbst” under remarks on LIS (tbst and control enter ) which decodes to: “ TB 
culture of stool has low utility as more than 90% cultures become contaminated. Alternative 
specimens such as blood, bone marrow or tissue are superior. Please contact microbiology lab if 
culture of stool is required”. 
Do not store the stool specimen. 
 
Colonic/perianal tissue samples: Routine culture is not performed but add coded comment “colon” 
under remarks on LIS (colon and control enter) which decodes to: “routine bacterial culture of perianal 
tissue and colonic biopsies yields normal enteric flora, and is thus not performed. If infection with 
enteric pathogens (Salmonella, Shigella etc) is suspected, please submit a stool sample.” 
 
Skin Biopsies: Routine culture can not always be performed due to insufficient sample. Add coded 
comment “skinbiopsy” under remarks on LIS (skinbiolpsy and control enter) which decodes to: 
“Insufficient specimen to perform all tests requested. TB culture and fungal culture requests will be 
prioritised. In future please submit 2 biopsy samples if bacterial, fungal and TB cultures are required.” 
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Specimens for TB culture are separated into 2 groups: 
(a) specimens forwarded from other benches 
(b) new specimens only for TB culture 
The specimens are stored in the reception area fridge in the designated boxes until collected by the 
TB lab staff. It is extremely important to refrigerate specimens that cannot be processed on the same 
day in order to reduce contamination. 
Each sample is accompanied by a form. Always make sure all the forms are date and time stamped. 
 
SORTING IN THE TB LAB 
1. Upon receiving: 
a) Ensure that specimens are adequately containerised. Leaking specimens are to be 
discarded with consent of one of the senior staff. However, as far as possible, theatre 
specimens must be saved. 
b) Always check that the name, folder number and any other details on the specimen 
correspond with that on the form. 
c) Always make sure that all the requests from the clinician are performed. 
d) Initial the top, front left hand corner of the request form. 
2. Separate specimens into the following groups: 
a) Specimens NOT FOR decontamination 
b) Specimens FOR decontamination 
c) Specimens for TB culture only that needs to be checked for sterility. 
d) Specimens for Genexpet. 
 
Specimens NOT FOR 
decontamination 
CSF’s. 
Fluids, Tissues, Bone 
biopsies, Curretings and 
Pus swabs which had NO 
GROWTH on the routine 
culture. 





Bronchial brushings (RXH) 
Urines, stools 
Fluids, tissues and pus 
swabs which had 






Write DC in the front of  the 
request form 
Specimens that need to be 
checked for sterility 
Fluids, Tissues, Pus swabs 
which have not been 
cultured in routine 
laboratory 
Fluids- spin down at 3200  rpm 
and use deposit. 
Tissues- crush. 
Inoculate the specimen onto a 
2%BA and incubate aerobically 
overnight. 
Assess the following day if 
decontamination is required  or 
not. 
Growth = decontaminate (D/C) 
No growth = No decontamination. 
124
Q-Pulse5/docs/active/ MIC0699v11 Page 8 of 13
In the event of a dispute concerning this document, the electronic version stored on Q-Pulse will be deemed to be 
the correct version
National Health Laboratory Service- All rights reserved
Speimens for Genexpert 
only
Sputa, Tracheal aspirates 
from adults 





Sputa and tracheal 
aspirates from children ≤13 
years. 
PREPARATION OF A BATCH
(a) Batches of specimens are prepared in numerically labelled boxes, and consist of a maximum of
30 specimens.
(b) The specimens are processed in the following order:
1. Specimens NOT requiring decontamination
2. Specimens requiring decontamination.
3. Decontamination solution QC.
REMEMBER to put specimens with a positive auramine result at the back of the batch to 
minimize cross-contamination. 
(a) A sterile tube (e.g. Sterilin tube) is used for each specimen that requires decontamination.
(b) Pre-label the specimens and the sterile tube (1-30). After registration, proper labelling will occur.
(c) Make a note of special processing requirements:
Samples for Auramine only = yellow dot on falcon tube. 
Samples not requiring microscopy = orange dot on form and falcon tube. 
Samples for culture and Genexpert =blue dot on falcon tube. 
Trial that requires extra e.g. Grams stains. 
(d) Place all the forms of the batch in a labelled sleeve and send for registration. Use appropriate
test method during registration.
 TBA/TBZ TB microscopy
 TBCUL TB culture 
 TBS TB sensitivity 
 PCRGX GenXpert 
 LJ CULTB 
 Use the profile available when registering trial forms.
(e) Each batch is accompanied by a TB processing worksheet generated electronically using
“MTBRG”.
This worksheet is created in the order of which the batch was processed. It also reflects reagents 
used as well as who is responsible for the different areas of the processing. 
(f) All samples for TB culture must be received in “Receive in Work area”, MTB.K.
TOPPLING
 All specimens requiring decontamination are toppled to the corresponding sterile tube.
 Topple a maximum of 5ml of specimen into the sterile tube.
 Always use the most representative portion of the sample.
 Pus swabs: transfer the swab to the sterile tube and add 2ml of sterile saline.
Vortex well to dislodge any organisms that may be present on the swab.
 Stool specimens: mix 5ml of stool with 5ml Middlebrook 7H9 medium and vortex well.
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 Contaminated bone: add sufficient sterile saline to cover the bone.
DECONTAMINATION
Prepare the decontamination solution. 
Method: 
i. Add an equal quantity of decontamination solution to the specimen using a separate pipette
for each specimen. Set timer for 20 minutes once added to the 1st specimen of the batch.
ii. After adding decontamination solution to all samples in the batch, any left over
decontamination solution is used as the QC. Pour 5ml of the left over decontamination solution
into a sterile tube and fill the tube up with PB as soon as possible. After this follow steps iii, iv,
vi and vii.
iii. MIX THOROUGHLY. SHAKE IF NECESSARY.
iv. Allow to stand on the bench for 20 minutes, vortexing the container at 5 minute intervals.
Proper attention should be given to the specimen treatment time (no more than 20 minutes- 
delays have adverse effects on the number of tubercle bacilli that survive the decontamination
process).
v. After 20 minutes, add pre-aliquotted phosphate buffer (PB - pH6.8) up to the 50ml mark using
a separate aliquot for each specimen and mix. Do not use an aliquot of PB for more than one
specimen. If there is any PB remaining in the aliquot, discard it.
vi. Centrifuge for 15 minutes at 3000 x g in a refrigerated centrifuge.
vii. After centrifugation, as each specimen is removed from the centrifuge, check for possible
breakage that may have occurred.
Carefully decant supernatant fluid into discard jar containing an appropriate disinfectant. Be aware  of 
the deposit or the swab/bone when decanting. This is an area where cross contamination can occur in 
the form of splash backs so please do it with caution. 
PREPARATION OF SMEARS FOR MICROSCOPY
All samples received for TB culture must have a TB microscopy done. 
An auramine is done on pulmonary, faecal and urine specimens. 
A Zhiel-Neelsen is done on all extra-pulmonary specimens. 
Microscopy is NOT done on bone marrow, blood cultures, bone biopsies and certain EQA samples 
(refer to the instructions for each EQA sample). 
Specimens that come from the routine laboratory will usually have either a ZN or an auramine result. 
There is no need to repeat the microscopy unless a sputum sample had a direct (ie unconcentrated) 
microscopy done and the result was negative, in which case the auramine must be repeated. 
Method: 
i. A clean slide is labelled for each specimen, and the laboratory number is indicated on each
slide.
ii. Onto each slide place a drop of precipitation fluid. This acts as a fixative as the
decontamination procedure depletes the specimen of protein.
iii. The above deposit is mixed thoroughly and a drop (30ul) is added to the precipitation fluid. Do
NOT use more than this as the smears will be too thick.
iv. Evenly spread the smear out about 1.5cm by 1cm.
v. Allow the smears to dry completely under the bio-safety cabinet, since mycobacteria can still
be viable at this stage.
INOCULATION OF MEDIA
For each specimen label a MGIT tube with the patient’s details. All media must have the patient’s full 
name and initial and specimen number. 
Check media requirements according to specimen type, clinical details or test requested. 
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The following specimens must have an LJ slope (green dot on MGIT) inoculated. 
 Culture for MOTTs or atypical mycobacteria is requested - LJ in the 30C incubator
 Clinical data suggests M.marinum (chronic soft tissue infection caused by fish hook or
injury whilst cleaning a fish tank) or M. ulcerans infection (chronic soft tissue infection) -
LJ in the 30C incubator
 Specimens from clinical trials if requested (see front page of request form or trial SOP)
- LJ in the 37C incubator
All EQA samples – LJ in the 30 or 37C incubator depending on clinical story provided 
Method: 
i. Add 800ul of MGIT PANTA to each tube just before inoculation.
ii. Resuspend the deposit with 0.5ml fresh PB (6.8). If an LJ, direct HAIN, GenXpert, or storage
is needed then re-suspend with extra 0.5 ml for each test method.
iii. Inoculate the MGIT with approximately 0.5ml specimen using a sterile plastic pipette. If LJ
required place 2-3 drops onto the slope.
iv. Discard the plastic pipette into the appropriate waste container inside the bio-safety cabinet.
v. Recap the MGIT tube tightly and mix by inverting the tube.
vi. Transfer pus swabs into the MGIT using a sterile forceps.
STORAGE OF SEDIMENT
Storage is performed as requested per trial.
Aliquot 0.5ml of decontaminated sample into a labeled storage tube. 
Enter details on “S” drive in the sediment storage folder.
Enter details under “STORE” test method on the LIS. 
Place in designated box at -70oC. 
INCUBATING OF MEDIA
After inoculation, place the MGIT tubes into the MGIT machine immediately according the BACTEC 
MGITTM 960 system user manual. 
Place the LJ slopes, with slightly loosened caps in the aerobic incubator, sloping overnight. The next 
day tighten the caps and put in the appropriate tray and incubator. 
All media / cultures are incubated for 42 days / 6 weeks. 
Large pieces of Bone or uncrushable tissues (if not sterile)
i. Add sufficient sterile saline to cover the bone
ii. Add an equal volume of NALC/NaOH
iii. Allow to stand on the bench for 20 minutes, shaking the container at 5 minute intervals.
iv. After 20 minutes, make up to 20ml with pre-aliquotted PB (pH6.8).
v. Leave the bone to stand for 20 minutes (do not centrifuge).
Aseptically place the bone directly into a MGIT tube. If the tissue or bone is too large, place into a 
sterile container and decant a sufficient volume of MGIT medium to cover the specimen. 
PROCESSING OF SPECIMENS NOT REQUIRING DECONTAMINATION
Bone / Tissues too small to crush 
 Aseptically place the bone or small tissue directly into a MGIT tube. If the tissue or bone is too
large, place into a sterile container and decant a sufficient volume of MGIT medium to cover the
specimen. Incubate with the LJ slopes. TB microscopy is not required on these specimens.
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i. If the specimen has not been centrifuged in the routine laboratory, then centrifuge for 15 
minutes at 3000 x g in a refrigerated centrifuge. 
ii. After centrifugation, prepare a smear for microscopy if this has not yet been done. The ZN stain 
is used for CSF, pleural and ascitic fluids. 
iii. Inoculate approximately 0,5ml of the specimen into a MGIT tube, and 2-3 drops onto an LJ 
slope if necessary. 
 
LIMITATIONS 
 Prolonged decontamination will result in loss of viability of Mycobacteria. 
 Incorrect concentration of the decontamination solution will affect the decontamination of the 
specimens. 
 
MEDIA AND SOLUTIONS 
Any MGIT tube not used immediately for inoculation of specimens must be stored in the dark 
(cupboard). 
 
HOUSEKEEPING IN THE TB LAB 
Mornings: 
Unpack LJ’s from the sloping tray and place in appropriate incubator. 
Read the 2% plate of previous day sterility checks. 
Collect all specimens and forms from the reception area. 
End of the day: 
Back up all MGIT machines 
Stock up all workstations with pipettes, swabs, Phosphate buffers, gloves and paper towels. 
Discard specimens from previous week. 
Wipe down benches daily with Agglusept. On days when molecular extraction is performed, use 0.5% 
- 1% solution hypochlorite, followed by 70% alcohol, for affected pipettes, surfaces & cabinets in 
addition to Agglusept.. 
Sign the Daily Housekeeping logsheets after cleaning. 
Quality control 
Refer to Internal Quality Control in the TB Laboratory SOP MIC0733. 
Refer to the BD BBL MGIT package Insert 
When opening a new box of PANTA, record the lot number and expiry date on the Logsheet for 
Control of Reagents and Package Inserts FRM /GEN/07. 
 
OUTSTANDING WORKLISTS 
The following outstanding lists must be checked: 
TBA / TBZ – MTB.M daily 
PCRGX – MTB.X daily 
PCRCU – MTB.P must be checked before and after the HAIN test has been performed. 
SEND - MTB.R weekly 
MTB.T (TBCUL, TBSN1) monthly 
CADM.H (STORE) twice a week 
MTB.K (TBCUL) 3 times a week 
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Any patient suspected of having TB should have an appropriate specimen sent for microscopy, which 
is the mainstay of diagnosis in South Africa. In some instances, it is also necessary to perform culture 
for mycobacteria. 
These instances include: 
 Repeated smear negative cases with ongoing clinical suspicion of TB 
 Suspected MDR cases 
 Suspected non-tuberculous mycobacterial infections 
 
REFERENCES 
Isenberg H. Clinical Microbiology Procedures Handbook, Volume 1 
Kent PT, Kubica GP. Public Health Mycobacteriology - A Guide for the Level III Laboratory. 1985. 
Centres for Disease Control, Atlanta Georgia. 
BD BBL MGIT package Insert 






SOP MIC0700 – MGIT / LJ / MycoF/Lytic positives processing 
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PROCESSING OF MGIT TUBES, LJ SLOPES and myco/f lytic bottles 
 
PURPOSE 
This SOP serves as a guideline for placing and removing MGIT tubes / LJ slopes into and from the 
incubator. It also describes how to follow-up positive MGIT tubes / LJ slopes and Myco/F Lytic bottles. 
 
PRINCIPLE 
The MGIT system is an automated, liquid medium based culture system for detecting mycobacterial 
growth. Once specimens have been inoculated, MGIT tubes are placed into a MGIT incubator unit. 
Growth is automatically evaluated by the machine by measuring changes in the fluorescence of the 
tube, which is influenced by a change in the oxygen tension in the medium. Once a change in 
fluorescence is measured, the tube is “flagged positive” by the incubator. 
 
LJ medium is a solid, egg based medium for culture of mycobacteria. It is often used as an adjunct to 
liquid based media, although there is some evidence that the MGIT media alone is sufficiently 
sensitive. Certain specimens (detailed in the specimen processing SOP) are inoculated onto LJ media 
as well. Growth is measured visually. 
 
The Myco/F-Lytic bottle is liquid culture used with the BACTEC 9000 blood culture system to allow the 
detection of mycobacteria, Growth is automatically evaluated by the machine by measuring changes 
in the fluorescence sensor at the bottom of the tube, which is influenced by a change in the oxygen 




This SOP applies to all MGIT, LJ cultures and MycoF/ Lytic bottles which have been inoculated with 
either clinical or quality control samples. 
This SOP must be followed by any medical technologist / student medical technologist / technician / 




The following abbreviations are used in this SOP: 
MGIT    Mycobacterial Growth Indicator Tube 
LJ    Lowenstein-Jensen medium 
AUR    Auramine stain 
ZN    Ziehl-Neelsen stain 
LED    Light emitting diode 
2% BA    2% Blood agar 
LIS    Laboratory Information System 
 
EQUIPMENT AND SUPPLIES  
Bactec MGIT 960 System User’s Manual 
Biosafety cabinet 
Glass slides 
MGIT tubes  
LJ slopes 
Myco/F-Lytic BACTEC culture bottles 
2% Blood agar plates  
Bactec 960 MGIT incubator unit 
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FREQUENCY 
Positive MGITs are unloaded Monday to Fridays excluding public holidays. 
Negative MGITs are removed daily excluding Sundays and public holidays. 
SAFETY PRECAUTIONS 
M. tuberculosis is spread by the airborne route. Many laboratory procedures are accompanied by the
formation of aerosols containing bacteria but most importantly, mycobacteria. All workers in the TB
laboratory must be aware of aerosol formation and the dangers thereof. Any work that involves
opening either a MGIT tube or an LJ slope MUST be performed in biosafety cabinet. 
Refer to the NHLS Safety Manual for additional information regarding Health and Safety. 
INCUBATION OF MGIT TUBES 
1) Incubate MGITs according to the BACTEC MGIT 960 System User’s Manual.
2) If a specimen is in a container other than a MGIT tube e.g. large bone, incubate at 37oC
aerobically. This culture will be inspected manually.
PROCESSING POSITIVE MGIITS
1) Remove positive MGIT tubes according to the BACTEC MGIT 960 System User’s Manual.
2) Print an ‘Unloaded Positive Report’ according to the BACTEC MGIT 960 System User’s Manual
and initial, date and file.
3) Read the 2% plate and record results on the MTBZN worksheet created the previous day.
4) Record on the LIS under notes if growth was observed on the 2% BA for any ZN positive MGITs.
5) Sort the positive MGITs:
a) Return MGITs positive >1 day but <7 days (MGITs are dated) to the same MGIT unit it was
removed from.
b) MGITs positive the previous day and where growth is obtained on the 2% BA, place the MGIT
in the contaminated box.
c) MGITs positive the previous day and where no growth is obtained on the 2% BA, return MGIT
to the same MGIT unit it was removed from.
6) Create an MTBZN worksheet per MGIT unit for all positive MGITs which are first time positive or
are positive again after 7 days.
7) Label a slide and a 2% BA plate for each MGIT.
8) Place a drop of precipitating fluid onto the slide to ensure adhesion of the smear.
9) Aspirate approximately 0.1ml from the bottom of the MGIT tube and inoculate the 2% BA and
slide.
10) Dry slides under the hood and perform the ZN stain according to Commonly Used Staining
Techniques SOP MIC0728.
11) Incubate the 2% BA overnight aerobically at 37ºC.
12) Read and record ZN results on the MTBZN worksheet:
a) Indicate ‘C+’ for cording
b) Indicate ‘+’ for no cording
13) If ZN is negative, date the MGIT tube and return to the same MGIT unit within 5 hours of removal.
14) Set aside smear positive MGITs and indicate on the label those where no cording was observed.
15) Enter results of the smear positive MGIT under TBCUL on the LIS.
a) Enter ‘P’ is cording was observed
b) Enter ‘Q’ if cording was not observed.
16) Follow the Positive MGITs and LJs for Identification flow diagram to determine what test to
perform on the positive MGIT.
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Positive MGIT tube 
 
Flagged positive 
and was followed 
up ≤7 days ago 




Place tube back in 
the MGIT unit  
Prepare ZN slide. Inoculate 
MGIT onto 2% BA 
ZN pos – record 
MTBZN report 
ZN neg 
Put tube aside 
and follow the 
Positive MGITs 
and LJs for 
Identification 
flow diagram 
Place back in the 
MGIT unit 
Read 2% BA plate 
and record on the 
unloaded positive 
report.  
Pos after > 1 day 
Replace tube in 
MGIT incubator 
and repeat ZN 
and 2% BA after 
7 days. 
No growth 





growth on 2% BA, 
will need 
decontamination 
Pos again the 
next day 
Send out as 
contaminated if 
original specimen had 
been decontaminated.  
If specimen is a trial 
specimen, original 
specimen was not 
initially 
decontaminated or, if 
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NEW POSITIVES AND TUBES PREVIOUSLY REMOVED > 7 DAYS AGO
1) Create an MTBZN worksheet per MGIT unit.
2) Label a slide for ZN staining and a quadrant on 2% BA plate to check for contamination
3) Work under the hood when working with the MGIT tubes.
4) Place a drop of precipitating fluid on the slide to ensure adherence of the smear.
5) Aspirate (fish) approximately 0,1ml from the bottom of the MGIT tube, inoculate the BA quadrant
and prepare a slide for a ZN.
6) Dry the slides under the hood and perform the ZN stain according Commonly Used Staining
Techniques SOP MIC0728.
7) Incubate the 2% BA plates overnight, aerobically at 35ºC.
8) Once the ZN has been read, record results on the MTBZN worksheet. Slides can be discarded.
9) If the ZN is negative, date the MGIT tube and return to the appropriate MGIT unit within 5 hours of
removal. Only the MGIT tube’s barcode needs to be scanned.
10) If the ZN is positive, refer to the ‘Positive MGITs / LJs for Identification’ flow diagram.
11) Place MGIT tubes or LJs in the box for the HAIN PCR test.
12) Read the 2% BA plates and record the results on the MTBZN worksheet.
13) Growth on 2% BA from MGITs that are ZN positive must be entered on the LIS.
14) Refer to the Flow Chart or Table 1 for the appropriate course of action depending on the results of
the 2% BA culture and the ZN.
15) If the culture is contaminated with an organism that may be Nocardia, consult with a pathologist or
registrar to determine whether the organism should be identified and reported.
16) ALWAYS remember to check whether an LJ slope was inoculated as well. If a specimen is being
discarded and an LJ was inoculated, the LJ can be incubated for the remainder of the 42 days
unless it also becomes contaminated
.





Specimen type ZN performed on 
MGIT 
Action 
Neg Growth Any specimen that 
has been 
decontaminated 
and is not a trial 
specimen. 
Negative Send out as contaminated





Pos Growth Any Negative Decontaminate 
Neg or Pos No growth Any Negative Re-incubate in MGIT machine. 
PROCESSING OF NEGATIVE MGIT TUBES 
1) Unload negative MGITs according to the BACTEC MGIT 960 USERS Manual.
2) Print an “unloaded negatives” report and initial, date and file.
3) Ensure that the number MGITs removed equals the number of results on the unloaded negative
report.
4) Negative MGIT results are reported via the interface.
5) Visually inspect all negative MGIT tubes.  If there appears to be TB colonies, perform a ZN.  If the
ZN is positive, follow the flow diagram for positive MGITs.
6) If ZN is negative report as negative on the LIS under TBCUL.
7) The negative MGIT tubes are sent for autoclaving before being discarded.
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PROCESSING OF MGIT CULTURES NOT IN THE MGIT INCUBATOR 
These are specimens such as bone that were too large to fit into a normal MGIT tube. 
 
1) Examine the culture medium weekly (usually a Monday) for any sign of visible turbidity 
2) If the bottle is turbid, proceed as for a positive MGIT culture (sections A or B depending on the 
age of the culture) 
3) If there is no visible growth after 6 weeks, perform a ZN stain on the liquid in the bottle. 
4) If the ZN is negative, send out as No Growth 
5) If the ZN is positive, follow the Positive MGITs / LJs for Identification’ flow diagram. 
 
LJ SLOPES 
LJs in the ‘going out’ tray and in the box awaiting Identification are read once a week. 
1) Rotate week indicators on the LJ trays 
2) Read the LJs in the ‘going out’ tray (week 6) and in the 30ºC and record results on the LIS under 
CULTB 
a)  N - Negative (no growth) 
b) P – positive (growth) 
c) ‘Contm’ - Contaminated  
3) Aerate LJ slopes in the week 3 rack and the box awaiting Identification as follows: 
a) Loosen caps – DO NOT REMOVE – and replace bottle in rack. 
b) Allow to stand on the bench until bottles have cooled to room temperature. 
c) Re-incubate overnight with the caps loose. 
d) Remove the rack the following day and allow to cool. Tighten the caps before replacing the 
rack in the incubator. 
 
LJ slopes with visible growth 
1. Find out if the corresponding MGIT has flagged positive yet. If so, work from the MGIT tube, 
and use the LJ as a backup if necessary. 
2. If the MGIT has not flagged yet, proceed by preparing a ZN slide.  
3. Using a cotton swab, remove a portion of the growth from the LJ slope, prepare a slide for ZN. 
4. If the ZN is positive, follow the Positive MGITs / LJs for Identification’ flow diagram. 
5. If the ZN is negative, and the slope appears contaminated, enter the result on the LIS as 
contaminated and discard the LJ slope.  
6. If the culture is contaminated with an organism that may be a Nocardia, consult with a 
pathologist or registrar to determine whether the organism should be identified and reported. 
 
LJs are sent for autoclaving before being discarded. 
 
POSITIVE TB BLOOD CULTURE BOTTLES 
BD MycoF-Lytic bottles and BacT/ALERT MB bottles. 
Positive TB blood culture bottles will be sent  from the blood culture lab without a form. A Gram stain 
will have been performed by the blood culture lab and a result of ‘no bacteria observed’ should be 
resulted on the LIS 
 
1) Add the blood culture details to the MTBZN worksheet 
2) Label a slide for a ZN stain 
3) Sterilise the top of the bottle with 70% Methylated spirits  
4) Using a syringe inoculate the slide, dry and perform a ZN stain according to Commonly Used 
Staining Techniques SOP MIC 0728. 
5) Read ZN slide and record results on the MTBZN worksheet 
6) Report ZN results in the remarks field under the CULBA test method on the LIS.  
7) If ZN negative: 
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a) Sub to LJ and place the bottle and LJ with the cap loose in the sloping box overnight at 37°C 
aerobically. The next day tighten the LJ cap and transfer the bottle and LJ to the ‘identification’ 
box.  
8) If ZN positive and sensitivity is required sub to LJ and incubate the bottle and LJ as per point 7a. 
a) NOTE a HAIN PCR test can not be performed directly from a blood culture. It must be subbed 
to an LJ and a HAIN PCR performed from a positive LJ. 
9) If ZN positive and no sensitivity is required, perform the BD MTB TBc ID test according to 
Identification of Mycobacterium species SOP. 
10) Note: Use the Positive MGITs / LJs for Identification’ flow diagram if a referral can be made. 
 
QUALITY CONTROL 
Internal Quality Control in the TB Laboratory MIC0733. 
Internal Quality Control GPL1863. 
 
LIMITATIONS 
Refer to Isenberg, H.D; Clinical Microbiology Procedures Handbook, Volume 2 
Bactec MGIT 960 System User’s Manual section  
 
CLINICAL APPLICATION 
Although microscopy is the primary means of diagnosing TB in South Africa, culture is sometimes 
indicated to make a diagnosis of TB. Detection of mycobacterial growth from a clinical specimen is 
one way of confirming a diagnosis of tuberculosis. 
 
ATTACHMENTS 
Appendix A (unloaded positives report) example 
Appendix B (unloaded negatives report) example 
 
REFERENCES 
Bactec MGIT 960 System User Manual.  
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Positive MGITs / LJ’s for Identification (Flow Diagram) 
 
ZN Positive 
Enter results on LIS 
 
1. Check scanned request form 
2. Check TB culture history 
3. Check trial request 
Determine 
- Only TB culture 
requested 
and patient is >14 years 
 
TB culture and sensitivity 
requested OR 
Patient ≤ 14 years and sensitivity 
not requested 
OR 
Clinical details suggest MDR / lack 
of response to TB treatment 
Mtb complex not 
identified in the 
last month from a 
specimen of the 
same site 
Mtb complex 
identified in the 
last month from a 




performed in the 
last 3 months from 
a specimen from 
the same site 
Sensitivity 
performed in the 
last 3 months, but 
identification 
performed more 
than a month ago 
Identification and 
sensitivity not   
performed in the 
last 3 months from 
a specimen from 
the same site 






On the LIS, enter 
identification and refer 
sensitivity result to the 
specimen on which 
sensitivity was 
performed. 
Perform MGIT TBc 
ID, and on the LIS, 
refer the sensitivity 
to the specimen on 
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IDENTIFICATION OF MYCOBACTERIA SPECIES 
 
PRINCIPLE 
Commercial kits are available for rapid identification and molecular identification of Mtb complex 
and genotypic susceptibility testing. 
 
The HAIN Lifescience GenoType kits, uses a DNA strip for molecular identification of 
Mycobacterium species. A DNA strip is also available for determining genotypic resistance to 
Rifampicin and isoniazid. The procedure includes DNA extraction, amplification and 
hybridization. 
 
MGIT TBc Identification Test is a chromogenic assay which detects the presence of a protein 
released by Mtb complex during culture in a MGIT. 
 
PURPOSE 
This Sop serves as a guideline for identification of Mtb complex, MOTTS, and Mycobacterium 
bovis BCG using a variety of commercial kits. 
 
RESPONSIBILTY 
The SOP must be followed by all Medical Technologists / Student Medical Technologists or 
Technicians / Medical Scientists / Registrars / Pathologists working in the TB laboratory. 
 
ABBREVIATIONS 
Mtb – Mycobacteria tuberculosis 
MOTTS – Mycobacteria other than tuberculosis 
PCR – Polymerase chain reaction 
ZN – Ziehl Neelsen 
NTM – Non-tuberculosis Mycobacteria 
ID – identification 
LJ – Lowenstein Jensen slope 
INH – Isoniazid 
AFB’s – Acid fast bacilli 
MDR – Multi-drug resistant 
 
HEALTH AND SAFETY 
Refer to the NHLS Health and Safety Manual. 
Refer to the following package inserts: 
· HAIN Genotype MTBDR plus 
· HAIN Genotype Mycobacterium CM 
· HAIN Genotype Mycobacterium AS 
· HAIN Genotype MTBC 
· BD MGIT TBc ID 
· HotStarTaq PCR 
· GT-Blot 48 Users Manual 
All procedures, where possible, must be performed in a Class II Biosafety Cabinet. 
 
MATERIALS AND REAGENTS 
HAIN LifeScience package inserts (instructions for use) are available from www.hain- 
lifescience.de/ifu.html. The IFU number is found on the outside of the kit box. 
HAIN Genotype MtbDR plus kit and package insert 
HAIN Genotype Mycobacterium CM kit and package insert 
HAIN Genotype Mycobacterium AS kit and package insert 
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HAIN Genotype MTBC kit and package insert 
BD MGIT TBc ID test kit and package insert 
HotStarTaq PCR enzyme and handbook 






0.2ml PCR tubes 
 
EQUIPMENT 











HAIN Genotype MtbDRplus – performed once a week 
HAIN Genotype Mycobacterium CM / AS – performed once a week 
HAIN Genotype MTBC – as required 
BD MGIT TBc ID – performed daily 
Refer to Turn-around Times for Microbiology and Virology SOP MIC0762. 
 
SAMPLES 
 Positive MGITs confirmed with a smear positive AFB result. 
 LJ’s with growth resembling Mycobacteria (not suitable for BD MGIT TBc ID). 
 Positive BD MYCO-F-LYTIC blood cultures confirmed with a smear positive AFB result 
(suitable for BD MGIT TBc only). 
 
PROCEDURE 
Follow the flow diagram below to determine what test to perform on MGITs which have flagged 
positive. 
BD MGIT TBc ID Test 
Performed on Positive MGITs confirmed with a smear positive AFB result and where only TB 
culture has been requested. 
 Label a test device with the ‘SCH’ number. 
 Perform according to the BD MGIT TBc ID package insert. 
 
HAIN Test 
 Create a worksheet using the HAIN worksheets provided in the kits, recording the ‘SCH” 
number and surname of the patient’s culture. 
 Label eppendorf tubes using the ‘SCH’ number. 
Extraction of DNA: 
 
Method 1: 
Alternative method used for TB cultures from MGIT and LJ slopes. (In-house extraction method) 
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MGIT tubes: 
· Aliquot 1 – 1.5ml of culture into the correctly labelled eppendorf tube.
LJ Slopes:
· Aliquot 1 -1.5ml of ultra pure water into an eppendorf tube.
· Make a heavy suspension of the colonies from the LJ slope in the water, using a sterile
swab.
Positive control: 
· Use a MGIT or LJ culture of H37RV strain.
Negative control:
· Use ultra pure water.
 Switch on the heating block and allow to reach a temperature of 95 – 105 °C.
 Incubate for 30 minutes in the heating block.
 Refrigerate tubes at 4°C for a minimum of 20 minuntes.
 Centrifuge for 5 mins at 10000rpm in a microfuge.
 Extracted suspensions are stored at 4°C.
Method 2: 
HAIN Lifesciences method used for MGIT and LJ TB cultures. 
Perform according to the HAIN package insert and Genolyse Protocol authorized by HAIN. 
Note: A heating block is used instead of a waterbath.
Amplification:
Mastermix is prepared first thing in the morning in the PCR clean room. 
Do not handle TB specimens prior to preparing mastermix. 
No lab coats from C18 must be worn in the PCR clean room. 
Wash hands before entering the PCR clean room. 
 Make up amplification mix according to the HAIN package insert.
 Make up amplification mix in a polypropylene tube using the following formula per test.
NB: multiply by the number of samples to be run.
Ultra Pure Water 1.1µl 
10x Buffer 5µl 
MgCl2 (25mM) 3.6µl 
Primer Nucleotide Mix 35µl 
HotstarTaq Polymerase 0.3µl 
 Aliquot 45µl into 0.2ml PCR tubes.
 Record each batch of mastermix and lot number details on the Mastermix Record Sheet
FRM/MOL/03.
Addition of DNA:
This procedure is performed in the Virology section. 
 Add the DNA to the mastermix according to the HAIN package insert.
Amplification profile:
 Using the thermocycler, amplify according to the profile stated in the HAIN package
insert.
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 Use of thermocycler:
Turn on thermocycler
Load tubes and close cover
Using the arrow keys select user
Press enter
Press run
Using the down arrow key select the required programme
Press accept (F1) for selected programme
Press accept (F1) to confirm volume
 Turn off thermocycler:
Press stop
Press stop to confirm stop
Press exit (F5) to end run
Switch off
Hybridization:
 Perform according to the HAIN package insert.
 Use the GT-BLOT 48 User Manual to operate the GT-BLOT 48.
RESULTS
MGIT TBc ID Test
 Refer to the BD MGIT TBc ID test package insert.
 Report results on the LIS.
 If the result is negative, charge using REFCH 0327.
HAIN Tests
 Cellotape the HAIN strips to the HAIN worksheet.
 Interpret results according to the appropriate package insert and record results on the
HAIN worksheet:
· HAIN Genotype MTBDR plus package insert
· HAIN Genotype Mycobacterium CM package insert
· HAIN Genotype Mycobacterium AS package insert
· HAIN Genotype MTBC package insert
 Record results on the LIS.
 Record all results of HAIN tests and any additional work under ‘notes’. This excludes
completed PCRCU results.
 ALL HAIN tests must be charged using REFCH 0447. This excludes completed PCRCU
results.
 All HAIN results must be checked for interpretation and reporting by a second person
and countersigned.
 Refer to datasheet DAT/TB/04 for additional work and comments on HAIN results.
ADDITIONAL PROCESSES
Selection of Isolates for Susceptibility Testing:
 Order phenotypic sensitivity testing:
· Isolates identified as Mtb complex but are inconclusive to INH and / or Rifampicin
· Isolates identified as Mtb complex but are Rifampicin monoresistant.
· Required by a trial.
 Check the notes field for a record of any growth on 2% blood agar to ensure culture is
pure for sensitivity testing.
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· Subculture INH resistant isolates for Streptomycin and Ethambutol sensitivity testing
when specifically requested.
· Subculture Rifamipicin resistant isolates for Greenpoint TB lab for 2nd and 3rd line
sensitivity testing (Ethionamide, Amikacin, and Ofloxacin).
 If culture is contaminated and from a sterile site and can not be referred to another
culture, send MGIT for re-decontamination.
 NOTE: 1st line sensitivity testing can be performed phenotypically and genotypically.
Comments:
 If awaiting 1st line phenotypic sensitivity testing on non-trial samples, add the following
comment:
“Awaiting phenotypic sensitivity results”
 If awaiting 2nd and 3rd line sensitivity testing, add the following comment:
“Awaiting 2nd and 3rd line sensitivity results”.
Subculture for MGIT DST:
 Label MGIT tube with ‘SCH’ number and type of sensitivity to be performed.
 Vortex culture.
 Pipette 800µl of growth supplement into a new MGIT tube.
 Pipette 500µl of the culture into the MGIT.
 Place in MGIT machine.
Subculture for LJ slope:
 Subculture isolates onto an LJ slope as determined by using the flow diagrams.
 Incubate at 37ºC for 42 days.
 Check the notes field for a record of any growth on 2% blood agar to ensure culture is
pure to sub to an LJ slope.
Storage of isolates:
Store isolates as required per trial. 
Order a STORE test. 
Label a storage tube. 
Aliquot 300µl of 50% glycerol into the storage tube 
Vortex culture 
Aliquot 1ml of the isolate into the storage tube 
Record details in the storage folder on S drive. 
Record details on DISA under store. 
QUALITY CONTROL
Refer to appropriate package inserts: 
· HAIN Genotype MTBDR plus package insert
· HAIN Genotype Mycobacterium CM package insert
· HAIN Genotype Mycobacterium AS package insert
· HAIN Genotype MTBC package insert
· BD MGIT TBc ID test package insert
· HotStarTaq PCR
· Record the lot number and expiry date of the strips used on the HAIN worksheets.
· Record all molecular run failures on the “Run Failure log form: Molecular FRM/MOL/05”.
 Each new HAIN Kit, MGIT TBc ID kit and HotStarTaq kit is recorded on the Logsheet for
Control of Reagents and Package Inserts FRM/GEN/12.
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 Each new lot number for MGIT TBc ID kit is controlled by running a positive control, 
H37RV MGIT culture, and a negative control, 7H9 middlebrook media from an 
uninoculated MGIT tube. 
 
LIMITATIONS AND REFERENCES 
Refer to appropriate package inserts: 
· HAIN Genotype MTBDR plus package insert 
· HAIN Genotype Mycobacterium CM package insert 
· HAIN Genotype Mycobacterium AS package insert 
· HAIN Genotype MTBC package insert 
· BD MGIT TBc ID test package insert 
· HotStarTaq PCR handbook 
 
 OUTSTANDING WORKLISTS 
Check the following outstanding worklists: 
 MTB.P – PCRCU / PCRTB – each HAIN run 
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Mtb + and 
Sensitivities inconclusive 
 
Report Mtb+ (PCRCU) 













TB culture only 
M. bovis BCG indicated 
clinically 
TB culture and sensitivities 





Report as Mtb 
complex 
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No Myco DNA AND 
evidence of contamination: 
Check cording / non – cording and 
comment appropriately * 
(notes and TB+) 
Mycobacteria species only 
Report: NTM 
(TBLP) 




High GC / No Myco DNA AND 
evidence of contamination: 
Check cording / non – cording and 
comment appropriately * 
(notes and TB+) 
See DAT/TB/04 
Mycobacteria species from 
STERILE SITES / trials 
requiring MOTT ID 
Do AS (notes) 
See DAT/TB/04 
Mycobacteria species only 









No Myco DNA and no 
evidence of contamination 
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Table of contents 
ISE technology 
This chapter provides you with an overview of ISE technology used by the 
cobas 6000. 
Components and function of the ISE unit ................................................................... A-5 
Sample probe, reaction cell, and ultrasonic mixer ............................................... A-6 
ISE pipetter ................................................................................................................ A-6 
ISE reagent compartment ........................................................................................ A-6 
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ISE  sipper   ...................................................................................................................  A-7 
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Components and function of the ISE unit 
 
Components and function of the ISE unit 
 
The figure below visualizes the liquid flow paths of the ISE unit. The following 
symbols are used in the figure: 
 
      Solenoid valve 


























R Q P O N M L 
 
A Internal standard (ISE IS) G Sipper nozzle M ISE rinse station 
B Diluent (ISE Dil.) H Reaction cell N Incubator bath 
C Reference solution (ISE Ref.) I ISE syringe O IS bath 
D ISE pipetter J Sipper syringe P Vacuum pump 
E Measuring electrodes K Water pump Q Vacuum tank 
F Reference electrode L Pinch valve R Vacuum reservoir 
Figure A-1 ISE liquid flow path diagram 
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Components and function of the ISE unit 
Sample probe, reaction cell, and ultrasonic mixer 
The ISE unit uses the sample probe, reaction cells, and ultrasonic mixer of the c 501 
module. 
Sample probe The sample probe transports sample liquid from the sample tube to a reaction cell. 
Reaction cell The reaction disk of the c 501 module carries the reaction cells. All reaction cells are 
seated in the controlled-temperature incubator bath. The incubator bath maintains 
the cells at the required temperature of 37C. 
Ultrasonic mixer After the sample probe has dispensed the sample into the reaction cell, the ISE 
pipetter adds ISE Dil.. The ultrasonic mixer of the c 501 module mixes the diluted 
sample. 
ISE pipetter 
The ISE pipetting system is composed of the ISE pipetter (consisting of pipetter arm 
and probe), the ISE syringe, and the ISE rinse station. 
ISE pipetter The ISE pipetter transports ISE Dil. to the reaction cell and ISE IS to the internal 
standard bath. 
The ISE pipetter probe is equipped with a level detector (capacitance method) which 
is applied to check and correct the filling volume of any bottle present in the ISE 
reagent compartment. 
ISE syringe The ISE pipetter is connected to the ISE syringe by tubing, which controls the 
pipetting action. 
ISE rinse station This rinse station is used for both ISE pipetter probe and ISE sipper probe. 
ISE reagent compartment 
The ISE reagent compartment provides five positions for reagent bottles: 
o ISE IS: Two bottles
o ISE Dil.: Two bottles
o ISE Ref.: One bottle
The reagent compartment is equipped with position sensors for each reagent bottle 
(reflection type). 
Internal standard bath 
Internal standard bath (IS bath) has two chambers for heating internal standard 
(ISE IS) to measuring temperature (37C). After heating, the ISE IS solution is 
aspirated by the sipper probe into the measuring flow path. The residual ISE IS 
solution is aspirated through the vacuum nozzle to empty the IS bath. 
The use of two chambers allows for an optimized flow of the analysis: While the 
content of one chamber is ready for use, fresh ISE IS is pipetted into the other 
chamber where it is given time to heat up for the next measurement. 
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The ISE sipper mechanism consists of a sipper nozzle and a sipper syringe. Between 
the sipper nozzle and the syringe is the ISE measuring flow path. 
 
Sipper nozzle The sipper nozzle lowers either into ISE IS solution in the IS bath or into sample 
solution in a reaction cell to aspirate the respective solution into the measuring flow 
path. 
 
Sipper syringe The sipper syringe provides the negative pressure for following functions: 
o Aspirate sample solution or ISE IS into the measuring flow path (measurement 
electrodes) 
o Aspirate ISE Ref. into the measuring flow path (reference electrode) 
o Aspirate measured sample solution, ISE IS, and ISE Ref. from the measuring flow 





The ISE measuring system is contained in a temperature-controlled compartment. It 
is composed of three ion specific electrodes and one reference electrode. 
The difference between the potentials at the reference electrode and the ion-selective 
electrode equals the electromotive force (EMF). For every test, the EMF of both 
ISE IS and diluted sample solution are measured for each sort of ions (Cl-, K+, and 
Na+). From these EMF values the results are calculated using the calibration curve. 
 
Measurement electrodes The measurement electrodes use a special design. Membranes with ion-selective 
binding capacity and an open liquid junction allow the selective measurement of the 
ion concentrations. The electrodes are directly connected to form a flow path for the 
diluted sample and the ISE IS solutions. 
 
Reference electrode The reference electrode uses the same design of the measurement electrodes. It is 
exclusively used as a reference for every measurement. ISE Ref. is aspirated through 
the electrode and a reference electrode potential is registered. 
 
Pinch valve The pinch valve is used to control the flow of liquid that passes the electrodes. 
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This section describes the sequence of the ISE measurement. 
 
Preparation First, the sample pipetter pipettes a sample into a reaction cell. Then, into this cell, 
ISE Dil. is pipetted by the ISE pipetter and mixing is carried out with the ultrasonic 
mixing unit. Next, the ISE pipetter dispenses ISE IS solution into the IS bath where it 
is heated to 37C. 
 
ISE IS measurement The ISE sipper aspirates ISE IS solution from the IS bath into the measuring flow 
path to perform an ISE IS measurement (single-point calibration). The residual 
ISE IS solution is aspirated through the vacuum nozzle to empty the IS bath. 
The sipper syringe aspirates ISE Ref. from the ISE Ref. bottle to the reference 
electrode to perform ISE Ref. measurement. 
 
Sample measurement The ISE sipper aspirates diluted sample from the reaction cell into the measuring 
flow path to perform the sample measurement. 
The sipper syringe aspirates ISE Ref. from the ISE Ref. bottle to the reference 
electrode to perform ISE Ref. measurement. 
For every ISE measurement, the analyzer measures three electromotive force values 
(EMF); for chloride, potassium, and sodium, where EMF denotes the difference in 
potential between the respective ion-selective electrode and reference electrode. 
 
Finalization Finally, the results are calculated from the electromotive forces of ISE IS and diluted 
sample. The ISE system is now ready for the next analysis. If there are no more 
samples to be analyzed, the ISE unit performs a final ISE IS measurement and stops. 
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Measurement sequence 
Summary This table summarizes the flow of an ISE analysis: 
Step   Time Actor Action 
Preparation of measurement 
1 0.0 s  Sample pipetter Pipettes sample (9.7 l) to cell 
2 12.0 s  ISE pipetter Aspirates (348 l) and dispenses ISE Dil. (291 l) 
to cell 
3 15.0 s  Ultrasonic mixing unit Mixes sample and ISE Dil. 
4 ISE pipetter Aspirates (590 l) and dispenses ISE IS (450 l) to 
IS bath 
5 IS bath ISE IS heats to measuring temperature (37C) 
Internal standard (ISE IS) measurement 
6 284.5 s ISE Sipper Aspirates ISE IS to Cl/K/Na electrodes (400 l) 
7 Sipper syringe via tubing Aspirates ISE Ref. from the ISE Ref. bottle to 
reference electrodes (65 l) 
8 292.0 s Electrodes Measure ISE IS 
Diluted sample measurement 
9 301.0 s ISE Sipper Aspirates sample to Cl/K/Na electrodes (250 l) 
10 Sipper syringe via tubing Aspirates ISE Ref. from the ISE Ref. bottle to 
reference electrodes (65 l) 
11 310.0 s   Electrodes Measure sample 
Finalization of measurement 
12 315.0 s Result calculation and output 
If there are more samples to be analyzed, go to 
step 1. 
If there are no more samples, repeat 6-8 and stop. 
Table A-1 Flow of ISE  analysis 
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This chapter provides you with an overview of the ion selective electrode test 
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The ISE unit performs indirect measurement of electromotive force (EMF) in 
millivolts between ion selective electrodes and the reference electrode. Indirect 
measurement means that all samples are diluted at a 1:31 ratio. 
The EMF values of each sample are converted to mmol/L values by a calculation 
algorithm that uses the EMF data together with data from a two-point calibration 
with two primary standards. 
A one-point calibration before and after each routine sample measurement is used to 
offset the drift between consecutive measurements. For this one-point calibration the 
internal standard (IS) is used. 
 
 
Calculation of unknown sample concentrations 
 
The concentration of the sodium, potassium, and chloride in a sample is calculated 
from the EMF of the specific electrode by the following equation, which is derived 




Cs  =  C.Value + CIS  10 
 








Concentration of the specific ion in sample 
Compensation value 
Concentration of the internal standard 
 
Electromotive force (voltage) of the unknown sample for the specific ion 
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Adenosine Deaminase Assay Kit 
Configuration 
The Diazyme Adenosine Deaminase reagent is provided in bulk 
and the following kit configuration: 
REF Kit Size 
DZ117A-K 
R1: 1 x 50 mL 
R2: 1 x 25 mL 
Intended Use 
Adenosine Deaminase (ADA) Assay Kit is for determination of 
ADA activity in serum, plasma, pleural fluid, and cerebrospinal 
fluid samples. 
Background 
ADA is an enzyme catalyzing the deamination reaction from adeno-
sine to inosine. The enzyme is widely distributed in human tissues, 
especially high in T lymphocytes. Published literature states that 
elevated serum ADA activity has been observed in patients with 
acute hepatitis, alcoholic hepatic fibrosis, chronic active hepatitis, 
liver cirrhosis, viral hepatitis and hepatoma.1,2 Increased ADA ac-
tivity was also observed in patients with tuberculous effusions.3 
These reports state that determination of ADA activity in patient 
serum may add unique values to the diagnosis of liver diseases in 
combination with ALT or γ-GT (GGT) tests and may also be useful 
in the diagnostics of tuberculous pleuritis.3 
Assay Principle 
The Diazyme ADA Assay is based on the enzymatic deamination of 
adenosine to inosine which is converted to hypoxanthine by purine 
nucleoside phosphorylase (PNP). Hypoxanthine is then converted to 
uric acid and hydrogen peroxide (H2O2) by xanthine oxidase 
(XOD). H2O2 is further reacted with N-Ethyl-N-(2-hydroxy-3-
sulfopropyl)-3-methylaniline (EHSPT) and 4-aminoantipyrine (4-
AA) in the presence of peroxidase (POD) to generate quinone dye 
which is monitored in a kinetic manner. The entire enzymatic reac-
tion scheme is shown below. 
Adenosine + H2O 
ADA 
Inosine + NH3 
Inosine + Pi 
PNP Hypoxanthine +  
Ribose-1-phosphate 
Hypoxanthine + 2H2O + 2O2 
XOD 
Uric acid + 2H2O2 
2H2O2 + 4-AA + EHSPT 
POD 
4H2O + Quinone dye 
( max 556nm) 
One unit of ADA is defined as the amount of ADA that generates 
one µmole of inosine from adenosine per min at 37C. 
Reagent – Working Solutions 
Reagent 1 
Tris HCl, pH 8.0      50 mM 
4-AA  2 mM 
PNP   0.1 U/mL 
XOD   0.2 U/mL 
Peroxidase   0.6 U/mL 
Stabilizers 
Reagent 2 
Tris-HCl, pH 4.0       50 mM 
Adenosine       10 mM 
EHSPT  2 mM 
Precautions 
1. USA: For Research Use Only. Not for use in diagnostic proce-
dures.
2. EU: For in vitro diagnostic use.
3. R1 is light-sensitive and should be stored in a dark place. 
4. Specimens containing human sourced materials should be han-
dled as if potentially infectious using safe laboratory procedures,
such as those outlined in Biosafety in Microbiological and Bio-
medical Laboratories (HHS Publication Number [CDC] 93-8395).
5. Avoid ingestion and contact with skin and eyes. See Material
Safety Data Sheet.
6. The reagents contain < 0.1% sodium azide, NaN3, as preserva-
tive. Sodium azide may react with lead and copper plumbing to
form highly explosive metal azide. On disposal, flush with a
large volume of water to prevent azide buildup.
7. Do not use the reagents after the expiration date labeled on the
outer box.
8. Additional safety information concerning storage and handling
of this product is provided within the Material Safety Data Sheet
for this product.
Reagent Handling 
ADA REAGENT comes in a liquid two-reagent system, ready-to-
use for both manual method and automated chemistry analyzers 
(kinetics). ADA CONTROL and CALIBRATOR are in lyophilized 
form, and need to be reconstituted with 1.0 mL of DI water before 
use. The reconstituted CONTROLS and CALIBRATOR are stable for 
1 week at 2-8C. CONTROLS and CALIBRATOR sold separately. 
Reagent Stability and Storage 
REAGENT are stable until their expiration date when stored at 2-
8C. 
Specimen Collection and Preparation 
Serum, heparinized plasma, pleural fluid, or cerebrospinal fluid may 
be assayed. Ideally, venous blood should be collected and handled 
anaerobically. Do not use citrate or oxalate as anticoagulant. 
Plasma and serum, after prompt separation from cells or clot, should 
be kept tightly stoppered. ADA content of blood is stable for 1 week 
when stored at 2–4°C. Pleural fluid should be collected in a sterile or 
heparinized tube and processed within 2 hours at room temperature or 
stored at 4°C or -20°C for 2 days and up to 2.5 years at -80°C.7,8,9   
Cerebrospinal fluid (CSF) should be clear and collected in a sterile 
tube without anticoagulant.  ADA is stable in CSF for 24 hours at 
25ºC, 7 days at 4ºC and 3 months at -20ºC.10 
Materials Provided 
See “Reagent – Working Solutions” section for REAGENT. 
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Materials Required but not Provided 
 Any instrument with temperature control of 37 ± 0.5°C that is
capable of reading absorbance accurately at 540nm – 550nm may
be used
 Controls for validating the performance of the Diazyme Adeno-
sine Deaminase Assay Kit (REF DZ117A-CON)
 Calibrators for the Diazyme Adenosine Deaminase Assay Kit are
provided separately (REF DZ117A-CAL) 
 0.9% Saline is needed as CALIBRATOR 0 
 General laboratory equipment
Assay Procedure 
Test Scheme for Chemistry Analyzers 
Application sheets for use of Diazyme Adenosine Deaminase Assay 
on automated clinical chemistry analyzers are available upon re-
quest.  Please call 858-455-4768 or email: support@diazyme.com. 
Calibration 
0.9% saline and the Diazyme Adenosine Deaminase Calibrator 
(REF DZ117A-CAL) are needed for calibration. The lot specific 
CALIBRATOR values are stated in the Certificate of Analysis. 
Quality Control 
We recommend that each laboratory use the Diazyme Adenosine 
Deaminase Control Set, listed under Materials Required section, to 
validate the performance of ADA reagents. The Diazyme ADA 
Control Set is available from Diazyme Laboratories (REF  
DZ117A-CON). The CONTROL interval and limits should be 
adapted to each laboratory’s individual requirements. Values ob-
tained should fall within the defined limits. Each laboratory should 
establish corrective measures to be taken if values fall outside the 
limits.  Each laboratory should follow federal, state, and local 
guidelines for testing QC material. 
Results 
The ADA results are printed out in U/L. Literature cites ADA activ-
ity tests in serum samples to be in the range of 0-15 U/L1-4. Litera-
ture citations show that for pleural fluid, values were found to be in 
the range of 0-30 U/L, and for cerebrospinal fluid (CSF), values 
were found to be in the range of 0-9 U/L.4,6
Limitations 
If the sample ADA activity is greater than 200 U/L, the sample 
should be diluted with saline before measurement. The result should 
be multiplied by the dilution factor. Assay is specific for ADA and 
has no detectable reaction with other nucleosides. The reagent solu-
tion should be clear. If turbid, the reagent may have deteriorated. 
Analytical Characteristics
5
Results from individual laboratories may vary. 
Precision 
The precision of the Diazyme Adenosine Deaminase Assay was 
evaluated on the Cobas Mira instrument according to a modified 
Clinical Laboratory Standards Institute EP5-A guideline. In the 
study, two serum specimens containing 11 U/L and 30 U/L ADA 
were tested with 2 runs per day with duplicates over 15 working 
days. 
Within Run Precision Run to Run Precision 
11 U/L 30 U/L 11 U/L 30 U/L 
No. of Data Points 30 30 30 30 
Mean (U/L) 11.11 30.74 9.63 29.62 
SD 0.16 0.45 0.47 0.59 
CV% 1.47 1.45 4.90 2.00 
Linearity 
The linearity of the procedure is from 0 – 200 U/L. 
Interference 
Assay is not affected by serum bilirubin up to 30 mg/dL, hemoglo-
bin up to 200 mg/dL, triglycerides up to 750 mg/dL, and ascorbic 
acid up to 4 mg/dL. 
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